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ABSTRACT

Intimate partner violence (IPV) is a public health problem of epidemic proportion; the only
known effective health care intervention is routine screening for IPV exposure. Despite
professional guidelines for routine screening, this intervention has been poorly adopted.
Expansion of screening efforts to the community pharmacy setting provides an opportunity to
have a substantial impact on the health, well-being of pharmacy patients. This investigation is
the first to examine IPV screening related to the pharmacy environment. An existing measure of
physicians’ readiness to manage IPV (PREMIS) was adapted for the community pharmacy
environment and validated in a national random sample of practicing community pharmacists.
Additionally, a study of female pharmacy consumers was conducted to examine the acceptability
of IPV screening in pharmacies. Results indicate that community pharmacists have minimal
exposure to IPV education/training. While respondents expressed concern regarding training and
time, they indicated that participation in screening may be valuable to patient health and as a
relative advantage for their pharmacies. Female pharmacists were more likely to report intent to
screen targeted patients for IPV. Consumers agreed that IPV screening is important for health
care providers to do, but were uncertain as to whether pharmacists specifically should engage in
screening. Comments indicated that consumers are unaware that pharmacists are trained in
patient communication/counseling, suggesting a need for recognition of the skills and
capabilities of community pharmacists. The potential for expanding IPV screening to
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community pharmacies should be prioritized among future studies of methods to address the
public health problem of IPV.
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1. INTRODUCTION

Interpersonal Violence: a Significant Public Health Problem
Intimate partner violence (IPV), also known as domestic violence, is a public health
problem of epidemic proportion in the United States, impacting more than 12 million people
each year (Black et al., 2011). According to the National Intimate Partner and Sexual Violence
Survey, 35.6% of women and 28.5% of men are physically assaulted, sexually assaulted, or
stalked by an intimate partner in their lifetime (Black et al., 2011). Annually, there are 4,741,000
physical assaults, 686,000 rapes, and 3,353,000 stalking victimizations of women and 5,365,000
physical assaults, and 519,000 stalking victimizations of men by intimate partners (Black et al.,
2011). Intimate partner violence can negatively impact the health and well-being of the victim
by causing injury or worsening health conditions. Physical injuries can be as minor as cuts and
scrapes or as serious as broken bones, brain injuries, organ damage, and even death (Tjaden &
Thoennes, 2000). Victims of IPV experience exacerbation of chronic diseases due to stress and
poor health behaviors (Crofford, 2007; Balousek, Plane, & Fleming, 2007; Humphreys & Lee,
2009), report pain more frequently, and use prescription pain medications more than those who
are not exposed to IPV (Bonomi, Anderson, Rivara, & Thompson, 2009). Both health care
utilization and health care costs are higher for women experiencing IPV, with IPV contributing
to an increased use of both primary and emergency care (Crofford, 2007). Women exposed to
IPV have health care costs that are approximately 60% higher than women not experiencing
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abuse (Ulrich et al., 2003). According to the Centers for Disease Control and Prevention (CDC),
IPV cost $8.3 billion annually when the economic impact was last updated in 2003 (National
Center for Injury Prevention and Control, 2003). The harm of IPV extends beyond the
immediate victim. For example, children of mothers exposed to IPV have increased health care
utilization and costs (Rivara et al., 2007b), and are at a greatly increased risk for child abuse
(Cannon, Bonomi, Anderson, & Rivara, 2009; Parkinson, Adams, & Emerling, 2001).
Due to the high prevalence of this serious health threat, Healthy People 2020 has multiple
objectives to reduce the rate of physical and sexual assault by intimate partners in the United
States (U.S.Department of Health and Human Services & U.S., 11 A.D.). These goals are in the
focus area of Injury and Violence Prevention (IVP). Table 1 includes the Healthy People 2020
goals related to intimate partner violence. The inclusion of these objectives in Healthy People
2020 recognizes the importance of interpersonal violence as a social determinant of health.

Table 1.

Healthy People 2020 Goals Related to Intimate Partner Violence

IVP-39 Reduce violence by current or former intimate partners
IVP-39.1 Reduce physical violence by current or former intimate partners
IVP-39.2 Reduce sexual violence by current or former intimate partners
IVP-39.3 Reduce psychological abuse by current or former intimate partners
IVP-39.4 Reduce stalking by current or former intimate partners
IVP-40 Reduce sexual violence
IVP-40.1 Reduce rape or attempted rape
IVP-40.2 Reduce abusive sexual contact other than rape or attempted rape
IVP-40.3 Reduce non-contact sexual abuse
IVP-42 Reduce children’s exposure to violence
Note: Adapted from “Healthy People 2020,” by U.S. Department of Health and Human Services
Office of Disease Prevention and Health Promotion, 2011. Available at
www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=24. Accessed November
18, 2011.
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Definitions of Interpersonal Violence
When discussing interpersonal violence it is important to be clear about how IPV is
defined. The World Health Organization’s (WHO) World Report on Violence and Health
defines intimate partner violence as behavior within an intimate relationship that causes physical,
sexual or psychological harm, including acts of physical aggression, sexual coercion,
psychological abuse, and controlling behaviors (Garcia-Moreno, 2002b). This definition is
widely used and has been operationalized in various ways. The CDC issued Intimate Partner
Violence Surveillance: Uniform Definitions and Recommended Data Elements for IPV and
provided clarity regarding the behavioral manifestation of IPV (Saltzman, Fanslow, McMahon,
& Shelley, 1999). The CDC defined physical violence as:
The intentional use of physical force with the potential for causing death, disability,
injury, or harm. Physical violence includes, but is not limited to: scratching, pushing,
shoving, throwing, grabbing, biting, choking, shaking, poking, hair-pulling, slapping,
punching, hitting, burning, use of a weapon (gun, knife or other object), and use of
restraints or one’s body, size or strength against another person. Physical violence also
includes coercing other people to commit any of the above acts (Saltzman, Fanslow,
McMahon, & Shelley, 1999, p. 11-12).
WHO utilizes the social ecology model (see Figure 1) to frame the problem of
interpersonal violence (Heise, 1998). This model organizes risk factors into individual,
relationship, community, and societal levels of influence. The model provides a framework to
investigate the complex relationships among the factors that are involved in IPV and can assist in
developing effective prevention and intervention efforts. The social ecology model supports a
comprehensive public health approach to IPV, emphasizing the need for policies and programs
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across many settings. Primary, secondary, and tertiary prevention strategies for IPV can be
guided by the model. The health care system response can have impact on factors influencing all
four levels in the model.

Figure 1. The Social Ecology Model of Interpersonal Violence

Society
(Macrosystem)

Community
(Exosystem)

Relationship
(Microsystem)

Individual
(Personal
History)

Figure 1. The social ecology model of interpersonal violence utilized to guide IPV work by
WHO. Adapted from “Violence against Women: An Integrated Ecological Framework,” L.L.
Heise, 1998, Violence Against Women, 4(3), p.263. Copyright 1998 by Sage Publications.

IPV Prevention and Intervention Efforts
There are multiple methods by which IPV can be prevented or by which interventions can
reduce the impact of the IPV. The health care system has always been actively engaged in
intervening to reduce the impact of injuries that have resulted from IPV by providing medical
treatment for injuries. However, medical treatment of this nature is an intervention that only
treats the physical injuries and does not serve as a preventive measure that could reduce the
future impact of violence. Efforts to prevent IPV and to reduce the future impact of IPV require
4

intervention of a different nature. Screening for IPV has been proposed as the most effective
method to prevent and reduce the impact of IPV in the future (McFarlane, Soeken, & Wiist,
2000).
Screening, identifying, and referring patients exposed to IPV presents an opportunity to
prevent further physical injuries and positively impact both the physical and mental health of
patients. Routine and regular screenings by skilled health care providers has been shown to
significantly increase the identification of IPV (McFarlane, Christoffel, Bateman, Miller, &
Bullock, 1991; McFarlane, Parker, Soeken, & Bullock, 1992; Sisley, Jacobs, Poole, Campbell, &
Esposito, 1999). A number of studies have demonstrated that IPV case identification increases if
structured protocols are implemented. These can include chart prompts (Olson et al., 1996),
additions to health history forms, and targeted documentation protocols (McLeer, Anwar,
Herman, & Maquiling, 1989; Coker, Bethea, Smith, Fadden, & Brandt, 2002). An investigation
in a family medicine practice found that IPV screening increased documentation and referrals by
increasing IPV positive women’s intention to disclose the exposure (Zeitler et al., 2006a). A
review of IPV interventions found that there was no difference among intensive counseling
interventions and simple screening and referral (McFarlane et al., 2000). These authors
concluded that abuse screening itself may be the most effective intervention (McFarlane et al.,
2000). Studies have found that women support IPV screening and believe health care providers
are the most appropriate person to ask them about IPV (Zeitler et al., 2006b; Zeitler et al.,
2006a). A survey by Brendtro and Bowker (1989) of self-identified abused women who had
successfully ended the violence found that the majority had sought help from health
professionals, a higher proportion than from any other source of help (Brendtro M & Bowker L,
1989). Evidence suggests that some IPV victims will seek services if provided referral materials
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(Leserman & Drossman, 2007) and several studies have demonstrated a significant increase in
safety behaviors and a decrease in violence after screening and referral of individuals identified
as IPV exposed (McFarlane, Groff, O'Brien, & Watson, 2006; Krasnoff & Moscati, 2002;
McFarlane, Groff, O'Brien, & Watson, 2005; McFarlane, Parker, Soeken, Silva, & Reel, 1998;
McFarlane et al., 2000). However, it is clear that screening needs to be routine as research has
shown that most victims who seek help report being screening multiple times before accessing
services (Ambuel, Hamberger, & Lahti, 1996).
The benefits of screening extend beyond the immediate patient. The American Academy
of Pediatrics recommendation states that “intervening on behalf of battered women may be one
of the most effective means of preventing child abuse” (American Academy of Pediatrics, 1998).
Given that IPV patients see a greater number of health care providers and use health services at a
higher rate compared to non-abused women (Koss, Koss, & Woodruff, 1991; Bonomi et al.,
2009), universal screening in health care settings has the potential to identify larger numbers of
IPV exposed patients.

Health Care System Response to IPV
Screening Recommendations
The health care system has recognized the seriousness of IPV and has been actively
recommending screening for over two decades. Because of the seriousness of this health threat,
nearly every national health care organization and professional group has called for routine
screening of IPV in health care settings. This began with U.S. Surgeon General C. Everett Koop
who declared IPV a public health crisis (Koop & Lundberg, 1992). In 1992 the American
Medical Association issued Diagnostic and Treatment Guidelines on Domestic Violence
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(American Medical Association, 1992), which declared that domestic violence was sufficiently
prevalent to justify routine screening of all women patients. Most other professional associations
have issued treatment guidelines to screen patients for IPV. The American College of Obstetrics
and Gynecology (ACOG) issued a technical bulletin in 1995 recommending screening of all
patients (American College of Obstetricians and Gynecologists, 1995). ACOG has repeated this
recommendation and published screening tools for use in practice (ACOG, 2010). Other
professional associations including the American Nurses’ Association (American Nurses'
Association, 1992), the American Academy of Pediatrics (American Academy of Pediatrics,
1998), the American Academy of Family Practice (American Academy of Family Practice,
1994), and the American College of Emergency Physicians (American College of Emergency
Physicians, 1995) have issued similar recommendations. In 2004 the Joint Commission first
added standards for how hospitals must respond to victims of domestic abuse, neglect, and
exploitation. In 2009 these standards were updated. Standard PC.01.02.09 states “The
[organization, critical access hospital, hospital, practice] assesses the [patient/resident] who may
be a victim of possible abuse and neglect” (Joint Commission, 2011b). This standard is
applicable to all types of care facilities that the Joint Commission accredits. Performance
elements include having criteria to identify individuals who may be victims, to assist with
referrals of victims, maintenance of a list of public and private agencies that can provide
assessment and care, staff education, screen at intake, and report cases internally and externally
as appropriate (Joint Commission, 2011a).
In a 2004 statement the United States Preventive Services Task Force (USPSTF) found
insufficient evidence to recommend for or against routine screening for IPV (U.S.Preventive
Services Task Force, 2004). This was primarily due to the lack of a validated instrument and the

7

lack of long-term follow-up of individuals screened to document reductions in exposure to IPV
after screening. In 2004 the Institute of Medicine (IOM) released a review, Advancing the
Federal Research Agenda on Violence Against Women, which called for improved data and
research infrastructure to address these challenges (Institute of Medicine, 2004). New research
has been published since the 2004 USPSTF recommendation. For example, standardized
assessment tools have been developed and found to be reliable and valid (Chen, Rovi, Vega,
Jacobs, & Johnson, 2005; Wathen & Macmillan, 2008; Weiss, Ernst, Cham, & Nick, 2003). In
July 2011 the IOM released the report Clinical Preventive Services for Women: Closing the Gaps
(Institute of Medicine, 2011). In this document, IOM reviewed the previous recommendation by
the USPSTF and reported that there is now sufficient evidence to move forward with a
recommendation that screening and counseling be a routine part of preventive care for women
(Institute of Medicine, 2011). Recommendation 7 states:
The committee recommends for consideration as a preventive service for women:
screening and counseling for interpersonal and domestic violence. Screening and
counseling involve elicitation of information from women and adolescents about current
and past violence and abuse in a culturally sensitive and supportive manner to address
current health concerns about safety and other current or future health problems.
(Institute of Medicine, 2011, p. 107)
Failure to Adopt IPV Screening
While the guidance and standards of care call for routine screening, and universal
screening is widely promoted, most investigations have found that screening is poorly adopted
and implemented in practice. Studies have shown that IPV screening rates differ according to
the specialty of the provider. For example, the estimated prevalence of screening by primary
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care and emergency room settings ranges from 1.5-30% (Plichta, 2004; Coker et al., 2002;
Daugherty & Houry, 2008; McGrath, Hogan, & Peipert, 1998). Women’s health specialists have
placed the most emphasis on screening; however, screening by obstetrician-gynecologists is only
slightly better, ranging from 10-39% (Bunn, Higa, Parker, & Kaneshiro, 2009; O'Reilly, Beale,
& Gillies, 2010). Studies consistently show that the majority of health care providers are not
following professional recommendations for universal screening (Bunn et al., 2009). In
pediatrics, a study found that only 4.2% of practices had protocols in place despite specific
policy statements and guidelines regarding IPV screening from the American Academy of
Pediatrics (Wright, Wright, & Isaac, 1997). Research shows that health care workers identify far
fewer cases than are described by surveys or police (Cann, Withnell, Shakespeare, Doll, &
Thomas, 2001), despite the fact that most victims have sought medical help (Fishman, Bonomi,
Anderson, Reid, & Rivara, 2010). One study demonstrated that even victims presenting with
acute injuries from IPV were treated without inquiry about IPV exposure (McGrath et al., 1998).
The lack of effective adoption and implementation of IPV screening is not altogether
surprising. There is ample evidence that practice guidelines alone do not adequately motivate
adoption and implementation of practice change (Dearing, 2009; Lomas, 1991). Despite this,
consensus statements, policy statements, and practice guidelines are frequently produced with
the assumption that practice change to reflect the guidelines will occur. It is likely that this
assumption is what leads to poor dissemination, as this assumption leads to a lack of attention to
the attributes of the new intervention and practice activity, provider knowledge and attitudes
about the area under review, and system barriers in the intervention development and
implementation (Dearing, 2009). This assumption can also lead to failures in communication of
the intervention. These dissemination failures occur even with large, national campaigns (Kerner
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et al., 2005). These failures have led to a call for increased use of theory in the design of
guidelines with the expectation that this will result in interventions that are more rigorously and
carefully developed. Increased attention to intervention attributes and other factors related to
implementation and dissemination will hopefully improve the success rate of adoption and
implementation (Dearing, Greene, Stewart, & Williams, 2011; Davies, Walker, & Grimshaw,
2010). The lack of theory in the development of IPV screening recommendations and guidelines
for most health care professions may be one of the reasons that screening, the only known
effective health care intervention for IPV prevention, has been so poorly adopted. These
findings indicate that theory-driven development of future IPV screening programs is needed to
prevent continued failure at the adoption and implementation stages.

Pharmacy and IPV
As described above, IPV screening has not been widely implemented, despite the
recommendations and treatment guidelines in multiple areas of health care and reports of
patients’ acceptance of screening. Clearly, additional methods to achieve routine screening are
needed. To date, pharmacists have not been considered as a part of the effort to address IPV.
This is a serious deficit as pharmacists are trusted members of the health care team with whom
individuals may have the most accessible and frequent contact. Including community
pharmacists in this public health effort could be one of the most effective mechanisms to address
this health care challenge.
Given the lack of research in this area, it is unclear why pharmacies and pharmacists have
not been engaged in this effort. Potential reasons for the lack of pharmacy involvement may
include pharmacists’ lack of awareness of the prevalence of IPV, lack of knowledge of the
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effectiveness of routine screening, lack of training in this area, and logistical barriers to screening
in the pharmacy setting. The only study that has examined this issue indicates that pharmacists
reported receiving no training on domestic abuse intervention, did not feel adequately prepared
to intervene, and were divided based on when they completed their education on whether they
believed this was an important activity for pharmacists to engage in (Ford & Murphy, 1996).
However, this study was conducted nearly 15 years ago. Over the past fifteen years many factors
have changed. First, there has been a significant increase in the public health effort related to
IPV. More importantly however, is the change that has taken place in pharmacy practice. The
practice of pharmacy care has evolved to include a significant public health focus (ASHP
Council on Pharmacy Practice, 2008; Babb & Babb, 2003; Calis KA et al., 2004; Calis et al.,
2004; Calis et al., 2004). Pharmacists are now actively engaged in public health initiatives such
as the provision of vaccinations (Grabenstein, Guess, Hartzema, Koch, & Konrad, 2001).
Pharmacists counsel patients regarding smoking cessation, diabetes management, and offer other
health promotion services (Dent, Harris, & Noonan, 2009; Fuller et al., 2007; Doucette, Witry,
Farris, & McDonough, 2009; Mehuys et al., 2011). Patients have embraced this role for
pharmacists and pharmacists have continued to expand public health activities (Hogue,
Grabenstein, Foster, & Rothholz, 2006). There is evidence to suggest that this expansion can be
an effective method of addressing public health challenges. For example, several studies have
found that pharmacy-based vaccination programs were more cost-effective compared to
traditional medical clinics and had a positive impact on immunization rates in populations that
had not previously been receiving immunizations (Prosser et al., 2008; Grabenstein et al., 2001;
Grabenstein, Guess, Hartzema, Koch, & Konrad, 2002; Steyer, Ragucci, Pearson, & Mainous,
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III, 2004). These findings indicate that community pharmacies can be effective settings to
positively impact the health status of a community.
While other members of the health care team have developed significant efforts related to
IPV interventions, nearly no further work related to pharmacists is evident in the literature.
Currently, there is no recommendation regarding involvement of pharmacists in care related to
IPV. However, community pharmacists serve as an important part of the health care team and
are likely seeing these patients. Given that IPV negatively impacts health behaviors, including
medication compliance (Lopez, Jones, Villar-Loubet, Arheart, & Weiss, 2010; McFarlane et al.,
2010), awareness of and participation in reducing the impact of IPV provides community
pharmacists with an opportunity to positively impact the health and well-being of their patients.
Pharmacists are uniquely positioned to play a pivotal role in health care screenings and patient
education. Just as community pharmacists have participated in other public health initiatives and
women's health programs, they may be an efficient and effective mechanism to widen the net of
IPV screening programs.
Studies have demonstrated that patients support universal screening in the health care
environment. However, no research regarding perceptions of IPV screening in the pharmacy
environment has been conducted. Expanding screening to another setting without evaluation and
planning to understand why it has not been efficiently and effectively adopted in other health
care settings is unwise and a potential waste of resources. Understanding factors such as
pharmacist and consumer perspectives on IPV screening in the community pharmacy
environment are important in determining if it is acceptable and feasible to expand IPV screening
to community pharmacies. To evaluate these issues thoroughly a theoretically-based planning
model is needed.
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Improving IPV Screening Through the Use of a Planning Model
Health Promotion Planning Model: PRECEDE-PROCEED
Thorough planning could shed light on how to effectively develop and implement IPV
screening. Green and Kreuter developed a model for planning and implementing effective health
promotion efforts (Green & Kreuter, 2005). This model, the PRECEDE-PROCEED model, is a
multidimensional framework for developing effective health promotion interventions to attempt
to improve the health and well-being of a population. It is a useful planning process that guides
the assessment of factors necessary for a successful program. In the area of interest in the
current project, IPV screening, PRECEDE-PROCEED may be useful in understanding the
factors that may be causing poor adoption of IPV screening in the health care environment and
could shed light on factors that serve to facilitate and hinder IPV screening in the community
pharmacy environment. It is important to note that the PRECEDE-PROCEED model is an
organizing model that guides the use of other theories to conduct the various steps of assessment.
The PRECEDE acronym stand for Predisposing, Reinforcing, Enabling constructs in
Educational Diagnosis and Evaluation. The PROCEED acronym stands for Policy, Regulatory,
Organizational Constructs in Educational and Environmental Development. The original
framework was developed by Green and colleagues and included only the PRECEDE factors
(Green, Kreuter, Deeds, & Partridge, 1980). The motivation for the development of the model
was that a clear evaluation and diagnosis of societal needs should be made prior to the
development and implementation of an educational intervention. The PRECEDE components
systematically examine factors necessary to identify a need and what factors are critical to the
development of an effective intervention.
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The PROCEED components (policy, regulatory, and organizational constructs in
educational and environmental development) were added to the framework in 1991 (Green &
Kreuter, 1991). The additions were made to adequately represent the importance of
environmental factors as health determinants. PRECEDE-PROCEED was revised in 2005 to
include a genetic component (Green & Kreuter, 2005). Figure 2 includes the complete model.
Since the inception of the model, respect for the people and the context has been the most
important underlying principle of the PRECEDE-PROCEED model. This means that
participation by the relevant community, individuals, or groups that are impacted by the area of
focus in the planning, programming, and evaluation of any intervention is critical.

Figure 2.

The PRECEDE-PROCEED Model

Phase 4
Administrative &
policy assesssment
and intervention
alignment

Phase 3
Educational &
ecological
assessment

Phase 5
Implementation

Phase 6
Process
evaluation

Phase 2
Epidemiological
assessment

Phase 7
Impact
evaluation

Phase 1
Social
assessment

Phase 8
Outcome
evaluation

Figure 2. The PRECEDE-PROCEED Model. Adapted from Green, L.W. & Kreuter, M.W.
(2005). A Framework for Planning. In Health Program Planning (pp 1-23). New York:
McGraw-Hill , p.10. Copyright 2005 by McGraw-Hill.
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In the first phase of the model a social assessment is conducted. This process assesses
the desires of the target population regarding indicators of quality of life. In the second phase an
epidemiological assessment is conducted. This assessment identifies specific health goals or
problems that are relevant to quality of life for the target population. Existing health data is
usually employed in this assessment to identify indicators of morbidity and mortality, risk
factors, incidence, prevalence, distribution, and intensity, among other factors. The
epidemiological assessment clarifies the rationale for the distribution of resources to particular
problems. The epidemiological assessment also identifies the genetic, behavioral, and
environmental determinants of health related to the area of focus. Phase three of the model is an
educational and ecological assessment. Potential ecological causal factors are organized into
three broad groupings – predisposing, reinforcing, and enabling factors. Predisposing factors can
include knowledge, attitudes, beliefs, values, and perceptions. These may either facilitate or
hinder implementation of change in the target area. Reinforcing factors include attitudes and
behavior of health and other personnel, peers, parents, employers, and others. These factors
represent the methods by which the individual will receive reward and feedback for adopting a
behavior. Reinforcing factors may result in encouraging or discouraging the continuation of a
behavior. Enabling factors include the availability of resources, accessibility, referrals, and
skills. Green and Kreuter refer to them as “vehicles or barriers” (Green & Kreuter, 2005).
Enabling factors are usually created by the social system. Examples include having health
insurance or the training to do a specific behavior. Together the factors evaluated in phase three
involve identifying the factors that have a direct impact on the behavioral or environmental
targets that were identified in phases one and two. These provide guidance as to what the most
important areas are to address in intervention development. Importantly, the PRECEDE-
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PROCEED model provides guidance to utilize specific theories in each of the phases of
assessment.
Once phases one, two, and three are completed the process of developing and aligning an
intervention begins. This is done in tandem with an assessment of the administrative and policy
issues related to the targeted area in phase four. In phase five the intervention is implemented.
Phase six consists of a process evaluation that examines the fidelity to the intervention in the
implementation. Phase seven examines the impact of the intervention and phase eight is an
evaluation of the outcome of the intervention.
The PRECEDE-PROCEED model has been used for over thirty years in health program
planning and evaluation. Over the years the model has been well validated as a useful tool that
results in improved programming and resulting outcomes. The model has guided programs from
small, local activities to multinational studies and has been the guiding model for rigorously
evaluated field trials. The authors of the model emphasize that there are four “hallmarks” of the
model. These include (1) flexibility and scalability, (2) evidence-based process and evaluability,
(3) focus on the principle of participation, and (4) process for adapting evidence-based best
practices to a target population (Green & Kreuter, 2005).
The PRECEDE-PROCEED model provides an excellent foundation to examine the
potential role community pharmacists could have in IPV screening. While it is clear that the
U.S. health agenda includes a focus on reducing the impact of IPV on health and quality of life,
additional investigation is needed before screening in community pharmacies is implemented.
There are two critical reasons for need of further investigation in this area. First, it is clear that
IPV screening recommendations and guidelines in other health care professions have not been
successfully implemented and disseminated at the level expected and needed. Second, expansion
16

of IPV screening into the community pharmacy environment would be a complex change to the
current IPV screening programs. The community pharmacy environment has great potential to
overcome some of the barriers of the physician’s office environment, such as availability and
cost to the patient. However, this environment has unique challenges related to lack of privacy
with patients, different provider training models, and uncertainty as to how to address IPV
disclosure. Given these two concerns of poor adoption of IPV screening in other health care
professions and the unique challenges of the pharmacy environment, additional investigation is
warranted to guide any potential guidelines and screening programs in the pharmacy
environment. This planning model is a useful method to organize the research that would assist
in developing an effective intervention. Given this focus on the developmental stage of IPV
screening in the pharmacy environment, this project focuses on the PRECEDE components of
this model. The data and insight gathered from the PRECEDE components are needed before
the PROCEED activities of intervention development, implementation, and evaluation can be
conducted.
Theoretical Terminology
In order to be clear about the use of terminology regarding theories, specific language
will be utilized. PRECEDE-PROCEED is often called a model, a theory, and a framework.
Early in the development of PRECEDE, the authors referred to it only as a framework. A theory
is a set of interrelated constructs that can predict and explain an outcome. They pointed out that
the primary purpose of PRECEDE was not to explain and predict phenomena, but rather to
organize constructs and variables to conduct a systematic planning process. However, as
researchers adopted, implemented, and validated PRECEDE, it was more frequently considered a
model or theory. The use of the term theory to describe PRECEDE-PROCEED comes from the
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idea that it is the set of constructs utilized to develop a logic model for a health promotion
intervention. A logic model details the constructs that explain how a program impacts an
outcome. As such, the logic model is the program theory and thus, PRECEDE-PROCEED is
often labeled a theory. PRECEDE-PROCEED provides guidance as to what theories can be
employed at the various steps to assess each of the components or steps of PRECEDEPROCEED. Thus, PRECEDE-PROCEED could be considered a theory that also guides the use
of additional theories (Lawrence W.Green, 2011; Green & Kreuter, 2005).
In order to reduce confusion, the term model is used in this project when discussing
PRECEDE-PROCEED. The various theories that are utilized in conducting the assessments in
each step of the PRECEDE-PROCEED model are termed theories. Further justification for this
is provided by the authors of PRECEDE-PROCEED whom now utilize the term model to
describe PRECEDE-PROCEED (Green & Kreuter, 2005). For these reasons, the language of
model will be used when discussing PRECEDE-PROCEED and theories when presenting the
theories utilized through the guidance of the PRECEDE-PROCEED model.

Purpose
IPV is a public health problem of epidemic proportions. The best available health care
intervention is routine screening of patients for exposure to IPV; however, IPV screening has not
been widely adopted and implemented. Additional venues for screening warrant investigation.
The purpose of this study is to investigate the potential role of community pharmacies in the
public health initiative to reduce the impact of interpersonal violence by significantly increasing
screening and referral of victims of interpersonal violence. To examine this possibility, this
proposal will utilize the PRECEDE-PROCEED model to guide the assessment of factors that
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may predispose, reinforce, or enable IPV screening in the community pharmacy setting.
Specifically, this study will:
1. Investigate community pharmacists’ readiness to participate in IPV screening, including
examining training, knowledge, attitudes, behaviors, and intentions related to IPV
screening by developing and testing an instrument adapted from an existing instrument
named the PREMIS (Physician Readiness to Manage Intimate Partner Violence Survey)
tool.
2. Examine potential demographic differences in intention to conduct IPV screening among
pharmacists.
3. Examine perceptions of the characteristics of the IPV screening innovation in community
pharmacies.
4. Examine female consumer’s attitudes and preferences for IPV screening in community
pharmacies.
The results of this study will assist in determining whether community pharmacies are an
appropriate place to conduct IPV screening, and if so, will provide tools and data to inform the
development of screening programs that will be effectively and efficiently adopted for
dissemination.
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2. BACKGROUND

Employing PRECEDE-PROCEED in Planning IPV Screening in Community Pharmacies
Interpersonal violence is a problem of epidemic proportion in the United States. The
health care system has the opportunity and responsibility to assist in ameliorating the negative
health impact of this epidemic. The most effective method available to do this is routine and
regular screening of patients for IPV exposure. This intervention has not been widely adopted
and implemented. Consideration of additional opportunities for screening is one potential way to
reduce the impact of IPV. A thorough planning process should be conducted before expansion
of IPV screening is recommended in order to improve the likelihood that a positive, successful
intervention can be developed and implemented. As discussed in Chapter 1, the PRECEDEPROCEED planning model is a useful tool in developing and implementing health programs.
The model has been used extensively over several decades. In this project assessment of factors
associated with IPV and IPV screening are the focus of the various assessment phases in the
PRECEDE-PROCEDE model.

Phase 1:

Social Assessment

Phase 1 of the PRECEDE-PROCEED model includes an assessment of the social
environment. One of the hallmarks of the model is participatory research, including community
engagement. In conducting the phase 1 social assessment, understanding the community’s needs
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and interest is key. The national health agenda is established through federal government efforts,
such as the Surgeon General, the Healthy People plans, and reports commissioned from the
Institute of Medicine. Interpersonal violence has been identified as a critical health problem for
many years, indicating that this is an area that the nation has a desire to focus on and address.
National Call for IPV Prevention and Intervention Efforts
Given the high prevalence and significant health harms associated with IPV, many health
care groups have called for action related to this public health problem. Nearly every national
health care organization and professional group has called for routine screening of IPV in health
care settings. As described in chapter one, treatment guidelines have been issued from groups
such as the American Medical Association, the American College of Obstetrics and Gynecology
(American College of Obstetricians and Gynecologists, 1995), and the American Academy of
Pediatrics (American Academy of Pediatrics, 1998), among others. The U.S. Surgeon General
accepted the recommendations of the Institute of Medicine in 2011 to include screening and
counseling as a routine part of preventive care for women (Institute of Medicine, 2011).
These recommendations have been made with the intention to reduce the negative health
impact of IPV before physical injuries result by assisting individuals with the process of getting
away from a partner who is harming them. Women who have experienced IPV see a greater
number of health care providers and use health services at a higher rate compared to non-abused
women (Koss et al., 1991; Bonomi et al., 2009). This increased health care utilization rate
makes universal screening in the health care environment one of the most promising methods of
identifying and assisting a large numbers of IPV exposed patients. Screening has been shown to
be effective at reducing the harm associated with IPV. Routine and regular screenings by skilled
health care providers has been shown to significantly increase the identification of IPV
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(McFarlane et al., 1991; McFarlane et al., 1992; Sisley et al., 1999). Having an IPV screening
program that documents and refers IPV positive women in a family medicine setting has been
shown to increase IPV positive women’s intention to disclose exposure (Zeitler et al., 2006a).
Importantly, surveys of women who have disclosed IPV exposure found that the majority who
had successfully ended the violence had sought help from health professionals. These women
reported health care professionals as their number one source of help, even greater than the
police and the legal system (Brendtro M & Bowker L, 1989). This finding is not surprising
given that several studies have demonstrated a significant decrease in violence and a significant
increase in safety behaviors after screening and referral of individuals identified as IPV exposed
(McFarlane et al., 2006; Krasnoff & Moscati, 2002; McFarlane et al., 2005; McFarlane et al.,
1998; McFarlane et al., 2000). IPV screening and referral programs were found to be at least as
effective as intensive counseling interventions in a review by McFarlane and colleagues
(McFarlane et al., 2000). These authors concluded that abuse screening itself may be the most
effective intervention (McFarlane et al., 2000).
The social assessment conducted as phase one of the PRECEDE-PROCEED model
indicates that the national health community desires to reduce the harms associated with IPV. It
is further clear that the most effective method for improving the health and well-being of those
exposed to IPV is to conduct routine screening for IPV. The PRECEDE-PROCEED model
recommends that if community-established goals and objectives are clear, then phase two,
epidemiological assessment is the next step in planning an effective intervention.
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Phase 2:

Epidemiological Assessment

Phase two of the PRECEDE/PROCEED model gathers the epidemiological data related
to the health area of interest. These data are important to be clear about the etiology of the area
of interest. Epidemiological data provides the evidence to set priorities and objectives in health
program planning. The epidemiology of interpersonal violence indicates that it is a highly
prevalent exposure that has a substantial negative health impact. An additional component of the
epidemiology is the penetration rate of the main intervention for IPV exposure, IPV screening.
Epidemiology of Interpersonal Violence
Data Sources
Interpersonal violence is one of the most widespread public health problems in the United
States. Ongoing surveillance of IPV has not been routinely conducted, however a number of
studies and national surveys have been completed to estimate the prevalence of IPV. The
National Intimate Partner and Sexual Violence Survey (NISVS) is a new survey that is being
utilized to track progress on the Healthy People 2020 IPV objectives. The NISVS was launched
in 2010 and was developed and fielded with support from the National Institute of Justice and the
Department of Defense. The goals of the survey are to describe the prevalence and
characteristics of IPV, to understand who is most likely to experience this kind of violence, to
examine the patterns and impact of IPV experienced by particular types of perpetrators, and to
estimate the health consequences of IPV. The survey was completed as a national random digit
dial phone survey (utilizing both landline and cell phone numbers) in the 50 states and the
District of Columbia in 2010 (Black et al., 2011). The last available national estimates of IPV
were from the National Violence Against Women Survey conducted by the National Institutes of
Justice in 1995-6 (Tjaden & Thoennes, 2000). Other federal data sources for estimates of IPV
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prevalence in the United States include the Behavioral Risk Factor Surveillance System (7 IPV
items), the National Violent Death Reporting System, the National Survey of Family Growth, the
Pregnancy Risk Assessment Monitoring System, and the National Crime Victimization Survey
(Centers for Disease Control and Prevention, 2010).
Prevalence
The 2010 National Intimate Partner and Sexual Violence Survey found that each year
women experience 5.4 million intimate partner related physical assaults and rapes (Black et al.,
2011). This represents 4.6% of women, with an additional 4.7% of men, experiencing intimate
partner physical assaults in the previous 12 months. Stalking is experienced by 2.8% (3.4
million) of U.S. women and 0.5% (519,000) U.S. men each year (Black et al., 2011). Lifetime
exposure rates indicate that at least more than a third of all U.S. women experience IPV at some
point in the lives. The National Intimate Partner and Sexual Violence Survey found that 35.6%
of women, compared to 28.5% of men, reported physical assault, sexual assault, or stalking by an
intimate partner in their lifetime (Black et al., 2011). These rates are higher than previously
reported from the National Violence Against Women Survey in 2000, which found that 25.5% of
women, compared to 7.9% of men, reported physical or sexual assault by an intimate partner in
their lifetime (Tjaden & Thoennes, 2000). A 1998 Commonwealth Fund survey found that 31%
of U.S. women report being physically or sexually abused by a husband or boyfriend at some
point in their lives (Collins, Schoen, & Joseph, 1999). Studies in health care settings have
identified even higher lifetime prevalence rates, as high as 50-55% of women reporting IPV
exposure (Duffy, McGrath, Becker, & Linakis, 1999; Bauer, Rodriguez, Quiroga, & FloresOrtiz, 2000; Coker, Smith, McKeown, & King, 2000). Rates are high even in privately insured,
employed women. A study conducted in a large U.S. health maintenance organization of stable
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female members (enrolled for 3 or more years) found a five year prevalence of 14.7% and 44.0%
lifetime prevalence (Thompson et al., 2006).
The impact of IPV is substantial. The National Intimate Partner and Sexual Violence
measured the impact of IPV on victims. IPV-related impacts measured included: being fearful,
concerned for safety, post-traumatic stress disorder (PTSD) symptoms, injury, needed medical
care, needed housing services, needed victim’s advocate services, needed legal services,
contacted a crisis hotline, missed at least one day work/school, contracted a sexually transmitted
disease, or became pregnant. Of female victims, 80.8% reported experiencing at least one of the
measured impacts. While psychological impacts were felt by many (72.2% were fearful, 62.3%
were concerned for their safety, and 62.6% experienced PTSD symptoms), a substantial number
also experienced physical harm. Nearly 42% were injured, 4.3% contracted a sexually
transmitted disease, and 4.8% became pregnant. These high injury rates are troubling. The
National Violence Against Women Survey found that assaults by intimate partners are
significantly more likely to result in injury compared to assaults by another type of perpetrator
(Tjaden & Thoennes, 2000). The lifetime prevalence of needing medical care for IPV-related
injuries is 22.1%, bringing more than 9 million women to a health care provider for IPV-related
injuries in their lifetime (Black et al., 2011). IPV can also be fatal. The Department of Justice
reports that 14% of all homicides in the U.S. are committed by intimate partners. In 2007 2,340
intimate partner homicides were committed and approximately 70% of the victims were women
(U.S.Department of Justice, 2012; 2012).
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Health Impact of IPV
Physical Health
The health impact of IPV is substantial and confers a health risk that is comparable to or
greater than many traditional risk factors such as obesity and smoking. A study conducted in
Victoria, Australia among women aged 18-44 using a burden of disease methodology found that
IPV was directly responsible for 7% of the overall burden of disease. IPV was responsible for
more disease burden than elevated blood pressure, tobacco use, and increased body weight (Vos
et al., 2006). Physical injuries from IPV can be as minor as cuts and scrapes and as serious as
broken bones, gun or knife wounds, organ damage, and even death (Tjaden & Thoennes, 2000).
Lifetime risk of severe injury as a result of IPV has been estimated to be 9% for women, with a
lifetime risk of up to 22% for any type of injury from IPV (Wilt & Olson, 1996). Guth and
Pachter found that 35% of emergency room visits, 50% of all acute injuries, and 21% of all
injured women requiring urgent surgery were the result of partner violence (Guth & Pachter,
2000). By 1989 violence had surpassed falls as the leading cause of injury in women (Grisso et
al., 1999). In addition to acute injury, immediate health impacts also include sexually
transmitted diseases, including HIV infection, pregnancy, and pelvic inflammatory disease.
Pregnant victims are more likely to enter prenatal care late, have pregnancy complications,
preterm births, and low birth-weight births (McFarlane et al., 1992; Bonomi, Anderson, Rivara,
& Thompson, 2007; Cokkinides, Coker, Sanderson, Addy, & Bethea, 1999; Berenson, Wiemann,
Wilkinson, Jones, & Anderson, 1994). Long-term health impacts of IPV exposure include
traumatic brain injury and neurological disorders resulting from injuries, gastrointestinal
disorders, central nervous system disorders, gynecological disorders, and the exacerbation of
chronic medical conditions such as cardiovascular disease, fibromyalgia, and asthma (Crofford,
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2007; Leserman & Drossman, 2007; Drossman, Talley, Leserman, Olden, & Barreiro, 1995;
Drossman, 1997; Breiding, Black, & Ryan, 2008; Corrigan, Wolfe, Mysiw, Jackson, & Bogner,
2003; Coker, Hopenhayn, DeSimone, Bush, & Crofford, 2009; Black et al., 2011). IPV has been
shown to have a negative effect on protective health behaviors such as medication adherence and
continuation of cancer therapies (Alexander R.W. et al., 1998; Lopez et al., 2010; Coker, Bond,
& Pirisi, 2006). Women recognize the health impact of IPV, as victims are more likely to define
their health as “fair” or “poor” and to say that they had needed medical care but did not get it
(Bonomi et al., 2006; Plichta, 2004; Alsaker, Moen, Nortvedt, & Baste, 2006). A recent study
found an association between cervical cancer and IPV, indicating that there may be a wider range
of health harms associated with IPV that have yet to be investigated (Coker et al., 2009).
Mental and Behavioral Health
IPV has a negative impact on mental health as well. Victims of IPV have increased rates
of depression, suicidal behavior, anxiety disorders, post-traumatic stress disorder, sleep
disturbances, substance abuse, and antisocial behavior (Bergman & Ericsson, 1996; Rivara et al.,
2009; Davis, Coker, & Sanderson, 2002; Coker et al., 2002). The negative impact of IPV on
health can also be exacerbated by the perpetrator restricting the victim’s access to health care
services, either completely or through supervising health care visits (Plichta, 2004; GarciaMoreno, 2002a). Women with a history of IPV are more likely to engage in negative health
behaviors, with studies indicating that the more severe the violence, the greater the likelihood
that the victim will engage in negative health behaviors. Harmful substance use, such as
smoking, excessive alcohol use, driving while intoxicated, and illegal drug use, is greater in
women exposed to IPV (Bonomi et al., 2006; Plichta, 2004). Victims are also more likely to
engage in risky sexual (i.e., multiple sex partners, unprotected sex) (Coker, 2007) and dietary
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(i.e., vomiting, fasting, overeating) behaviors (Ackard & Neumark-Sztainer, 2002; Baldo &
Baldo, 1996; Baldo, Wallace, & O'Halloran, 1996; Gidycz, Orchowski, King, & Rich, 2008).
Special Populations
Of particular concern are vulnerable populations, including pregnant women. There is
ample evidence that IPV increases during a pregnancy (McFarlane, Parker, & Soeken, 1996).
Each year an estimate 324,000 pregnancy women are exposed to IPV (Gazmararian et al., 2000).
IPV in pregnancy is more common than gestational diabetes or preeclampsia (Parsons, Goodwin,
& Petersen, 2000). One study found that 17% of pregnant women had been exposed to IPV in
the previous 12 months (McCloskey et al., 2005). While pregnancy can serve as a general
stressor that might exacerbate negative behaviors, an additional reason for the increase may be
related to the loss of control over the victim’s body as the pregnancy develops (Campbell et al.,
2003). Homicide is the leading cause of pregnancy-associated deaths, responsible for 13-24% of
deaths in pregnancy, most by intimate partners (Greenfield, Rand, & Craven, 1998; Rennison,
2003).
Family Impact
IPV negatively impacts the whole family. It is estimated that more than 3 million
children witness IPV each year (Gelles RJ, 1987). A review of studies examining IPV and child
maltreatment found that they co-occur in 45-70% of studies, with IPV usually preceding the
onset of child abuse (Holt, Buckley, & Whelan, 2008). Children of abused mothers are more
likely to die before the age of five, to have higher rates of certain illnesses, and to have lower
rates of immunization (Silverstein, Conroy, & Sandel, 2008). Witnessing violence negatively
impacts the development of children and is associated with greater emotional, social, cognitive,
academic, and behavioral problems (Wolfe, Lobozzo, Frye, & Sharp, 2003; Kolbo, 1996). Child
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abuse has life-long implications, impacting involvement in IPV as an adult and even obesity in
adulthood (Alvarez, Pavao, Baumrind, & Kimerling, 2007; Cannon et al., 2009). IPV
prevention programs are critical to reducing the short and long-term impact of IPV on children
(Carter, Weithorn, & Behrman, 1999).
Economic Impact of IPV
Multiple studies have documented elevated health care utilization and costs for women
with a history of IPV. The economic cost of IPV in the United States was estimated to be more
than $5.8 billion per year in 1995, with $4.1 billion in health care services, and the remaining
costs attributable to lost productivity and earnings (National Center for Injury Prevention and
Control, 2003). When updated to 2003 dollars, the CDC estimated that IPV costs exceeded $8.3
billion, include $6.2 billion for physical assault, $460 million for rape, $461 million for stalking,
and $1.2 billion in the value of lost lives (Max, Rice, Finkelstein, Bardwell, & Leadbetter, 2004).
An investigation of total annual health care costs for women in a managed care indicate that
costs for women experiencing IPV are significantly higher (42% higher) than never-abused
women. Interestingly, this study found that a prior history of abuse, even if abuse ceased more
than five years ago, was associated with higher health care costs, indicating that IPV has a longlasting impact on health status and health care utilization (Bonomi et al., 2009). Women
experiencing non-physical abuse (stalking or psychological abuse) have also been found to have
significantly more prescription fills and higher pharmacy costs compared to women who have
never been abused (Rivara et al., 2007a; Bonomi et al., 2009). Two studies found that IPV
exposure is one of the most powerful predictors of physician visits and outpatient care for
women (Koss et al., 1991; Bergman & Brismar, 1991). The CDC estimates that more than
971,000 outpatient physician visits, 232,000 dental visits, 1 million physical therapy visits,
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807,000 overnight hospital stays, 486,000 ED visits, 320,000 outpatient hospital visits, and
95,000 ambulance calls each year are directly due to IPV. Increased utilization and cost for
women exposed to IPV is a clear burden on the health care system. The economic impact of IPV
extends beyond the health care system. For example, women who have experienced severe
aggression by partners are more likely to have periods of unemployment and to be receiving
public assistance (Kimerling et al., 2009; Yancey, Gabel-Hughes, Ezell, & Zalkind, 1994;
Zorrilla et al., 2010). A 2005 study found that women experiencing IPV reported an average of
7.2 days of lost work productivity and 33.9 days in productivity losses associated with other
activities (Arias & Corso, 2005).
Studies have also documented significantly higher health care utilization and costs for
children whose mothers experienced IPV, even if the abuse stopped before the children were
born (Rivara et al., 2007b). Children exposed to IPV in their homes had a greater use of
emergency room care and primary care. These children were also three times more likely to use
mental health services compared to children who had not been exposed (Campbell &
Lewandowski, 1997). Children whose mothers had a history of IPV that ended prior to the
child’s birth had a greater utilization of mental health, primary care, specialty care, and
pharmacy services compared to children whose mothers had no IPV history (Rivara et al.,
2007a).
Gender and IPV
It is evident that IPV is more prevalent in women compared to men. Further, the vast
majority of research in this area has been conducted with female populations. There is little
research about IPV in men and the immediate health impact, the long term health and economic
impact, or health care utilization patterns and costs. Importantly, many of the recommendations
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and guidelines from professional associations only address female patients. The literature
regarding screening practices, acceptability, and effectiveness only addresses female patients.
Given the lack of guidance regarding the need for IPV screening in men, the lack of tools
validated with male patients, the absences of professional guidelines in other health care areas to
screen men, and any literature documenting the acceptability or effectiveness of screening men
in health care settings, this project will focus on IPV screening only in female patients.
Epidemiology of IPV Screening
Routine, universal screening for IPV in female patients is an evidence-based treatment
recommendation included in the standards of care for many health care professionals. However,
most investigations have found that IPV screening is not widespread and has been poorly
adopted and implemented in practice settings. Research has documented differences in IPV
screening rates that differ according to the specialty of the provider. Primary care and
emergency room IPV screening rates are estimated to be between 1.5-30% (Plichta, 2004; Coker
et al., 2002; Daugherty & Houry, 2008; McGrath et al., 1998). A major push for screening by
the professional association for obstetrician-gynecologists has resulted in screening rates in the
rage of 10-39% (Bunn et al., 2009; O'Reilly et al., 2010). Studies consistently show that the
majority of health care providers are not following professional recommendations for universal
screening (Bunn et al., 2009). In pediatrics, a study found that only 4.2% of practices had
protocols in place despite specific policy statements and guidelines regarding IPV screening
from the American Academy of Pediatrics (Wright et al., 1997).
Despite evidence from women who have successfully left abusive relationships that
health care providers are the most important resource for victims (Fishman et al., 2010; Brendtro
M & Bowker L, 1989), research shows that health care workers identify far fewer cases than are
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described by surveys or police (Cann et al., 2001). These findings indicate that additional
screening opportunities are needed to achieve routine screening for all patients.
The phase two assessment of the epidemiological data regarding IPV and IPV screening
indicate that IPV is highly prevalent and that there is a substantial threat to health and well-being
from IPV exposure. Further, IPV screening has not been widely adopted and disseminated. This
adoption failure is a critical problem as screening is the only known intervention to implement
with IPV victims. The phase three assessment will examine predisposing, reinforcing, and
enabling factors that influence screening. Factors that influence both the behavior of
practitioners and the environment, such as patient acceptability and logistical barriers, are
assessed in phase three.

Phase 3:

Educational and Ecological Assessment

Phase three of the PRECEDE-PROCEED model calls for assessment of the educational
and ecological environment. Specifically, this phase conducts an examination of factors that
predispose, reinforce, and enable intervention by directly impacting behavior and the
environment. In the area of IPV screening, examination of factors that predispose, reinforce, and
enable screening are the focus.
Key Determinants of Screening
Patient-Level Factors
While substantial barriers exist to screening for IPV, most studies have found that both
patients and clinical care providers are comfortable with screening methods. A 2007 study by
Chen and colleagues investigated multiple methods of screening (self-administered, medical
staff-administered, physician-administered) and found that the rates of IPV disclosure were
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similar across all three methods of administration (Chen et al., 2007). The majority of patients
(93.4%) reported being comfortable with the screening. Those with a positive screen were less
comfortable with the medical staff screening. The time spent screening was similar among the
three methods (ranged from 2 to 15 minutes). Survey research with patients suggests that
interactive computer-based screening can achieve higher rates of disclosure compared to
personal interviews for sensitive topics (Turner CF, Ku L, & Rogers SM, 1998). A 2007 review
of screening methods found that computer-assisted screening may identify a higher prevalence of
IPV compared to written and interview screening methods (Renker & Tonkin, 2007). There is
some evidence to suggest that computerized screening is both acceptable and potentially
preferable to patients (Wathen & Macmillan, 2008). Renker and Tonkin identified a number of
advantages to computer-assisted screening (Renker & Tonkin, 2007). Advantages for patients
include increased privacy, the ability to tailor the screening tool to fit patient characteristics, the
ability to use audio streaming for low-literacy populations, and the ability to display resources in
a confidential manner. Additionally, computer-assisted screening can provide clear information
about mandatory reporting requirements. Victims may fail to disclose because of concern that
the information will be reported to the authorities (which is required in only a few states).
Knowledge of the mandatory reporting requirement (or lack thereof) gives victims full control
over their decision to disclose, and may subsequently increase IPV disclosures which can result
in increased support and provision of resources (Renker & Tonkin, 2006; Phelan, 2007).
Advantages for providers include reduction in time required, low-cost, consistency in screening,
accuracy and completeness of information, and enhanced patient comfort (Rhodes et al., 2006).
While there are significant patient-level concerns (i.e., comfort, safety) regarding IPV
screening in the health care environment, patients are clearly receptive to screening (Stenson,
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Saarinen, Heimer, & Sidenvall, 2001). In fact, failure to communicate with patients regarding
IPV may have negative consequences. Plichta found that IPV exposed women were significantly
less satisfied with their physicians and poor communication was one of the primary reasons for
this dissatisfaction (Plichta, 1996). A study by Zeitler and colleagues found that 95% of women
in a women’s health clinic reported that they would not mind a health care provider asking them
about exposure to violence (Zeitler et al., 2006b). Health care providers were preferred over
others such as mother, father, social worker/counselor, coach, or other family member. In this
same study 90% of the women reported that they believe that every patient should be screened
for IPV. This changed only slightly for women currently experiencing IPV, with 70% of them
reporting they supported universal screening (Zeitler et al., 2006b). Chang found that when IPV
information and posters were displayed, IPV exposed patients felt that the health care provider
was a safe person to talk to about abuse (Chang, Theodore, Martin, & Runyan, 2008).
Qualitative studies of women who have escaped abuse indicate that even brief physician
conversations can be helpful (Gerbert, Abercrombie, & Caspers, 1999). Caralis and
Musialowski found that the majority of abused women (74%) wanted their physician to ask
about IPV exposure, and 68% would report IPV if asked (Caralis & Musialowski, 1997). IPV
victims have reported that they would support laws requiring a physician or nurse to screen for
IPV because it would facilitate securing help to end the abuse (Malecha et al., 2000). A key
determinant of IPV screening is patient acceptability and the literature clearly demonstrates that
patients find it not only acceptable, but desire it.
Despite this, there are patient-level barriers to IPV screening. Patient-level barriers for
routine screening in the pediatric setting have been a fear of being reported to child protective
services, need for immediate resources, a belief that the child’s care comes first, and a lack of
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staff empathy (Dowd, Kennedy, Knapp, & Stallbaumer-Rouyer, 2002). Other patient-level
factors that hinder disclosure include embarrassment, concerns about police involvement, fear of
perpetrators retaliation, fear of perpetrators direct intervention to stop access to care,(Rodriguez,
Ryan, Rowan, & Foy, 1996; Rodriguez, Quiroga, & Bauer, 1996) desire to keep family together
(Rodriguez et al., 1996), belief that physicians are too busy (Rodriguez et al., 1996), and lack of
trust in the health care provider (Bauer et al., 2000). An overview of qualitative studies done
regarding acceptability of IPV screening from the patient’s perspective identified ten first-order
constructs and four second-order constructs (see Table 2) (Feder et al., 2009). The constructs
identified are similar to what has been found in quantitative studies. Studies of patients’
perspectives of IPV screening have been conducted in a number of settings and about various
providers but have not been conducted regarding pharmacies and pharmacists. Patients’
perspective about IPV screening by pharmacists is unknown.
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Table 2.

Patients’ Perspectives on Intimate Partner Violence Screening – First &
Second-Order Constructs

First-Order Constructs
Women find screening beneficial even if they are not ready to disclose.
Women gain a sense of support and relief from discussing their situation with someone.
Screening may be more acceptable to women where there is already an established
relationship with the health-care professionals.
Screening may be more acceptable to women if the health care professional’s manner is
compassionate and non-judgmental.
Women are concerned that health care professionals do not have the time to listen to them
and discuss their situation; screening women for IPV may lead to women disclosing abuse,
and may facilitate the woman leaving the relationships or seeking help.
Women expressed concerns about potential negative repercussions of screening: break of
confidentiality, the involvement of children’s services, legal repercussions, being judged.
Screening may be more acceptable to women when given a reason for screening.
Acceptability of screening may vary depending on whether the screening is conducted
face-to-face or by written questionnaire; acceptability of screening may depend on the
gender and the profession of the health care professional.
Second-Order Constructs
Women believe the primary aim of screening should be education rather than eliciting
disclosure.
Screening is generally acceptable to women.
Certain factors increase acceptability of screening: health care professionals manner;
being asked in a safe and confidential environment; giving a reason for asking; not
pressuring women to disclose; and the quality of the relationship the women has with the
professional.
Concerns about lack of time, potential breach of confidentiality, and fear of involvement of
child protective services.
Note: Adapted from “How far does screening women for domestic (partner) violence in different
health care settings meet criteria for a screening program?” by G. Feder, J. Ramsay, D. Dunne,
M. Rose, C. Arsene, R. Norman, et al., 2009, Health Technol.Assess., 13(16), p. iii-xiii.
Copyright 2009 by Crown.
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Provider-Level Factors
As with patient perspectives, there is a lack of research examining potential providerlevel factors in the community pharmacy setting. However, a number of qualitative and
quantitative studies have been conducted with physicians to examine areas of concern related to
IPV screening. Studies conducted with other providers, such as nurses, midwives, dentists, and
chiropractors, have identified similar concerns (Johnston, 2006; Hindin, 2006; Bacchu, Mezey,
& Bewley, 2002; Shearer, Forte, Dosanjh, Mathews, & Bhandari, 2006; Love et al., 2001). It
may be that similar attitudes and areas of concern would be applicable to pharmacists as well.
Provider Attitudes
Attitudinal barriers to IPV screening that have been identified include a belief that IPV is
a personal situation that should remain between partners, discomfort due to personal experience
with IPV, concern that it is an overwhelming social issue, frustration with patients unwillingness
to discuss violence, and fear of offending patients (Rittmayer & Roux, 1999; Bates & Brown,
1998; Chamberlain & Perham-Hester, 2000). Studies regarding physician attitudes about IPV
screening indicate that physicians may hold negative attitudes toward victims. Specifically,
physicians have reported that it is not their place to intervene, violence is a family matter, it is
not a health issue, violence doesn’t occur in the socio-economic group that they care for, and that
patients may be offended if asked about abuse (Parsons, Zaccaro, Wells, & Stovall, 1995;
Saunders, Hamberger, & Hovey, 1993; Sugg, Thompson, Thompson, Maiuro, & Rivara, 1999;
Cullinane, Alpert, & Freund, 1997; Friedman, Samet, Roberts, Hudlin, & Hans, 1992; Reid &
Glasser, 1997). One study found a high prevalence of victim-blaming beliefs, with 55% of
physicians reporting that they believed that their patients’ personalities lead them to being abuse
and 34% reported that they believed that the victim must be getting something out of the
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relationship or she would leave (Garimella, Plichta, Houseman, & Garzon, 2000). Physicians
have also reported feeling uncomfortable or unable to diagnose or follow-up victims of IPV
(Sugg et al., 1999), personal discomfort due to a personal history with IPV (Sugg et al., 1999;
Rodriguez, McLoughlin, Bauer, Paredes, & Grumbach, 1999; McGrath et al., 1997), and
frustration that screening is futile because victims will not accept help (Parsons et al., 1995;
McGrath et al., 1997). Provider characteristics, such as male gender, older, and more years in
practice have been associated with greater victim-blaming characteristics and lower rates of
screening (Garimella et al., 2000). Nurses, women, and community mental health workers have
been found to have significantly more positive attitudes and knowledge (Cann et al., 2001).
Provider specialty has also been linked to attitudes and knowledge, with obstetricians and
psychiatrists reporting fewer victim-blaming beliefs and more awareness of resources to assist
IPV victims. Positive attitudes are not enough, as even those reporting generally positive
attitudes toward IPV, indicate that they are not comfortable talking about it (Cann et al., 2001).
Nevertheless, most providers report that in general IPV screening is part of a health care
providers role (Berger, Bogen, Dulani, & Broussard, 2002).
Provider Knowledge and Training
Barriers related to provider knowledge have also been documented. These include lack
of formal training or education about IPV (Sugg et al., 1999), lack of awareness that IPV is
present in their population (Rittmayer & Roux, 1999; Rodriguez, Bauer, McLoughlin, &
Grumbach, 1999), and lack of knowledge of referral resources (McGrath et al., 1997). Lack of
training in IPV allows provider stereotypes of abuse victims to guide any screening (Gremillion
& Kanof, 1996). One study demonstrated that among women experiencing IPV, women who
were Caucasian were significantly more likely to have their IPV status documented (Coker,
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Pope, Smith, Sanderson, & Hussey, 2001). Failure to appropriately train health care providers
and to have a standardized screening protocol could be contributing to health disparities in IPV.
Two of the most frequently reported knowledge-level barriers that have been identified include a
general lack of training (Sugg et al., 1999; Gadomski, Wolff, Tripp, Lewis, & Short, 2001;
Lapidus et al., 2002) and lack of awareness of appropriate referrals (Garimella et al., 2000).
Other knowledge-deficits that have been identified include lack of access to information about
the management of IPV (Centers for Disease Control and Prevention, 1998).
System-level Barriers
System-level barriers have also been cited by providers as presenting a challenge to IPV
screening in the health care setting. These barriers include lack of time, lack of collegial support,
lack of provider continuity, lack of referral resources, and legal concerns (Rodriguez et al., 1999;
McGrath et al., 1997; Parsons et al., 1995; McGrath et al., 1997; Sugg et al., 1999; Lapidus et al.,
2002; Gerbert, Caspers, Bronstone, Moe, & Abercrombie, 1999).
Phase 3 Assessment Summary
Clearly there are factors that support and hinder IPV screening by health care providers.
Table 3 summarizes these factors. It is important to note that for some of these factors, they
likely do not currently exist for many health care providers and are thus an appropriate target
area for intervention. For example, many practitioners lack knowledge and training in how to
screen for IPV. Developing and implementing continuing education programs to address this
would be an appropriate step to address this factor. It is clear that there are some areas about
which further research is needed to better assess both provider and consumer-level factors related
to IPV screening.
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Table 3.

Predisposing, Reinforcing, and Enabling Factors Related to Intimate Partner
Violence Screening

Predisposing
Knowledge: provider must have knowledge of IPV harm and how to screen
Attitudes: provider must have positive, supportive attitude about screening
Beliefs/Values: provider must believe IPV is wrong
Perceptions: provider must believe screening is helpful and that it is possible to help
victims
Reinforcing
Attitude of peers: professional guidelines/recommendations supporting IPV screening
Attitudes of patients: patients find screening acceptable, preferable
Enabling
Availability of Training: provider must receive training in how to screen
Availability of Screening Tools: adequate, appropriate screening tools must be available
Availability of Referrals: community resources must be available to refer victims to
Practice Rules: requiring documentation of screening for all patients
Skills: provider must be capable and confident in ability to conduct screening

Measuring Provider-level Factors
The assessment reported above is based on what has been reported in the literature to
date. Unfortunately, most of the studies that have investigated provider-level factors involved in
IPV screening have developed their own surveys and have not validated the measures. It is
difficult to develop successful educational and training programs to build skills and improve
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confidence in screening abilities without a validated tool to better understand health care
providers’ educational needs and to assess training program outcomes. At least three studies
have tried to systematically investigate provider-level factors such as these by developing sound
measures. The first study investigating factors influencing health care provider identification
and response to IPV found eight constructs related to whether routine inquiry was conducted.
These constructs were: preparedness, self-confidence, professional supports, abuse inquiry,
practitioner consequences of asking, comfort following disclosure, practitioner lack of control,
and practice pressures. Preparedness appeared to be the most important construct for initiating
IPV screening. This study shed light on critical barriers, namely inadequate preparation, to a
universal screening program (Gutmanis, Beynon, Tutty, Wathen, & Macmillan, 2007b).
The second study developed a tool for measuring physician readiness to manage IPV.
The instrument, developed and validated by Short et al. in 2006 (Short, Alpert, Harris, Jr., &
Surprenant, 2006), is the PREMIS (Physician Readiness to Manage Intimate Partner Violence
Survey) tool. This instrument was developed to address the lack of a tool that assessed
knowledge, attitudes, and beliefs using current IPV literature as the standard and to assess selfreported practice behaviors related to IPV. PREMIS is a 67-item 15 minute comprehensive
survey that measures a physician’s preparedness to manage IPV patients. The tool examines
knowledge, attitudes, beliefs, and self-reported behaviors. The survey items were developed by
a review of existing survey tools in the literature. A content analysis was conducted through
review by an outside group of IPV educators. The review group was asked to choose from the
existing items or to develop new items that reflected theoretical constructs and measured core
IPV educational outcomes based on the literature. The characteristics of the instrument were
evaluated in two separate populations of physicians. The initial study sample was 166
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physicians who were subscribers of a continuing medical education website. A revised version
of the survey instrument was then tested with a group of 67 primary care physicians. The scale
was found to have six good-fit factors (see Table 4 for scales and alpha coefficients). Two
additional opinion scales (constraints and victim autonomy) were utilized during the instrument
development for future testing, but not used in the final version of the instrument. PREMIS was
shown to be reliable and valid, sensitive to change, and capable of discriminating trained from
untrained providers (Short et al., 2006). Construct validity checks included evaluation of the
Rand coefficient for the relationship between the empirically derived scales and the objective
values assigned to the original theoretical constructs developed by the expert panel. The Rand
coefficient was 0.89, indicating a high degree of association between the original theoretical
constructs and the empirically derived scales. A second method of evaluating construct validity
was to examine the correlation between instrument scales which were related. For example
actual knowledge was correlated with perceived knowledge as expected. A third measure of
construct validity examined the extent to which self-evaluated knowledge, attitudes, and beliefs
predicted self-reported behaviors. This analysis found significant correlation between scores on
practice issues, all background scales, actual knowledge, and six of the eight opinion scales
(alcohol/drugs and victim autonomy were not significantly associated with practice issues). An
external validity study conducted site visits to physicians’ offices and compared observed
practice activities to reported practice activities related to IPV and found a high correlation
between the two. When the instrument was given to the second study sample, the psychometric
properties of the tool were consistent between the two groups of providers.
Two other studies have utilized the PREMIS scale. The first adapted it for use in a
population of students in medicine, nursing, social work, and dentistry (Connor, Nouer, Mackey,
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Tipton, & Lloyd, 2011). A factor analysis of the adapted student PREMIS instrument identified
six of the eight factors identified in the original PREMIS instrument (see Table 4). The
Workplace Issues and the Constraints scales were not identified, which was expected as this was
a student population. The adapted measure found a new scale, IPV screening, that had good
reliability (α =0.74).

The Connor et al. study demonstrates that the PREMIS scale can

successfully be modified for use in other provider groups in addition to physicians. The second
study translated the PREMIS instrument into another language (Greek) and tested it in a sample
of primary care physicians in Greece (Papadakaki, Prokopiadou, Petridou, Kogevinas, & Lionis,
2012). The translated measure found all of the scales found in the original PREMIS study and
the IPV screening scale found in the student study (see Table 4). The PREMIS instrument has
demonstrated that it can be adapted for other health care provider groups and settings, making it
an ideal scale for adapting to the pharmacist population. The development of a pharmacyspecific measure could guide the development of training, screening methods, and protocols for
use in this unique setting.
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Table 4.
Scales

PREMIS Scales across Prior Studies
Short et al. n=67

Connor et al. n=286

Papadakaki et al. n=80
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Alpha

Total
Items

Mean (SD)*

Alpha

Total
Items

Mean (SD)*

Alpha

Total
Items

Mean (SD)*

BACKGROUND
Perceived Preparation

0.96

12

3.67 (1.05)

0.97

12

3.80 (1.52)

0.93

9

4.08 (1.17)

Perceived Knowledge

0.96

16

3.55 (0.97)

0.97

16

3.83 (1.42)

0.96

16

3.36 (1.22)

Actual Knowledge

n/a

18

26.0 (5.18)

n/a

18

23.9 (5.68)

n/a

18

18.52 (4.58)

OPINIONS
Preparation

0.85

5

4.20 (1.11)

0.89

4

not reported

0.78

4

3.70 (1.24)

Legal Requirements

0.82

4

3.92 (1.15)

0.91

3

not reported

--

--

--

Workplace Issues

0.79

6

4.18 (1.05)

--

--

not reported

0.78

5

3.09 (1.13)

Self-Efficacy

0.69

6

3.68 (1.26)

0.80

7

not reported

0.75

3

4.78 (1.22)

Alcohol and Drugs

0.70

3

4.46 (0.61)

0.48

2

not reported

<0.5

2

4.05 (0.80)

Victim Understanding

0.69

7

5.06 (0.78)

0.46

3

not reported

0.63

4

4.10 (1.24)

Constraints

0.47

2

4.65 (1.26)

--

--

not reported

0.61

3

4.33 (1.38)

Victim Autonomy

0.37

3

4.32 (0.83)

0.36

3

not reported

--

--

--

IPV Screening

--

--

--

0.74

2

not reported

0.58

2

34.45 (1.40)

*On a scale from 1 (strongly disagree) to 7 (strongly agree)

Diffusion of Innovation
The PREMIS instrument allows for examination of many of the provider-level factors
related to IPV screening. However, provider-level factors are not the only issues to consider in
developing and implementing an effective IPV screening program that will be effectively
adopted and implemented. The PRECEDE-PROCEED model recommends the use of additional
theories in phase 3 to guide the assessment of the predisposing, reinforcing, and enabling factors
for an intervention. Given the need to understand why IPV screening has not been adopted and
implemented at the rate necessary to have an impact on IPV, Diffusion of Innovation theory is a
particularly relevant theory that may provide insight into some of the reasons this evidence-based
recommendation and practice has not been widely adopted. These insights can inform the
development of future efforts to more widely diffuse IPV screening successfully into other
environments such as community pharmacies.
Rogers describes the diffusion process “as the process by which (1) an innovation (2) is
communicated through certain channels (3) over time (4) among members of a social system”
(Rogers, 2003). An innovation is simply something that is perceived to be new by a potential
adopter of the innovation. The innovation could be an object, a practice or process, or an idea.
The perceived characteristics of an innovation explain some of the differences in adoption rate.
Rogers categorizes these characteristics as relative advantage, compatibility, complexity,
trialability, and observability. Relative advantage is the degree to which an innovation is
perceived to be better than what it is replacing. Compatibility refers to the perception of the
degree to which an innovation is consistent with the needs, values, and experience of the adopter.
Complexity is the degree to which the innovation is considered to be difficult to use or adopt.
Trialability refers to the perception that an innovation could be experimented with on a limited
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basis without serious impact or commitment. Finally, observability is the degree to which
adoption of the innovation is visible to others. An innovation that is perceived to have strong
relative advantage, greater compatibility, trialability, observability and low complexity will be
adopted and diffused more rapidly than other innovations.
The second element in the diffusion process is the communication process. There are
multiple means by which news of an innovation can travel and these channels have a significant
impact on the rate of diffusion. Methods of communication can include mass media channels
(such as radio, television, newspapers, journals, etc.) or interpersonal channels (peer networks,
face-to-face exchange, etc.). Interestingly, diffusion studies have shown that most potential
adopters do not evaluate an innovation based on studies of its outcome. Instead, they rely upon
subjective evaluation of the innovation conveyed to them from other individuals who are like
them and have already adopted the innovation. This indicates that peer recommendation plays
an important role in diffusion.
The third element in the diffusion process is time. The decision to utilize an innovation is
a process a potential adopter goes through during which he/she gains knowledge of the
innovation, forms a favorable or unfavorable attitude toward the innovation, decides to accept or
reject the innovation, implements the innovation, and then seeks confirmation or reinforcement
regarding his/her decision. This process occurs over a period of time and factors that influence
each of the steps in the decision process can influence the speed of diffusion of the innovation.
The final element in the diffusion process is the social system into which the innovation is
released. The social system provides boundaries for the innovation. It can facilitate or hamper
innovation. The social structure, the system norms, and opinion leaders can all impact in a
positive or negative manner the diffusion of an innovation.
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Diffusion of Innovation theory is helpful in guiding assessment of factors that are
predisposing, reinforcing, and enabling for a particular innovation. In the current investigation,
the innovation of IPV screening has been poorly diffused throughout the health care system.
This deficit can be addressed by utilizing the Diffusion of Innovation theory to frame an
assessment of the characteristics of the innovation, the adopters, and the environmental setting
into which this innovation is released. The PREMIS instrument can provide insight into the
characteristics of the adopters, in this case the health care providers conducting IPV screening.
However, this instrument does not adequately address the innovation-level factors, which in this
case would be characteristics of the IPV screening intervention. For example, if IPV screening is
not perceived to provide a relative advantage by either the pharmacist or the consumer, then it is
unlikely to be adopted. Relative advantage could be improved health of the patient or it could be
increased customer loyalty for a community pharmacy patient who desires the IPV screening
service. Assessing pharmacist and consumer perceptions of the characteristics of the innovation
of IPV screening could yield important insights that could guide the development of an
intervention that could effectively and efficiently be successfully adopted and disseminated.

Consumer Perspective
A thorough assessment of factors that are involved in predisposing, reinforcing, and
enabling IPV screening in the community pharmacy setting must include not only the
pharmacist’s perspective but also include the consumer’s perspective. It is not appropriate to
move forward with IPV screening in the community pharmacy setting with knowledge only of
the provider’s perspective. It is entirely possible that critical predisposing or reinforcing factors
related to the consumer will provide evidence that screening is either undesirable or alternatively
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of high importance. Only through study of consumer factors will important issues such as
willingness to return to a community pharmacy that conducts screening be considered.

PRECEDE-PROCEED Summary
If planning is done carefully and is guided by theory, intervention and dissemination is
more likely to be effective. The PRECEDE-PROCEED model provides a framework to guide
the development of effective interventions. Phase one assessed the social environment and
documented the need for a focus on IPV prevention and intervention. Phase two assessed the
epidemiology of IPV and clearly demonstrated that IPV is a highly prevalent exposure that
results in negative health outcomes. The phase three assessment has demonstrated that
additional research is needed to complete this assessment to determine what factors may
predispose, reinforce, and enable IPV screening in the pharmacy environment. Other health care
providers have not widely adopted and implemented IPV screening so it is crucial to conduct the
phase three assessment with a focus on community pharmacists and an emphasis on their
particular perceptions of the predisposing, reinforcing, and enabling factors related to this
intervention. Further, there is evidence to suggest that IPV screening is acceptable to patients in
health care settings; however, additional study is needed to determine if it would be acceptable to
consumers in a community pharmacy environment.
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3. METHODOLOGY

Purpose
The purpose of this study was to investigate the potential role of community pharmacists
in the public health initiative to reduce the impact of interpersonal violence (IPV) by
significantly increasing the screening and referral of victims of interpersonal violence. To
examine this possibility, the PRECEDE-PROCEED model was used to guide the assessment of
factors that may predispose, reinforce, or enable IPV screening in the community pharmacy
setting. Specifically, this project conducted two separate studies. The first study investigated
community pharmacists’ readiness to participate in IPV screening, including examining training,
knowledge, attitudes, behaviors, and intentions related to IPV screening by developing and
testing an instrument adapted from an existing instrument, the PREMIS (Physician Readiness to
Manage Intimate Partner Violence Survey) tool. Potential demographic differences in intention
to conduct IPV screening were also examined. In addition, this study examined pharmacists’
perceptions of the innovation characteristics of IPV screening in community pharmacies and
their impact on intention to conduct IPV screening. The second study examined female
consumers’ attitudes and preferences for IPV screening in community pharmacies to determine if
IPV screening in the community pharmacy setting is feasible and acceptable. The results of this
study will assist in determining if community pharmacies are an appropriate place to conduct
IPV screening, and if so, will provide data to inform the development of educational initiatives
and screening programs that can be effectively and efficiently adopted for dissemination.
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It should be noted that the primary consideration in all research activities related to IPV is
safety and respect for all victims. This ethical consideration supersedes any desirable study
methodology. Review and approval by The University of Mississippi Institutional Review
Board (IRB) was obtained prior to initiation of this study. Participant consent was obtained prior
to the collection of any data. Data security protection measures were employed as required by
the IRB.

Survey of Community Pharmacists
Overview
This study was conducted as a formative research initiative to understand community
pharmacists’ perspectives on IPV screening in the community pharmacy setting. The goals of
this exploratory project were to study community pharmacists’ readiness to participate in IPV
screening, including examining training, knowledge, attitudes, behaviors, and intentions related
to IPV screening by developing an instrument adapted from the existing PREMIS tool; to
examine potential demographic differences in intention to conduct IPV screening; and to
examine perceptions of the characteristics of the IPV screening innovation in community
pharmacies and their impact on intention to conduct IPV screening.
The main outcome of this study is the newly adapted instrument for use with community
pharmacists that assesses knowledge, attitudes, behaviors, and intentions related to IPV
screening in addition to assessing community pharmacists’ perceptions of innovation
characteristics of the intervention of IPV screening. The development of such an instrument is
necessary for two reasons. First, it allows a standardized evaluation of pharmacists’ knowledge,
attitudes, behaviors, and intentions related to IPV and IPV screening that can be compared to
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other health care providers. Secondly, the data collected with this instrument can guide the
development of future educational initiatives, policy recommendations, and potentially the future
development of screening programs in the community pharmacy setting. It is important to
determine if the factor structure of the PREMIS instrument is the same or different for
pharmacists compared to physicians. These differences have implications for the ability to
utilize training programs and screening methods that were developed in other health care settings
in a pharmacy setting. Therefore, the first two research questions addressed these issues:

Research Question 1:
What are pharmacists’ knowledge, attitudes, behaviors, and intentions related to IPV?
Research Questions 2:
Does the Pharmacy PREMIS have a factor structure similar to the Physician PREMIS
factor structure?

Prior work with other health care providers indicates that female providers are more
comfortable with IPV screening compared to male providers and that the number of years in
practice is related to IPV screening behaviors. Specifically, those who have finished training and
practiced ten years or less were found to be more likely to initiate and conduct IPV screening
(Gutmanis, Beynon, Tutty, Wathen, & Macmillan, 2007a; Gutmanis et al., 2007a). For these
reasons, differences in pharmacist characteristics and intention to engage in IPV screening were
investigated in the first a priori hypothesis:
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H1: Pharmacist characteristics, specifically female gender and fewer years since
completing training, are positively related to intention to engage in IPV screening.

The second set of a priori hypotheses are related to the newly created instrument and
examined the relationship between community pharmacists’ perceptions of the innovation
characteristics of the IPV screening intervention and their relationship to intention to screen for
IPV.

H2: Perceptions of intervention characteristics as measured by diffusion constructs are
related to intention to engage in IPV screening. Specifically:
H2a: Positive perceptions of relative advantage are related to greater intention
to engage in IPV screening.
H2b: Positive perceptions of compatibility are related to greater intention to
engage in IPV screening.
H2c: Positive perceptions of trialability are related to greater intention to
engage in IPV screening.
H2d: Positive perceptions of visibility are related to greater intention to engage
in IPV screening.
H2e: Positive perceptions of complexity are related to reduced intention to
engage in IPV screening.
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Sample Population
The study sample consisted of community pharmacists from across the U.S. A database
of contact information of community pharmacists, including email addresses, was purchased
from Integrated Medical Data, a data services company. The database has over 18,000 verified
email addresses for community pharmacists from across the United States. A random sample of
6,000 community pharmacists was drawn and provided to the investigators. This data set served
as the sample frame. Sample size was determined based on the study design of a factor analytic
approach. Recommendations include between 5 to10 cases per variable in a factor analysis, up
to 300 cases (Tinsely & Tinsley, 1987). Beyond 300 cases this ratio can be relaxed (DeVellis,
2012). In this survey study there were 32 variables to be considered in the primary factor
analysis, resulting in a need for approximately 160 to 320 respondents.

Survey Development
The survey instrument for this study was adapted from the PREMIS instrument described
in Chapter 2. As described in Chapter 2, previous studies have found the PREMIS instrument to
be comprehensible, reliable, valid, and adaptable to health care providers beyond physicians
(Short et al., 2006; Connor et al., 2011; Papadakaki et al., 2012). Development of the survey
instrument occurred in several steps depicted in Figure 3. In step one the survey items were
adapted for use with pharmacists. These adaptations were made to address the unique practice
characteristics, activities, and concerns of a community pharmacy practitioner. Specifically, the
respondent profile and practice issues section were adapted to match the pharmacy profession.
Additionally, the opinions section was adapted to reword clinical examination terms and items to
assess intention to screen were added as it is anticipated that few pharmacists have conducted
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screening to date so assessing screening behavior only is less optimal for this population.
Finally, the demographic and IPV history items were adapted as the PREMIS instrument did not
use standardized demographic or IPV history items. The demographic and IPV history items
were replaced with those utilized in the national Behavioral Risk Factor Surveillance System
(BRFSS) surveys. The demographic items from the most recent survey in 2011 were utilized
(Centers for Disease Control and Prevention, 2011) and the IPV history items from 2007
(Centers for Disease Control and Prevention, 2007), the most recent survey year that IPV history
was assessed by BRFSS, were utilized.
Following the adaptation of the original PREMIS measure, step two of development was
conducted. In this step items were generated for assessment of pharmacist’s perceptions of the
innovation characteristics of IPV screening. Items were developed to assess perceptions of the
following characteristics of IPV screening: relative advantage, compatibility, trialability,
observability, and complexity. Sample items are included in Table 5. After these items were
generated, the third step of development was completed. This consisted of expert review of the
measure by researchers with expertise in IPV screening, community pharmacy practice, and
health behavior theory. Suggested revisions were incorporated and a pilot instrument was
finalized. The pilot survey was then built in Qualtrics, an online survey system. Before the
instrument was pilot tested, cognitive interviews were conducted. Cognitive interviews, a
recommended step prior to administering a pilot survey, can detect any challenges in
understanding navigation, wording of directions and questions, visual layout, etc. (Willis, 2005).
These interviews were conducted by the investigators as they have the highest level of awareness
of how to address any challenges or problems that are detected. Three cognitive interviews were
conducted with practicing community pharmacists recruited from the local area. Revisions

54

based on the cognitive interviews were made and the revised pilot instrument was then
administered as an online survey to a convenience sample of faculty in a school of pharmacy and
local practicing community pharmacists. This process resulted in the resolution of small
programming issues and a clarification in the introductory information. The final survey
instrument was then programmed into Qualtrics for administration with the study sample. The
complete survey is included as Appendix B.
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Figure 3.

Community Pharmacist Survey Development Process

Step 1: Adapt PREMIS to fit
pharmacists

Step 2: Develop perception of
innovation characteristics items

Step 3: Expert review

Step 4: Program pilot

Step 5: Cognitive interviews

Step 6: Pilot survey

Step 7: Field final survey
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Table 5.

Pharmacy PREMIS Survey – Innovation Characteristics Sample Items

Complexity
Conducting IPV screening in a community pharmacy would be difficult.
My practice setting allows me adequate time to respond to victims of IPV.
Pharmacists don’t have the time to assist patients in addressing IPV.
Compatibility
There is a role for community pharmacists in public health initiatives.
The community pharmacy is a good place to provide health education.
Pharmacists are trusted members of the health care team.
Community pharmacies are the most accessible health care facilities for patients.
Pharmacy patients are willing to discuss private information with pharmacists.
I think it is a good idea to screen for IPV in the pharmacy setting.
Relative Advantage
Adding new services to a community pharmacy can improve business.
Providing IPV screening services in a pharmacy would result in a relative advantage
compared to other pharmacies that do not offer this service.
Providing IPV screening services would be a benefit to pharmacy patients.
Visibility
I have seen IPV patient education or resource materials in other pharmacies.
I have seen IPV patient education or resource materials in other health care settings (e.g.,
physicians’ offices, hospitals).
I have seen other health care providers screen for IPV.
Trialability
It would be difficult to try IPV screening in the community pharmacy setting.
Pharmacists receive adequate training in patient counseling.
There is adequate private space for me to provide care for victims of IPV.
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Survey Administration
The Dillman tailored design method was utilized to reduce survey error (Dillman, Smyth,
& Christian, 2009). The survey procedures were designed to encourage high rates of sample
participation. A personalized email invitation to participate in the survey was sent to all
members of the study sample. The invitation was designed to appeal to the pharmacists’ sense of
responsibility as a member of the profession to participate in improving models of care. This
“appeal for help” is recommended in the Dillman method to engage and encourage survey
respondents. Although not ideal, a lottery system of participant incentives was initially utilized
as this is the most feasible option for a web-based survey administration. The invitation
informed participants that upon completion of the survey they could opt in to be entered into a
drawing to win one of four $50 Amazon gift cards. The survey was emailed at 6am CST on a
Tuesday in March 2012. A series of reminder emails were sent to non-respondents. The first
reminder was on Friday morning of the same week the survey was initially released. The initial
email and first reminder generated a small number of responses. As a result permission was
sought and obtained from the IRB to increase the incentive to a $10 Amazon gift card for every
participant. A new email message announcing the new incentive was sent on Tuesday morning,
with two follow-up emails (two days and four days) later. Each contact had a unique, brief
message asking for participation. Following the tailored design method, follow-up messages
included items such as a reminder that the time to respond is limited. Directions to access and
navigate the survey were written to be clear and easy to follow. Each sample member was sent a
unique link to the survey so that response rates could be tracked and any individual could only
complete the survey once. The text of the emails is included as Appendix A. Evaluation of the
first completed surveys was conducted immediately to detect any potential problems that were
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missed (e.g., problems with the ability to move page to page within the survey). The survey
remained live ten days after the final reminder was sent. The survey was then closed and the
data from the completed sample was prepared for analysis.
Analyses
Once the survey administration period closed, the data were transferred from Qualtrics
into a study-specific database in SPSS 20.0 (Chicago, IL) for management and analysis. Data
were reviewed for missing data and any survey missing responses to more than 10% of the items
were deleted from the analysis file. Coding was completed, including reverse scoring relevant
items. Respondent and practice characteristics were tabulated to describe the study population.
Response rate was calculated as the number of completed surveys compared to the
number distributed. Two methods were utilized to estimate potential non-response bias. First,
study respondents were compared to the population values from the complete database of
pharmacists’ emails that Integrated Medical maintains. Respondents were compared on
pharmacy type and position in the pharmacy. Chi-square tests were conducted to determine if
differences on these variables existed between these two groups. Additionally, a time-trends
extrapolation method was used to examine potential non-response bias. The first 20% of
respondents were compared to the last 20% of the respondents on demographic and practice
variables. The assumption underlying this test is that individuals who respond later to a
questionnaire are similar to those who do not respond at all (Armstrong & Overton, 1977). A
comparison of the IPV exposure items was also conducted, as it may be the case that IPV
exposed individuals are more or less likely to respond to a survey of this nature.
A multivariable regression analysis was conducted to examine the relationship between
intention to screen for IPV and the pharmacist characteristics variables of gender and years since
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training was complete. Intention to screen targeted patients for IPV was treated as the
dependent variable and gender and years since training were included in the model as
independent variables. Regression diagnostics were utilized to assess the assumptions of
linearity, homoscedasticity, independence of the error term, and normality. Parameters were
estimated using Ordinary Least Squares method. The F statistic was utilized to assess the
hypothesis that gender and years since training significantly help predict intention to engage in
targeted screening for IPV.
Maximum likelihood exploratory factor analysis was utilized to evaluate the
psychometric properties of the adapted PREMIS instrument with community pharmacists.
Results were compared to the original results by Short et al. and to the results of the instrument
adapted for use in two additional populations, health care students and Greek physicians.
Exploratory factor analysis was appropriate for this study as the measure being tested has only
been utilized in three studies, two of which utilized an adaptation of the original instrument and
found slightly different factor structures compared to the original study. The current study
adapted the measure for use with practicing community pharmacists and this adapted measure
has never been tested before. Because the training and practice of community pharmacists is
considerably different from physicians, a different factor structure may be found. Three steps
were taken prior to analysis to examine the factorability of the data. First, the variable-to-case
ratio was calculated to determine if the study met the recommendation of a 1:5-10 ratio for factor
analysis (Tinsely & Tinsley, 1987). Second, Bartlett’s test for sphericity was estimated to test
for the presence of correlations among the variables. Finally, the Kaiser-Meyer-Olkin measure
of sampling adequacy (KMO MSA) was calculated. The KMO MSA is the ratio of the sum of
the squared correlations to the sum of the squared correlations plus the sum of the squared partial
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correlations. This index ranges from 0 to 1 and will be 1 when each variable is perfectly
predicted by the other variables without error. A result of 0.70 or higher indicates the data are
factorable. If the result is lower than 0.70, then the MSAs for individual variables are utilized to
identify variables for deletion to achieve a higher overall KMO MSA value.
Maximum likelihood exploratory factor analysis with an oblique rotation based on
eigenvalues great than one was used to replicate the analysis approach that was used in all three
of the studies of this instrument (Papadakaki et al., 2012; Connor et al., 2011; Short et al., 2006).
This iterative method of factor analysis is a preferred extraction method because it employes a
statistical test to determine the number of factors to be extracted. The procedure begins with one
factor and increases the number of factors one at a time until the model achieves goodness of fit
as demonstrated by the Χ2 test. Once the appropriate number of factors has been determined, the
extracted factors will be subjected to oblique rotation to foster interpretability. Oblique rotation
was selected because it is anticipated that the factors may be inter-correlated and oblique rotation
allows this, whereas orthogonal rotation does not. Additionally, oblique solutions in explanatory
factor analysis are more likely to generalize to confirmatory factor analysis than orthogonal
solutions are. Utilizing oblique rotation makes it more likely that the factors found will be
useable for a future confirmatory factor analysis. Following the recommendation of Thompson,
the promax method of oblique rotation was utilized with a pivot power of 4 (Thompson, 2004).
Factors were examined for both statistical and theoretical soundness. Items were considered for
deletion if a factor loading was lower than 0.32 (Tabachnick & Fidell, 2001) or if an item crossloaded on multiple factors. Only factor loadings greater than 0.20 were displayed in the analysis.
Reliability and validity were then evaluated. Cronbach’s alpha was used to examine internal
consistency within identified scales. Correlation between the scales was used to measure
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construct validity. Correlations were considered weak if r < 0.30, moderate if r is between 0.30
and 0.70, and strong if r > 0.70. Statistical significance for all tests was set at α < 0.05.
Items related to perceptions of the innovation characteristics of the IPV screening
intervention were utilized in a second exploratory factor analysis that was conducted in the same
manner as the analysis conducted for the Pharmacy PREMIS items. The resulting factor scores
on the perceptions of innovation characteristics measure were then utilized in a multivariable
regression analysis to examine the relationship between these variables and intention to engage
in IPV screening of targeted patients. Regression diagnostics were utilized to assess the
assumptions of linearity, homoscedasticity, independence of the error term, and normality.
Parameters were estimated using Ordinary Least Squares method. The F statistic was utilized to
assess the hypothesis that diffusion innovation constructs significantly help predict intention to
screen for IPV. Finally, a content review was conducted to report a summary of comments.

Consumer Survey
Overview
The aim of the consumer study is to examine female consumers’ attitudes and
preferences for IPV screening in community pharmacies. As in the community pharmacists
study, focus groups were not utilized to assess patient preferences as IPV victims are unlikely to
truthfully respond in a group setting. A panel survey, although convenient, is unlikely to be
effective in IPV research as individuals who have been or are currently exposed to IPV are
unlikely to participate in a panel. For this reason a panel survey was not utilized for the
consumer study. The consumer study was conducted as a cross-sectional survey of employees of
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a southeastern university in order to gain an understanding of the general public’s perspective on
IPV screening in pharmacies. The intent of this survey is not scale development, but rather is
exploratory in nature. Currently there is no existing standardized instrument in the literature to
assess consumer or patient preferences regarding IPV screening. However, understanding
customer-level factors that may facilitate or hinder diffusion of screening programs in the
community pharmacy environment is essential in understanding how to appropriately proceed
with IPV screening in the community pharmacy environment. In addition to the descriptive data,
one hypothesis was tested in this study:

H3: There is a difference in preference for IPV screening in the community pharmacy
between women who have experienced IPV compared to women who have not
experienced IPV.

Sample
A cross-sectional survey design was utilized to explore patients’ perspectives on IPV
screening in community pharmacies. As discussed in Chapter 2, IPV rates are highest in women
and nearly all research regarding screening acceptability, prevalence, and effectiveness has been
conducted with female patients. For these reasons the study population of interest for this
investigation focused on female consumers who utilize community pharmacies. A convenience
sample of female employees of a southeastern university was used in this cross-sectional survey.
A recent investigation of pharmacy use patterns was conducted in this population (Jariwala,
2009). The results indicated that nearly all respondents used pharmacy services and the majority
utilized community pharmacies for these services. Additionally, approximately 200 individuals
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(male and female) completed the survey. A power analysis for the current study was conducted
to determine the sample size needed to detect a statistically significant difference between
women who have experienced IPV and those who have not on whether or not they prefer
community pharmacy IPV screening. With one covariate in the model, an α=0.05 and β=0.80, a
sample size of 52 is needed to detect an effect size of 0.40 and a sample of 128 participants is
needed to detect an effect size of 0.25 (Faul, Erdfelder, Lang, & Buchner, 2007).
Survey Development
Items for the cross-sectional survey of consumers’ perspectives of IPV screening in
community pharmacies were derived from previous surveys regarding patients’ perspectives in
investigations of IPV screening implementation. Specifically, items about consumer-level
factors associated with acceptability (does the consumer want IPV screening?), relative
advantage (would the consumer prefer a pharmacy that offered this service?) and
complexity/simplicity (does IPV screening impinge negatively on consumer time/effort making
it difficult to conduct screening?) were included. These items were based on previous surveys
and included items to specifically address the pharmacy setting. Demographic and IPV history
items were also included in this survey. As in the survey of pharmacists, the demographic and
IPV history items utilized were from the national Behavioral Risk Factor Surveillance System
(BRFSS) surveys. The demographic items from the most recent survey in 2011 were utilized
(Centers for Disease Control and Prevention, 2011) and the IPV history items from 2007
(Centers for Disease Control and Prevention, 2007), the most recent survey year that IPV history
was assessed by BRFSS, were utilized. The insights of IPV victims regarding acceptability and
safety are particularly important to the future development of any IPV screening program. The
complete survey is included as Appendix C. As in the community pharmacist study, the pre-test
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instrument development process included review by experts and cognitive testing with potential
sample members. A pilot test of the instrument was conducted with a convenience sample of
eight employees and minor revisions were made. The final instrument was then programmed
into Qualtrics for administration with the study sample.
Survey Administration
Administration of the cross-sectional survey of female consumers’ attitudes and
preferences for IPV screening in community pharmacies was conducted in a manner similar to
that described in the community pharmacists survey reported above. The survey was
programmed in Qualtrics and administered as a web-based survey. The survey was distributed
via the university’s daily email summary to all female employees of the university. The
introductory email is included as Appendix D. None of the communications referred to
individuals by name in order to enhance the anonymous nature of the survey. Electronic
distribution and administration was selected for this survey as it was anticipated that more
employees would feel comfortable completing an online survey than writing down responses to
questions regarding IPV. Participation in an opt-in lottery for incentives was also offered,
however the four $50 gift cards were to the campus bookstore and cafe. The campus-wide
university email system does not allow for specific prompts. However, the survey was posted in
the daily email to all female employees for two weeks. After the survey closed, data from the
completed sample was prepared for analysis.
Analyses
Once the survey study period closed, the data were transferred from Qualtrics into a
study-specific database in SPSS 20.0 (Chicago, IL) for management and analysis. Data were
reviewed for missing data and any survey missing responses to more than 10% of the items were
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deleted from the analysis file. Respondent characteristics were tabulated to describe the study
population.
Response rate was calculated as the number of completed surveys compared to the
number distributed. Characteristics of the survey respondents were compared to the known
characteristics of the university’s workforce on factors such as race to determine if the
distribution of the respondents differed from the population values on these factors, indicating a
potential non-response bias. As in the survey of community pharmacists, a time-trends
extrapolation method was used to examine potential non-response bias. The first 20% of
respondents were compared to the last 20% of the respondents on demographic variables. The
assumption underlying this test is that individuals who respond later to a questionnaire are
similar to those who do not respond at all (Armstrong & Overton, 1977). Descriptive analyses
were conducted to characterize the study sample. Results were reported as mean ± SD and
percentages. Correlation between variables regarding IPV preference and opinions about
pharmacies/pharmacists and IPV screening were computed to examine potential relationships
between these constructs. Differences between IPV positive and negative respondents were
examined to determine if community pharmacy IPV screening would be more or less acceptable
to IPV victims. The responses of known victims can shed light on whether screening in a
pharmacy setting has any special concerns for victims that have not been identified in studies in
other health care settings. A one-way ANCOVA analysis was conducted with IPV exposure as
the independent variable and desire for community pharmacy IPV screening as the dependent
variable to test hypothesis three. The covariate that was considered for inclusion in the model
was level of agreement with the item “I trust the pharmacist when it comes to health matters”.
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Statistical significance was set at α < 0.05. A content review was conducted to report a summary
of comments.
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4. RESULTS

Community Pharmacists Study
The cross-sectional survey designed to explore the perspective of community pharmacists
regarding IPV screening in the pharmacy environment was distributed to a random national
sample of a total of 6,000 community pharmacists. A total of 189 respondents participated in the
pharmacists study. This resulted in a response rate of 3.15%. After a review of the data, 45
responses were not included in the analyses as they had not completed 90% of the survey. A
final sample of 144 participants contributed data to the analyses, resulting in a net usable rate of
2.40%.

Participant Characteristics
Descriptive analyses indicated that the mean age of participants was 47.9 years (±11.8
years), with a range of 28 to 80 years of age. Table 6 reports the sex and race of the study
participants. In order to characterize the training characteristics, participants were asked to
report their most advanced pharmacy training and to indicate any post graduate training they may
have had. As can be seen in Table 6, the majority of respondents had either a B.S. in Pharmacy
or a Pharm.D. Interestingly, a significant number of respondents indicated “Other” to the postgraduate training item. Examination of the explanations provided for those who checked
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“Other” found that many indicated either “none” or certificate in a variety of areas such as
nuclear medicine and health care management. Participants reported that they have been
practicing an average of 23.3 years (±12.5) (range 0 to 60), including their residency.

Table 6.

Pharmacist Study Participant Characteristics
Percent

n

52.8%
47.2%

76
68

84.7%
3.5%
7.6%
0.7%
0.7%
2.8%

122
5
11
1
1
4

5.6%
93.8%
0.7%

8
135
1

59.7%
37.5%
2.1%
0.7%

86
54
3
1

16.0%
2.8%
19.4%
31.9%

23
4
28
46

Sex
Female
Male
Race
White
Black/African American
Asian
Native Hawaiian/Pacific Islander
American Indian/Alaskan Native
Other
Hispanic
Yes
No
Don’t know/Not sure
Most advanced pharmacy training
B.S. in Pharmacy
Pharm.D.
M.S. in Pharmacy
Other
Postgraduate training
Residency
Fellowship
Graduate School
Other

Examination of the practice characteristics of the study participants indicates that they
work in a variety of types of pharmacies and hold a variety of positions. Interestingly,
approximately half of the study sample reported working in a pharmacy that offers advanced
pharmacy services. As anticipated given the reported level of advanced pharmacy services
offered, 57.6% reported that their pharmacy had a private counseling area, with 34.9% reporting
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that this area is used often. Daily fill rates and other practice characteristics are included in
Table 7.

Table 7.

Practice Characteristics

Type of pharmacy
Chain
Grocery/General Merchandise
Independent
Other
Position
Owner/Partner
Employee manager/Asst Manager
Staff/employee pharmacist
Relief pharmacist
Other
Extent involved in key decisions
Not at all
A little
Some
A good amount
To a great extent
Offer advanced pharmacy services
YES
NO
Have a dedicated private counseling area
YES
NO
Frequency of use of private counseling area
Never
Rarely
Sometimes
Often

Percent

n

11.8%
28.5%
34.0%
32.6%

17
41
49
47

18.1%
27.8%
47.2%
2.1%
4.9%

26
40
68
3
7

15.3%
17.4%
16.0%
27.1%
24.3%

22
25
23
39
35

53.5%
46.5%

77
67

57.6%
42.4%

83
61

-0
13.3%
11
51.8%
43
34.9%
29
Mean (±SD)
326.3 (±674.3)

Average number of fills per day in your pharmacy
Percent of fills involving patient counseling other than
ordinary prescription consultation
22.7% (±26.3)
Average number of pharmacist FTEs in your pharmacy
5.76 (±17.1)
Average number of pharmacy tech FTEs in your pharmacy 7.58 (±26.8)
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IPV Training
Interestingly, some pharmacists reported exposure to IPV training. The majority of
exposure reported was reading their institution’s protocol and watching a video (see Table 8).
Other sources of training reported included personal therapy and a women’s studies course.
Individuals who reported any previous training about IPV were asked to estimate the total
number of hours of training they have experienced. The mean number of hours of training was
5.51 (±7.06) hours, with a range of 0 to 30 hours.

Table 8.
None

Pharmacist Intimate Partner Violence Training Activities
Percent
n
67.4%
97

Read institution’s protocol

13.2%

19

Watched a video

11.1%

16

Attended lecture/talk

9.0%

13

Attended skills based training/workshop

2.8%

4

Pharmacy/other school classroom workshop

2.8%

4

Pharmacy/other school clinical training

2.8%

4

Residency/fellowship/post-grad training

--

0

Continuing Education

8.3%

12

Other

2.1%

3

Pharmacist Study Non-response Bias
As previously indicated, non-response bias was assessed by comparing study respondents
to the population values of the population from which the study sample was drawn. Respondents
were compared on pharmacy type and position in the pharmacy. Chi-square tests were
conducted to determine if differences on this variables existed between these two groups. No
significant differences between the groups were found on the variables examined (see Table 9).
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Table 9.
Variable

Estimation of Non-Response Bias: Comparison to Sample Population
Population Study Sample
X2
p-value

Type of pharmacy
Chain

12,173

17

Grocery/General Merchandise

136

41

Independent

2,986

49

Other

2,100

47

Position
Owner/Partner

1,251

26

Employee manager/Asst Manager

2,982

40

Staff/employee pharmacist

22,838

68

Relief pharmacist/Other

535

10

8.00

0.092

2.00

0.157

The second method utilized to assess non-response bias was a time trends extrapolation
in which the first 20% (n=29) of respondents was compared to the last 20% (n=29) of
respondents. T-tests and chi-square tests were conducted to determine if differences in
demographic and practice variables existed between these two groups. All of the respondents in
these two groups reported their race as “white”. No significant differences between the groups
were found on any of the variables examined (see Tables 10 and 11).
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Table 10.
Variable
Age

Estimation of Non-Response Bias:
Data
First 20%
Mean±(SE)
50.0 (2.5)

Time Trends Extrapolation of Parametric
Last 20%
Mean±(SE)
47.6 (2.3)

t-value

p-value

0.72

0.47

Years of practice

26.0 (2.5)

23.2(2.6)

0.77

0.44

FTE Pharmacists at site

3.6 (0.8)

2.5(0.3)

1.37

0.18

FTE Techs at site

4.0 (1.0)

4.6 (0.7)

-0.48

0.63

Fills per day at site

257.9 (59.6)

245.1 (25.5)

0.20

0.84

% fills with counseling

18.1 (4.5)

24.1 (5.7)

-0.83

0.41

Hours previous IPV training 4.7 (2.50

4.9 (2.6)

-0.52

0.96

Number staff IPV trained

5.0 (0.2)

-0.45

0.66

4.9 (0.24)
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Table 11.
Variable

Estimation of Non-Response Bias: Time Trends Extrapolation of NonParametric Data
First 20% Last 20%
X2
p-value

Sex
Female
Male
Hispanic
Yes
No
Don’t know/Not sure
Most advanced pharmacy training
B.S. in Pharmacy
Pharm.D.
M.S. in Pharmacy
Other
Position
Owner/Partner
Employee manager/Asst Manager
Staff/employee pharmacist
Relief pharmacist
Other
Extent involved in key decisions
Not at all
A little
Some
A good amount
To a great extent
Offer advanced pharmacy services
YES
NO
Personally threatened with IPV
YES
NO
Don’t know/not sure
Do not want to answer
Personally experienced IPV attempt
YES
NO
Don’t know/not sure
Do not want to answer
Personally experienced IPV
YES
NO
Don’t know/not sure
Do not want to answer

16
13

18
11

0
29
0

1
28
0

16
12
1
0

19
10
0
0

4
8
14
2
1

0.284

0.59

1.018

0.31

14.39

0.49

2.368

0.67

3.494

0.48

0.276

0.60

1.198

0.55

1.066

0.79

0.525

0.77

4
8
15
0
2

2
5
4
11
7

6
6
5
8
4

14
15

16
13

4
24
0
0

5
22
0
1

3
25
1
0

3
23
1
1

5
23
0
1

7
20
0
1
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Analysis of the Pharmacy PREMIS Instrument
Background Scales
The original PREMIS instrument had three background scales assessing perceived
knowledge, perceived preparation, and actual knowledge. The perceived preparation scale
included 12 items that assessed how prepared pharmacists felt to work with IPV victims and
responses ranged from 1 (not prepared) to 7 (quite well prepared). The mean score on this 12
item scale was 27.76 (±17.28). The internal consistency of this scale was high (α=0.970). The
perceived knowledge scale contained 16 items that assessed respondents’ perceived knowledge
about IPV. Responses on these items ranged from 1 (nothing) to 7 (very much). The mean score
for this 16 item scale was 35.36 (±23.06). The internal consistency of this scale was also high
(α=0.978). The IPV knowledge scale included 18 items and the mean score on this scale was
20.83 (±6.04), with a range from 6 to 32.
Opinion Scales
Exploratory factor analysis was employed with the 32 opinion items of the PREMIS
instrument adapted for pharmacists to explore and refine the underlying structure of the items in
this population. In order to determine the factorability of the data in this sample, the variable-tocase ratio was examined. A total number of 32 variables were considered in this analysis,
making the variable-to-case ratio 32 to 144. The Kaiser-Meyer-Olkin (KMO) measure of
sampling adequacy was 0.731, indicating the suitability of the data for factor analysis. Bartlett’s
test of sphericity was significant (X2 =2370.63; df =465; p<0.001 ). This indicates that there is
sufficient correlation between the items, which is an indicator for the appropriateness of factor
analysis in this data set. Maximum Likelihood Factor (MLF) analysis with oblique rotation of
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the 32 opinion items identified a 9 factor solution that was statistically sound (X2=277.57;
df=222; p <0.007) that explained 54.65% of the variance; however, 23 of the items had similar
loadings in at least two factors, indicating complex loadings. Despite the fact that this solution
was statistically sound, the solution lacked a good theoretical basis. Variables with low
communalities or loading scores below 0.32 were removed from analysis. The final MLF factor
solution had five factors utilizing 18 items and accounted for 64.16% of the variance. Only
loadings greater than 0.20 were shown; all of the items loaded exclusively on one factor in the
final solution. Four of the five identified scales had Cronbach’s α > 0.70 and were thus
considered to have acceptable reliability. The fifth scale demonstrated moderate reliability (α =
.676). The identified Opinions scales, with reliability coefficients and sample items, are included
in Table 12.
Innovation Characteristics Scales
A second exploratory factor analysis was conducted to examine the innovation
characteristics items added to the pharmacist adaptation of the PREMIS instrument. The same
method of exploratory factor analysis was utilized. The factorability of the data in this sample
was assessed by examining the variable-to-case ratio. A total of 19 variables were considered in
this analysis, making the variable-to-case ratio 19 to 144. The Kaiser-Meyer-Olkin (KMO)
measure of sampling adequacy was 0.793, indicating the suitability of the data for factor
analysis. Bartlett’s test of sphericity was significant (X2 =1097.60; df =153 ; p<0.0001 ). This
indicates that there is sufficient correlation between the items, which is an indicator for the
appropriateness of factor analysis in this data set. Maximum Likelihood Factor (MLF) analysis
with oblique rotation of the of the 19 innovation characteristics items identified a 5 factor
solution that was statistically sound (X2=121.26; df=73; p <0.0001) that explained 55.79% of the
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variance; however, 9 of the items had similar loadings in at least two factors, indicating complex
loadings. Despite the fact that this solution was statistically sound, the solution lacked a good
theoretical basis. Variables with low communalities or loading scores below 0.32 were removed
from analysis. The final MLF factor solution had four factors utilizing 13 items and accounted
for 60.68% of the variance. Only loadings greater than 0.20 were shown. Three of the four
identified scales had Cronbach’s α > 0.70 and were thus considered to have acceptable
reliability. The fourth scale demonstrated moderate reliability (α = .686). The identified
Innovation Characteristics scales, with reliability coefficients and sample items, are included in
Table 12.
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Table 12.

Pharmacist PREMIS Opinion Scales

Scales

Alpha

Total
Items

Item
Mean (SD)*

Sample Item

BACKGROUND
Perceived Preparation

.970

12

2.31 (0.003)

How prepared do you feel to appropriately respond to disclosures of abuse?

Perceived Knowledge

.978

16

2.21 (0.004)

How much do you feel you know about what questions to ask to identify IPV?

Actual Knowledge

n/a

18

What is the strongest single risk factor for being a victim of intimate partner violence?

Practice Issues

n/a

21

20.83 (6.04)
(range 6-32)
9.44 (6.95)
(range 0-28)

OPINIONS
Efficacy -

.856

7

2.68 (0.013)

I feel comfortable discussing IPV with my patients.

Workplace/Self

For every IPV victim you have identified in the past 6 months, how often have you documented
patient’s statements about IPV in record?

My practice setting allows me adequate time to respond to victims of IPV.
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Preparation

.956

3

3.01 (0.0001)

I don’t have the necessary skills discuss abuse with an IPV victims who is female.

Legal Requirements

.954

3

2.93 (0.007)

I am aware of legal requirements in this state regarding reporting of suspected cases of IPV.

Alcohol and Drugs

.795

2

4.63 (0.010)

Use of alcohol or drugs is related to IPV victimization.

Constraints

.676

3

4.31 (0.031)

Pharmacists do not have the time to assist patients in addressing IPV.

4.72 (0.600)

Providing IPV screening services in a pharmacy would result in a relative advantage compared to

INNOVATION CHARACTERISTICS
Relative Advantage

.841

5

other pharmacies that do not offer this service.
Compatibility

.806

3

5.83 (0.148)

Community pharmacists are trusted members of the health care team.

Trialiability

.720

4

3.56 (0.032)

It would be difficult to try IPV screening in the community pharmacy setting.

Visibility

.686

2

3.16 (0.155)

I have seen IPV patient education or resource materials in other pharmacies.

*On a scale from 1 (strongly disagree) to 7 (strongly agree)

Construct Validity
The construct validity of the instrument in the pharmacist population was assessed by
estimating the correlation between the instrument’s scales. As expected the perceived
knowledge score was significantly correlated with the perceived preparation score (r=.889;
p=0.01) and the amount of previous training (r=.409; p=0.01). These results are similar to both
Short et al. and Connor et al., both of which found correlation between perceived knowledge and
perceived preparation. Correlation matrices of all of the variables are reported in Tables 13-16.

Table 13.

Correlations between Preparation and Knowledge Items/Scales
Perceived
Knowledge

Perceived Preparation

Perceived
Preparation
1

Actual
Knowledge

Practice
Hours
Issues IPV Training

Perceived Knowledge

.889**

1

Actual Knowledge

.119

.106

1

Practice Issues

.126

.086

-.041

1

Hours Previous IPV Training

.409**

.402**

.213

.126

1

**p<0.01 (all two-tailed)

Table 14.

Correlations between Opinion and Background Scale Items/Scales

Workplace/Self-Efficacy

Perceived
Perceived
Preparation Knowledge
.606**
.623**

Actual
Knowledge
.129

Hours Previous
IPV Training
.323*

Staff Preparation

.262**

.243**

.009

.268

Legal Requirements

.531**

.636**

.240**

.084

Alcohol/Drugs

.277**

.245**

-.110

.174

Constraints

-.022

-.052

.175

.309*

*p<0.05; **p<0.01 (all two-tailed)
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Table 15.

Correlation between Opinion Scales

Work/Self-Efficacy

Work/Self
Staff
Legal
Efficacy
Preparation Requirements
1

Staff Preparation

.217**

Alcohol/
Drugs

Constraints

1

Legal Requirements .526**

.155

1

Alcohol/Drugs

.241**

-.074

.168*

1

Constraints

.125

.174*

-.238**

-.342**

*p<0.05; **p<0.01 (all two-tailed)

Table 16.

Correlation between Innovation Characteristics Scales
Compatibility

Relative Advantage

Relative
Advantage
1

Compatibility

.622**

1

Trialability

.430**

.029

1

Visibility

.233**

.1212

.199*

*p<0.05; **p<0.01 (all two-tailed)
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Trialability

Visibility

1

1

Research Questions
Research Question 1
The first research question in this study addressed pharmacists’ knowledge, attitudes,
behaviors, and intentions related to IPV screening.
Knowledge
Overall, participating pharmacists reported little exposure to training related to IPV, with
the majority (67.4%) reporting no training at all. The PREMIS instrument included a set of
questions to assess actual knowledge about IPV. The mean score on this scale was 20.83±6.04.
This is slightly higher than the reported mean in the study of Greek physicians (18.53±4.58), but
lower than the reported mean in the health care student study (23.9±5.68) and in the original
study of physicians (26.00±5.18) (Short et al., 2006; Connor et al., 2011; Papadakaki et al.,
2012). Interestingly, participants are generally uncertain if there is a legal mandate to report IPV
cases involving competent adults in the state in which they practice (77.6% reported “Unsure”).
Attitudes
Participants reported relatively low levels of perceived preparedness and knowledge
related to IPV screening. The item mean on the perceived preparation scale was 2.31
(SD=0.003) in this sample of pharmacists on a scale of 1 (strongly disagree) to 7 (strongly
agree). This is lower than reported in the original physician sample (3.67±1.05), the student
sample (3.80±1.52), and the Greek physician sample (4.08±1.17). Perceived knowledge was
similarly lower than reported in the other samples. Participants in this study reported low levels
of self-efficacy and workplace efficacy related to IPV screening and indicated concern about
constraints related to time and training for IPV screening.
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Unique to the Pharmacy PREMIS were items related to perceptions of innovation
characteristics associated with IPV screening. Pharmacists reported agreement with the
statement that there is a role for community pharmacists in public health initiatives and that the
pharmacists are trusted and accessible. This sample reported uncertainty about screening for IPV
in the pharmacy setting (see Table 17).

Table 17.

Perceptions of Innovation Characteristics of Intimate Partner Violence
Screening in the Pharmacy
Mean (SD)*

There is a role for community pharmacists in public health initiatives.

5.30 (1.56)

Pharmacists receive adequate training in patient counseling.

3.82 (2.04)

Adding new services to a community pharmacy can improve business.

4.98 (1.63)

The community pharmacy is a good place to provide health education.

5.65 (1.33)

Pharmacists are trusted members of the health care team.

6.21 (1.15)

Community pharmacies are the most accessible health care facilities for patients.

6.16 (1.19)

Pharmacy patients are willing to discuss private information with pharmacist.

5.11 (1.51)

Providing IPV screening services would be a benefit to pharmacy patients.

4.93 (1.55)

Conducting IPV screening in a community pharmacy would be difficult.

5.05 (1.62)

Providing IPV screening services in a pharmacy would result in a relative advantage
compared to other pharmacies that do not offer this service.

4.16 (1.69)

It would be difficult to try IPV screening in the community pharmacy setting.

4.54 (1.68)

I have seen IPV patient education or resource materials in other pharmacies.

1.77 (1.17)

I have seen IPV patient education or resource materials in other health care settings
(e.g., physician’s offices, hospitals).

3.60 (2.08)

I have seen other health care providers screen for IPV.

2.71 (1.91)

I think it is a good idea to screen for IPV in the pharmacy setting.

4.25 (1.78)

.
*On a scale from 1 (strongly disagree) to 7 (strongly agree)
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Behaviors and Intentions
Participants reported minimal identification of IPV cases in their clinical practice. When
asked how many new cases would you estimate you have identified in the past six months, only
three participants (2.2%) reported identifying a case. One respondent (0.7%) reported screening
all new patients for IPV. Six respondents (4.2%) reported screening patients with abuse
indicators. Three respondents (2.1%) reported screening patients periodically and four (2.8%)
reported screening all female patients periodically. For respondents who identified a case, the
most common actions were to refer the patient to other assistance, to provide information, and to
counsel the patient about options she/he may have. Participants responded to three items related
to intention to participate in continuing education and screening for IPV on a scale of 1 (strongly
disagree) to 7 (strongly agree). Respondents endorsed intention to participate in continuing
education (Table 18). There was a significant difference between intentions to conduct screening
with all patients compared to targeted patients, with respondents more willing to conduct
screening with targeted patients (X2=129.62; df=36; p<0.0001).

Table 18.

Intentions Related to Continuing Education & Screening for Intimate
Partner Violence
Mean (SD)*
I would enroll in continuing education about IPV.
5.15 (1.79)
I would conduct IPV screening with all pharmacy patients.
3.34 (1.83)
I would conduct IPV screening with targeted pharmacy patients. 4.74 (1.75)
*On a scale from 1 (strongly disagree) to 7 (strongly agree)

83

Research Question 2
The second research question in this study addressed the similarities and/or differences of
the factor structure identified in the Pharmacy PREMIS instrument compared to the Physician
PREMIS factor structure. The background scales of perceived preparation and perceived
knowledge function similarly in the pharmacists samples as they did in all three of the previous
studies. The same factor analytic strategy of the items related to opinions of IPV and IPV
screening that was used in all three of the previous studies was utilized in this study. Several of
the same factors were identified (Preparation, Legal Requirements, Alcohol and Drugs,
Constraints). While the Opinions Scale did find several of the same factors, there were a number
of differences between the Pharmacy PREMIS and the other studies. First, the Pharmacy
PREMIS identified a single factor for self-efficacy and workplace-efficacy, whereas the previous
studies found these to be two separate factors. Second, the number of items in some of the scales
was not identical. For example, the preparation scale had fewer items in the Pharmacy PREMIS
(3 items) compared to the Physician PREMIS (5 items), and the student and Greek physician
versions (4 items each). Finally, several of the factors identified in the original instrument
(victim understanding and victim autonomy) and in the other adaptations of the instrument (IPV
screening) were not found in the Pharmacy PREMIS (see Table 19).
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Table 19.

Comparison of PREMIS Scales across Studies

Scales
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Short et al.
Alpha Total Mean (SD)*
Items

Connor et al.
Alpha Total Mean (SD)*
Items

Papadakaki et al.
Alpha Total Mean ±(SD)*
Items

PHARMACY
Alpha Total Mean±SD*
Items

BACKGROUND
Perceived Preparation

0.96

12

3.67 (1.05)

0.97

12

3.80 (1.52)

0.93

9

4.08 (1.17)

0.970

12

2.31(0.003)

Perceived Knowledge

0.96

16

3.55 (0.97)

0.97

16

3.83 (1.42)

0.96

16

3.36 (1.22)

0.978

16

2.21(0.004)

Actual Knowledge

n/a

18

26.0 (5.18)

n/a

18

23.9 (5.68)

n/a

18

18.52 (4.58)

n/a

18

20.83(6.04)

Practice Issues

n/a

21

12.35 (7.44)

n/a

--

not used

n/a

21

17.82 (5.93)

n/a

21

9.44(6.95)

OPINIONS
Preparation

0.85

5

4.20 (1.11)

0.89

4

not reported

0.78

4

3.70 (1.24)

0.956

3

2.68(0.013)

Legal Requirements

0.82

4

3.92 (1.15)

0.91

3

not reported

--

--

--

0.954

3

3.01(0.0001)

Workplace Issues

0.79

6

4.18 (1.05)

--

--

not reported

0.78

5

3.09 (1.13)

Self-Efficacy

0.69

6

3.68 (1.26)

0.80

7

not reported

0.75

3

4.78 (1.22)

0.856

7

2.68(0.013)

Alcohol and Drugs

0.70

3

4.46 (0.61)

0.48

2

not reported

<0.5

2

4.05 (0.80)

0.795

2

4.63(-.01)

Victim Understanding

0.69

7

5.06 (0.78)

0.46

3

not reported

0.63

4

4.10 (1.24)

--

--

Constraints

0.47

2

4.65 (1.26)

--

--

not reported

0.61

3

4.33 (1.38)

0.676

3

Victim Autonomy

0.37

3

4.32 (0.83)

0.36

3

not reported

--

--

--

--

--

--

IPV Screening

--

--

--

0.74

2

not reported

0.58

2

34.45 (1.40)

--

--

--

*On a scale from 1 (strongly disagree) to 7 (strongly agree)

Workplace & Self-efficacy:

-4.31(.031)

Hypothesis Testing
Intention to Screen for IPV and Pharmacist Characteristics
A multivariable regression analysis was conducted to examine hypothesis one which
stated that pharmacist characteristic variables (gender and years since training) are associated
with the pharmacists’ intention to screen targeted patients for IPV. These were the only
variables consider for this analysis as the literature in other health care practice areas has only
found gender and time since training to be associated with intention to screen and actual
engagement in screening programs. The assumptions of linearity, homoscedasticity, and
independence of the error terms were tested with a scatter plot of the studentized residuals
compared to predicted values. A normal probability plot was examined to assess normality.
Data demonstrated linearity, homoscedasticity, independence, and normality. A correlation
matrix was examined for multicollinearity and the variables were not found to be highly
correlated (defined as a correlation of .90 or greater) (Hair, Anderson, Thatham, & Black, 1998).
Hypothesis one is partially supported – female gender is positively associated with intention to
screen targeted patients for IPV; however, there is no significant relationship between years since
training and intention to screen for IPV.
Table 20.
Testing for Hypothesis 1
Relationship between intention to screen targeted patients for intimate partner violence and
pharmacist characteristic variables
Standardized Coefficient
t value
p value
Gender
0.177
2.012
0.0001
Years since training

-0.096

F(2,138)

3.797*

Adj R-Sq

0.038

Standard error of the estimate

1.713

-1.092

*p<0.025
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0.277

Perceptions of Innovation Characteristics and Intention to Screen for IPV
A multivariable regression analysis was conducted to examine hypothesis two which
stated that perceptions of the intervention characteristics are associated with the pharmacists’
intention to screen targeted patients for IPV and specifically that relative advantage,
compatibility, trialability, and visibility are positively associated with intention to screen.
Hypothesis 2e which stated that positive perceptions of complexity are related to reduced
intention to engage in IPV screening could not be tested because a complexity factor was not
identified in the factor analysis. A model with all four of the innovation attributes was employed
to test Hypothesis two and individual regression models with each innovation attribute were
conducted to test Hypotheses 2a-d. The assumptions of linearity, homoscedasticity, and
independence of the error terms were tested with scatter plots of the studentized residuals
compared to predicted values. Normal probability plots wer examined to assess normality. Data
demonstrated linearity, homoscedasticity, independence, and normality. A correlation matrix
was examined for multicollinearity and the variables were not found to be highly correlated
(defined as a correlation of .90 or greater) (Hair et al., 1998). Hypothesis two was supported –
the full model of perceptions of the innovation characteristics of the intervention of IPV
screening was associated with increased intention to screen targeted patients for IPV.
Hypothesis 2a-d examined each attribute of the innovation of IPV screening. Hypotheses 2a-d
were supported – specifically relative advantage, compatibility, trialability, and visibility, are
each individually associated with increased intention to screen targeted patients for IPV (see
Table 22).
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Table 21.
Testing for Hypothesis 2 – Full Model
Relationship between intention to screen targeted patients for intimate partner violence and
innovation characteristics factor scores
Standardized Coefficient
t value
p value
Relative Advantage
0.596
6.745
0.0001
Compatibility

0.091

1.148

0.253

Trialability

0.104

1.510

0.133

Visibility

0.112

1.854

0.066

F(4,133)

40.02***

Adj R-Sq

0.533

Standard error of the estimate

1.199

***p<0.0001

Table 22.
Testing for Hypotheses 2a-d – Individual Innovation Characteristics
Relationship between intention to screen targeted patients for intimate partner violence and
individual innovation characteristics factor scores
Standardized F(df)
Adj R-Sq
SEM
p
Coefficient
Relative Advantage
0.723
149.14(1,137) 0.520
1.215
0.0001
Compatibility

0.478

40.25(1,137)

0.223

1.546

0.0001

Trialability

0.386

23.76(1,137)

0.143

1.623

0.0001

Visibility

0.283

11.81(1,137)

0.073

1.688

0.001
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Pharmacist Experience with Intimate Partner Violence
The items assessing exposure to intimate partner violence were completed by all but 3 of
the participants. Analysis of responses regarding exposure to intimate partner violence indicates
that the levels of exposure are similar to the rates reported nationally, with 14.2% reporting ever
being threatened with physical violence (with an additional 0.7% responding don’t know/not
sure and 2.2% responding do not want to answer), 17.0% reporting that an intimate partner had
ever attempted physical violence against them (with an additional 1.5% responding don’t
know/not sure and 2.2% responding do not want to answer), and 17.9% reporting that an intimate
partner had ever hit, slapped, kicked or otherwise hurt them (with an additional 1.5% responding
don’t know/not sure and 2.2% responding do not want to answer). These values were compared
to the values obtained utilizing the same survey items in BRFSS utilizing chi square analyses and
no significant differences were found (Table 23).

Table 23.

Pharmacist Study Sample Intimate Partner Violence Rates Compared to
Rates Reported in BRFSS
Percent responded YES
Study
BRFSS
X2
p value
Sample
Intimate partner ever:
-threatened you with physical violence

14.2%

19.2%

1.423

>0.492

-attempted physical violence against you

17.0%

14.5%

0.778

>0.678

-ever hit, slapped… hurt you

17.9%

20.2%

0.228

>0.989
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Pharmacist Participant Feedback
A number of pharmacist study participants provided comments in response to two
opened-ended questions. The first question appeared in the section of the survey addressing IPV
screening in pharmacies and solicited “any other thoughts about community pharmacies,
pharmacists, and intimate partner violence.” A total of 17 participants (11.8%) provided
comments. The complete, unedited comments in response to this item are reported in Table 24.
A review of the comments indicates that while a few participants believe IPV screening could be
done, most cited concerns about time and acceptability. Interestingly, one comment raised the
issue of the speed with which a corporation would move to address this issue and a second raised
the issue of who would cover the cost.
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Table 24.

Pharmacist Study Participant Comments to Open-ended Intimate Partner
Violence Screening in Pharmacy Question

If we have referral sites (which we do in our community) these screenings could be done at the
pharmacy level.
Never really thought about IPV as it pertains to my practice before.
would be a useful resource
in our store, we are almost constantly filling prescriptions. Most of the time, we only have one
pharmacist on duty. We can't afford to halt the entire filling process to screen/counsel/etc for
IPV.
i have recently found out about a couple, that my family knows well, where the husband was
abusing the wife. I wish that I had had the skills to identify and help her earlier and potentially
help other people. This is a very relevent topic for me right no and I am extremely interested in
how i could help in my personal and professional life
Unless there is a counseling area that is completely private I don't believe this would ever work.
Screening should be conducted on a targeted audience because some patients would avoid the
pharmacy practice even if they were not a victim because the very subject causes some patients
to be uncomfortable discussing it.
I worked with a fellow pharmacist whose husband had battered her even when she held her child
in her arms. He stopped beating her physically but continue to do so financially and emotionally.
She left the job about 6 months ago and had to file for bankrupcy. He spent all her money and
left her financially drained. I listened to her but she stayed married to him so not to appear a
failure to her family. It would have been her second divorce. She was totally dependent on him. I
felt sad being around her.
This would be a tremondous effort to identify and impact domestic violence. However, training of
pharmacists or pharmacy staff needs to start in the pharmacy schools to be effective.
This is the first time I've ever heard of IPV and pharmacy. We deliver medical equipment and
our continuing education provides online courses in neglect and abuse bu not specifically IPV.
I DON'T FEEL I HAVE THE TRAINING TO DO IPV SCREENING
This is not a subject that i have ever had to directly deal with
Time is the greatest problem esp in a busy retail practice. It would be very difficult to have a
program in place but would be very helpful to know the laws and how to council if the need
would arise/
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I believe after the many years in community Pharmacy that the idea of having any Pharmacist to
screen for IPV or ask questions of that nature in the absence of "signs" would be repugnant.
Pharmacists have little time for other duties besides checking rx's, counciling etc. These are
physicians or professional 's in hospitals or police associated employee duties, not the
pharmacist.
WHO PAYS?
It is an important topic, but I believe that corporations can be a bit slow to change with
supporting pharmacy initiatives to screen patients in this manner.

The second question that solicited feedback was in the final section after the IPV
screening items. This item was “If there are any additional comments you would like to share
with us about domestic violence screening in a pharmacy, we welcome your input in the box
below. Thank you.” A total of 10 participants (6.9%) provided comments. The complete,
unedited comments in response to this item are reported in Table 25. A review of the comments
indicates that there is clearly a need to provide education and training to prepare pharmacists to
take on this role. Suggestions for other methods of expanding screening were also made.
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Table 25.

Pharmacist Study Participant Comments to Open-ended Intimate Partner
Violence in Pharmacy Question

There is the more obvious domestic "physical" violence among intimate partners but there can
also be the much less obvious and less evident/detectable "emotional & mental" abuse among
intimate partners as well and hopefully these screenings can help with his area as well.
Adequate education would be mandated before these types of services could be offered in the
community pharamcy setting.
Education through the National Home Infusion Association would be great. Home infusion
services have a unique ability to care for patients in their homes - an additional ability to screen
in their own environments.
You don't mention emotional, verbal and financial abuse. Very serious too
this survey seems difficult and yet in some senses redundant.. not the last 3-4 pages but the front
pages and really busyness is an issue patient privacy is another huge issue and some people
want to hide issues with the people they know .. so familiarity has its good and bad points. The
anticoagulation practice i work in is much more conducive than the community pharmacy but I
think that this should be targeted in the md office for patients on narcotics and their families. As
far as the follow up it would be hard to get patients families involved truthfully due to the fear of
not getting medicine... Really a catch 22. We have reported elder abuse in our clinic before
financially so and that is an issue that really was never resolved . community resources ae very
lacking and patients at least elderly ones are isolated and dementia issues really don't help
matters.
I was fortunate to get out of the relationship where I was threatened and hit - happened over 35
years ago. I have been happily married a person who was the opposite of this person and I
thought my experience with domestic violence was over. Unfortunatel, our daughter found
herself in a relationship where she experienced domestic violence. Her boyfriend's family
convinced her she had to marry the boy once she found out she was pregnant - and she thought
she loved the fellow. She didn't tell us about the omestic violence at first but once she did, we
helped her get out of that marriage. Unfortunately she lives in fear of when he is going to show
up even though there is a restraining order……What little I know about resources for victims of
domestic violece comes from this experience and not any training or educational programs formal or informal. IF some sort of formal training could be incorporated into pharmacy
cirricula, I think it would be beneficial. For practicing pharmacists, continuing educatio
programs would be beneficial. I suspect that are those out there who don't have a clue how big
this problem really is and probably think it doesn't affect them. As pharmacists, we could be just
that person to offer some help and advice to that patient hat needs it most…..In my opinion, I
think abusive behavior in general is increasing especially as 'social media outlets' are being
used more and more frequently. I know from experineces with my daughter that kids these days
say awful things to and about ach other on these social media sites - and I think the fact so many
people can chime in at one time, it makes people think they can get away with anything.....and
not be held responsible for their actions……Thank you for conducting this survey and undertking
such a project. I hope much good will come from it.
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I feel that pharmacists are not trained in this area but we should be.
The most useful materials are those that identify the victims of IPV as normal and successful. If
everyone considers IPV a problem only of poor, MediCaid mothers with alcoholic spouses, a
huge number of upper middle class
No. I am a member of Al-Anon, so I am well aware of IPV and other abuse, but think that having
Pharmacists involved in providing screening wrong.
I understand this is a growing problem, however pharmacist may advise or recommend patient
to physician or proper authority to council or advise them but pharmacist's are not trained to
council abused patients.
Adequate education would be mandated before these types of services could be offered in the
community pharmacy setting.
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Consumer Study
The survey designed to explore the pharmacy consumer’s perspective of IPV screening in
the pharmacy environment was distributed to a total of 1,970 female employees of a public,
southeastern university. A total of 64 respondents participated in the consumer study. This
resulted in a response rate of 3.25%. After a review of the data, 4 responses were not included in
the analyses as they had not completed more than 10% of the survey. A final sample of 60
participants contributed data to the analyses, resulting in a net usable rate of 3.05%. The survey
program recorded the start and stop times for each participant. The mean time for survey
completion was 7.01 minutes (±4.34 minutes), with a range of 1.93 to 27.43 minutes.
Consumer Participant Characteristics
Descriptive analyses indicated that the mean age of participants was 43.3 years (±11.3
years), with a range of 23 to 67 years of age. Table 26 reports the race, marital status, level of
education, and income level for the study participants. Participants reported high levels of
general health, with the majority of participants indicated that their health was very good or
excellent and no participants reporting poor health (Table 27).
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Table 26.

Consumer Study Participant Characteristics
Percent

n

86.7%
11.7%
--1.7%

52
7
0
0
1

Hispanic
Yes
No
Don’t know/Not Sure

1.7%
98.3%
--

1
59
0

Marital Status
Married
Divorced
Widowed
Separated
Never Married
A member of an unmarried couple

71.7%
10.0%
0%
1.7%
16.7%
--

43
6
0
1
10
0

Level of Education
Never attended school/only attended kindergarten
Grades 1-8 (elementary)
Grades 9-11 (some high school)
Grade 12 or GED (high school graduate)
College 1-3 years (some college/technical school)
College 4 years or more (college graduate)
Attended or completed graduate school

---3.3%
11.7%
21.7%
63.3%

0
0
0
2
7
13
38

Annual Household Income
<$19,000
$20,000 - $24,999
$25,000 - $34,999
$35,000 - $49,999
$50,000 - $74,999
>$75,000
Not reported

-1.7%
8.3%
15.0%
31.7%
40.0%
3.3%

0
1
5
9
19
24
2

Race
White
Black/African American
Asian
Native Hawaiian/Pacific Islander
American Indian/Alaskan Native
Other
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Table 27.

Consumer Study Participant General Health
Percent

n

Excellent

15.0%

9

Very Good

45.0%

27

Good

36.7%

22

Fair

3.3%

2

Poor

--

0

Consumer Study Non-response Bias
Potential non-response bias was assessed by two methods. First, the characteristics of the
study participants were compared to the university’s workforce. This analysis indicated that the
while a greater proportion of survey respondents reported their race/ethnicity as white, a chisquare test did not indicate that there was a significant difference (86.7% in study sample
compared to 77.8% of all university employees, X2 = .991, p=n.s.). Additionally, the study
sample reported a high level of education and income, indicating that many of the respondents
were likely faculty and/or professional personnel. Given that approximately 84% of the
university faculty report their ethnicity as white, the sample is slightly more diverse than the
faculty.
The second method utilized to examine potential non-response bias was a time-trends
extrapolation method that compared the first 20% of respondents with the last 20% of
respondents. A t-test and chi-square tests were conducted and the results indicated that there
were no significant differences between these two groups. The mean age for the first 20% was
42.6±9.9 compared to 44.4±14.5 for the last 20%. No differences in reported race, marital status,
household income level, educational attainment, nor general health were detected. Inspection of
the data indicated that the first 20% were slightly more likely to have been exposed to IPV
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compared to the last 20% of respondents; however, cell sizes were too small to permit statistical
analysis (see Table 28). This finding is not surprising as individuals who have experienced IPV
may have been more likely to attend to the notice of the survey as the topic has a heightened
personal connection for them.

Table 28.

Comparison of Intimate Partner Violence Exposure among First and Last
20% of Respondents
Number responded YES
First 20%
Last 20%
Intimate partner ever threatened you with physical violence
2
2
Intimate partner ever attempted physical violence against you

3

2

Intimate partner ever hit, slapped… hurt you

3

1

Pharmacy Use Patterns
The majority of participants have regular exposure to a pharmacy to fill prescriptions.
Sixty percent of participants (n=36) reported that they visit to fill a prescription for themselves or
family member at least once per month, with an additional 28.3% (n=17) reporting that they visit
once every few months to fill a prescription. Only five participants (8.3%) reported visiting
about once per year, while two participants (3.3%) reported that they had not visited a pharmacy
to fill a prescription in more than a year. Participants are filling prescriptions for a number of
individuals in their household, including spouse/partner, children, and other household members
(see Table 29 for number of prescriptions routinely taken by household members). Participants
reported using a number of types of pharmacies to fill prescriptions, including chain, grocery
store or general merchandise store, and independent pharmacies, with a few participants using
mail order pharmacies (see Table 30). The majority of participants have a single pharmacy that
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they use to fill these prescriptions, with 68.3% reporting using only one pharmacy and 31.7%
reporting the use of two pharmacies to fill these prescriptions. No participants reported using
more than 2 pharmacies to fill these prescriptions. This result was further emphasized with
96.7% of participants reporting that they had a regular pharmacy that they like to go to, with only
one participant indicating that they did not have a regular pharmacy. Interestingly, while 96.7%
(n=58) of the participants reported that they had a regular pharmacy, they do not necessarily have
a regular pharmacist. Only 45% (n=27) of the participants agreed or strongly agreed with the
statement “I have a regular pharmacist”, while 25% (n=15) of the participants responded that
they either disagreed or strongly disagreed with the statement. Overall, these results indicate that
this sample has experience with community pharmacies as a consumer.

Table 29.

Number of Prescription Medications by Household Members

Self

0
30.0%

1-2
43.3%

3-5
25.0%

>5
N/A
1.7% 0%

Spouse/Partner

40.0%

23.3%

10.0%

1.7% 25.0%

Children

36.7%

15.0%

1.7%

3.3% 43.3%

Other Household Member

28.3%

3.3%

1.7%

0%

Table 30.

66.7%

Types of Pharmacies Utilized to Fill Prescriptions
Percent report using
40.0%

n
24

Grocery/General Merchandise Store Pharmacies

48.3%

29

Independent Pharmacies

33.3%

20

Mail Order Pharmacies

10.0%

6

Other

1.7%

1

Chain Pharmacies
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Experience with Pharmacy Care and Opinions about Community Pharmacies and
Pharmacists
Few of the participants have experience with advanced pharmacy care services. Only 4
(6.7%) reported ever receiving counseling from a pharmacist or pharmacy technician about a
health behavior. Despite this lack of experience with advanced pharmacy care services, most
participants reported that they agree that the pharmacy is a good place for health education and is
a good place to be screened for health care problems such as high blood pressure (see Figures 4
and 5). Participants apparently prefer to utilize a pharmacy that offers health education and
screening programs, with 58.3% indicating some level of agreement with this.

Figure 4.

The Pharmacy is a good place for health education

35.0%

31.7%

30.0%

26.7%

25.0%
20.0%
15.0%
8.3%

10.0%
5.0%

13.3%

11.7%
5.0%

3.3%

0.0%
Strongly
Disagree

Disagree

Somewhat Neither Agree Somewhat
Disagree nor Disagree
Agree

Agree

Scale 1 (strongly disagree) to 7 (strongly agree); Mean = 4.87; SD = 1.62

100

Strongly
Agree

Figure 5.

The pharmacy is a good place to receive health care screenings like blood
pressure
33.3%

35.0%
30.0%
25.0%

21.7%

20.0%

20.0%
15.0%
8.3%

10.0%

10.0%

5.0%
5.0%

1.7%

0.0%
Strongly
Disagree

Disagree

Somewhat
Disagree

Neither
Agree nor
Disagree

Somewhat
Agree

Agree

Strongly
Agree

Scale 1 (strongly disagree) to 7 (strongly agree); Mean = 5.07; SD = 1.77

Participants reported the highest levels of agreement with the statement that the
pharmacist gives good advice about medication, although there is also substantial agreement
with the statements that the pharmacy and the pharmacist are good places to go for advice
regarding health care and health matters (see Figure 6). Overall, participants reported relatively
high levels of agreement with the statements “I trust the pharmacist when it comes to health
matters” and “I can talk comfortably with a pharmacist” (see Figures 7 and 8).
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Figure 6.

Advice in the Pharmacy Environment

50.0%
45.0%
40.0%
35.0%
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
Strongly
Disagree

Disagree

Somewhat Neither Agree Somewhat
Disagree
nor Disagree
Agree

Agree

The Pharmacy is a good place for health care advice
The Pharmacy is a good place to get advice about health matters
The Pharmacist gives good advice about medications

Scale 1 (strongly disagree) to 7 (strongly agree);
Health care advice: Mean = 4.90; SD = 1.74
Advice about health matters: Mean = 5.05; SD = 1.67
Good advice about medications: Mean = 5.57; SD = 1.56
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Figure 7.

I trust the pharmacist when it comes to health matters

30.0%

26.7%

28.3%

25.0%
18.3%

20.0%
15.0%

11.7%
8.3%

10.0%
5.0%
5.0%

1.7%

0.0%
Strongly
Disagree

Disagree

Somewhat Neither Agree Somewhat
Disagree
nor Disagree
Agree

Agree

Strongly
Agree

Scale 1 (strongly disagree) to 7 (strongly agree); Mean = 4.88; SD = 1.71

Figure 8.

I can talk comfortably with a pharmacist

30.0%
26.7%
25.0%
20.0%

18.3%

15.0%
11.7%
10.0%
5.0%

18.3%

13.3%

8.3%
3.3%

0.0%
Strongly
Disagree

Disagree

Somewhat Neither Agree Somewhat
Disagree
nor Disagree
Agree

Scale 1 (strongly disagree) to 7 (strongly agree); Mean = 4.52; SD = 2.07
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Opinions about Intimate Partner Violence and Screening for Intimate Partner Violence
Overall, participants reported high levels of agreement that IPV is a serious health threat.
There was less agreement with the belief that screening for IPV can assist individuals in leaving
dangerous relationships (see Figure 9).

Figure 9.

Perceptions about Intimate Partner Violence

70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
Strongly
Disagree

Disagree

Somewhat Neither Agree Somewhat
Disagree nor Disagree
Agree

Agree

Strongly
Agree

I think IPV is a serious threat to the health of an individual
I believe asking about IPV can help people get out of dangerous relationships

Scale 1 (strongly disagree) to 7 (strongly agree);
Threat to the health of an individual: Mean = 6.35; SD = 1.31
Asking can help people get out of dangerous relationships: Mean = 5.42; SD = 1.36

While participants indicated high levels of agreement with the idea that screening for IPV
is an important activity for health care providers to do, they reported lower levels of agreement
with the concept of screening in the pharmacy setting (see Figure 10).
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Figure 10.

Perceptions of Screening for Intimate Partner Violence

35.0%
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
Strongly
Disagree

Disagree

Somewhat Neither Agree Somewhat
Agree
Strongly
Disagree
nor Disagree
Agree
Agree
I think screening for IPV is an important thing for health care providers to do
I think screening for IPV should happen in a pharmacy
I would like my pharmacy to offer screening for IPV

Scale 1 (strongly disagree) to 7 (strongly agree);
Screening is an important thing for health care providers to do: Mean = 5.65; SD = 1.36
Screening should happen in a pharmacy: Mean = 3.23; SD = 1.72
Would like my pharmacy to offer screening: Mean = 3.95; SD = 1.55
If screening for intimate partner violence was conducted in a local pharmacy, participants
reported they would prefer it to be done via a written form as compared to any other method (see
Table 31). However, 40% reported that they did not think pharmacies should conduct screening
for domestic violence.
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Table 31.

Preference for Acceptable Methods of Intimate Partner Violence Screening if
Offered in a Pharmacy
Percent Reported Acceptable
n
Verbal (pharmacist-conducted)
21.7%
13
Written (screening form)

38.3%

23

Computer (computerized questionnaire)

28.3%

17

40.0%

24

None – I do not believe pharmacies
should screen for IPV

Potential barriers to IPV screening examined included access to a comfortable place to
conduct IPV screening and the time required to conduct screenings. Participants reported
concern about the lack of a comfortable place to conduct screenings in their pharmacies and the
impact in terms of time that screening will take in the place they fill their prescriptions (Figure
11.) Despite these concerns participants expressed some interest in IPV screening (Figure 12).

Figure 11.

Potential Barriers to Intimate Partner Violence Screening

30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
Strongly
Disagree

Disagree

Somewhat Neither Agree Somewhat
Disagree nor Disagree
Agree

Agree

My pharmacy has a comfortable place to do screening for IPV
Screening for IPV would slow things down too much at the pharmacy

Scale 1 (strongly disagree) to 7 (strongly agree);
My pharmacy has a comfortable place to do screening: Mean = 2.75; SD = 1.55
Screening would slow things down too much: Mean = 4.27; SD = 1.63
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Figure 12.

Consumer Preference for Intimate Partner Violence Screening

60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
Strongly
Disagree

Disagree

Somewhat Neither Agree Somewhat
Disagree nor Disagree
Agree

Agree

Strongly
Agree

I would prefer to go to a pharmacy that offers screening for IPV
I do not want to fill Rx in a pharmacy that asks about IPV

Scale 1 (strongly disagree) to 7 (strongly agree);
Prefer pharmacy that offers screening: Mean = 3.53; SD = 1.43
Do not want to fill Rx in a pharmacy that asks about IPV: Mean = 3.23; SD = 1.72

Consumer Experience with Intimate Partner Violence
The items assessing exposure to intimate partner violence were completed by all but one
of the participants. Analysis of responses regarding exposure to intimate partner violence
indicates that the levels of exposure are similar to the rates reported nationally, with 20.3%
reporting ever being threatened with physical violence, 18.3% reporting that an intimate partner
had ever attempted physical violence against them, and 18.6% reporting that an intimate partner
had ever hit, slapped, kicked or otherwise hurt them. These values were compared to the values
obtained utilizing the same survey items in BRFSS utilizing chi square analyses and no
significant differences were found (Table 32). When asked if a health care provider had ever
asked about domestic violence, only 9 (15%) indicated that they had been screened by a health
care provider. Respondents reported that screenings had been conducted by nurses (n=5),
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physicians (n=6), and staff at a physician’s office (n=1). No participant reported being screened
by other health care providers, including pharmacists. Interestingly, there were no differences
between those who reported IPV exposure compared to those who did not regarding screening.
This may indicate that health care providers are not more likely to conduct targeted screenings
for women who may present with some indication of IPV exposure, reiterating the need for
routine screening as compared to screening as indicated.

Table 32.

Consumer Study Sample Intimate Partner Violence Rates Compared to
Rates Reported in BRFSS
Percent responded YES
Study
BRFSS
X2
p value
Sample
Intimate partner ever:
-threatened you with physical violence

20.3%

19.2%

0.043

>0.979

-attempted physical violence against you

18.3%

14.5%

0.702

>0.704

-ever hit, slapped… hurt you

18.6%

20.2%

0.071

>0.965

Acceptability of IPV Screening
This is the first investigation of the potential for IPV screening in the community
pharmacy environment. Given the lack of investigation in this area, it was difficult to determine
what factors may or may not influence preferences related to IPV screening in this environment.
In order to examine potential influences on the preference for IPV screening in the community
pharmacy, the correlation between items indicating positive or negative preference for IPV
screening and other opinions about pharmacies and pharmacists that may related were calculated.
Table 33 reports these correlations. Clearly, preference for a pharmacy that offers screening for
IPV is highly, positively correlated with beliefs that the pharmacy is a good place for health
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advice, that the pharmacist is trustworthy, and that they pharmacy is a good place for health
education and screenings. It may be that those who are aware that pharmacists are trained and/or
able to do advance practice activities have more comfort and preference for IPV screening in the
pharmacy environment.
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Table 33.
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I think screening
for DV should
happen in a
pharmacy.
I would like my
pharmacy to do
screening for DV.
I would prefer to
go to a pharmacy
that offers
screening for DV.
I do not want to
fill prescriptions in
a pharmacy that
asks about DV.
Screening for
domestic violence
would slow things
down too much at
the pharmacy.
I think screening
for DV is an
important thing for
health care
providers to do.
I think domestic
violence is a
serious threat to
the health of an
individual.
I believe asking
about DV can help
people get out of
dangerous
relationships.

Correlation of Intimate Partner Violence Screening Preference Variables with Pharmacy Opinion Variables
I think the
pharmacy is a
good place for
health education.

I think the
pharmacy is a
good place to get
health care advice.

I think the
pharmacy is a
good place to be
screened…

I think the
pharmacist gives
good advice about
medications.

I think the
pharmacist gives
good advice about
health matters.

I trust the
pharmacist when it
comes to health
matters.

I can talk
comfortably with a
pharmacist.

I would prefer to
go to a pharmacy
that offers health
ed/screenings.

.314*
p<.015

.315*
p<.014

.254
p<.051

.325**
p<.011

.240
p<.065

.246
p<.058

.170
p<.194

.239
p<.066

.282*
p<.029

.275*
p<.034

.224
p<.086

.245
p<.059

.185
p<.158

.198
p<.130

.120
p<.362

.216
p<.097

.426**
p<.001

.429**
p<.001

.373**
p<.003

.326**
p<.011

.304*
p<.018

.336**
p<.009

.248
p<.056

.373**
p<.003

-.311*
p<.016

-.263*
p<.042

-.222
p<.089

-.240
p<.065

-.217
p<.096

-.187
p<.153

-.227
p<.081

.014
p<.913

-.295*
p<.022

-.224
p<.086

-.112
p<.394

-.068
p<.608

-.235
p<.070

-.242
p<.062

-.129
p<.326

-.100
p<.446

.078
p<.552

.085
p<.519

.080
p<.544

.183
p<.162

.178
p<.173

.090
p<.496

.084
p<.523

.144
p<.272

.102
p<.438

.104
p<.427

.164
p<.209

.142
p<.279

.043
p<.743

.162
p<.217

-.019
p<.884

.133
p<.309

.072
p<.585

.111
p<.398

.045
p<.735

.159
p<.224

.192
p<.141

.088
p<.505

.182
p<.163

.267*
p<.039

Note: * = p<.05; ** = p<.01

Table 34.

Correlation between Intimate Partner Violence Opinion and Screening Preference Variables
I think screening
for DV should
happen in a
pharmacy.
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I think screening
for DV should
happen in a
pharmacy.
I would like my
pharmacy to do
screening for DV.
I would prefer to
go to a pharmacy
that offers
screening for DV.
I do not want to
fill prescriptions in
a pharmacy that
asks about DV.
Screening for
domestic violence
would slow things
down too much at
the pharmacy.
I think screening
for DV is an
important thing for
health care
providers to do.
I think domestic
violence is a
serious threat to
the health of an
individual.
I believe asking
about DV can help
people get out of
dangerous
relationships.

I would like my
pharmacy to do
screening for DV.

I would prefer to
go to a pharmacy
that offers
screening for DV.

I do not want to
fill prescriptions in
a pharmacy that
asks about DV.

Screening for
domestic violence
would slow things
down too much at
the pharmacy.

I think screening
for DV is an
important thing for
health care
providers to do.

I think domestic
violence is a
serious threat to
the health of an
individual.

I believe asking
about DV can help
people get out of
dangerous
relationships.

1

.868**
.000

1

.803**
.000

.778**
.000

1

-.530**
.000

-.474**
.000

-.492**
.000

1

-.415**
p<.001

-.406**
.001

-.405**
.001

-.474**
.000

1

.513**
p>.000

.442**
p>.000

.401**
p<.001

-.138
p<.293

-.049
p<.710

1

.419**
p<.001

.402**
p<.001

.377**
p<.003

-.007
p<.933

.011
p<9.933

0.610**
p>.000

1

.

.375**
p<.003

.317*
p<.0113

.407**
p<.001

-.108
P<.413

-.128
P<.329

.694**
p>.000

.469**
p>.000

1

Note: * = p<.05; ** = p<.01

The correlations among the items related to opinions regarding IPV and IPV screening
were also examined (see Table 34). As would be expected responses to beliefs in the seriousness
of the health threat of IPV, the value of screening in helping people get out of dangerous
relationships, and the importance of health care provider screenings, are correlate positively
related to preference for IPV screening in the pharmacy and are negatively correlated with
beliefs that screening would slow things down too much at the pharmacy and agreement with the
statement that one would not want to fill a prescription in a pharmacy that screens for IPV.

IPV Victims’ Preferences Regarding IPV Screening in the Pharmacy Setting
First and foremost in all research and intervention development related to intimate partner
violence is the requirement that the intervention have value for the victim. If women who have
experienced IPV report significant concern about screening for IPV in the pharmacy setting,
intervention development in this setting should be reconsidered. In order to investigate this issue
a comparison of responses between women who reported exposure to IPV and those who did not
was carried out. Individuals reporting any exposure to IPV were compared to those reporting no
exposure on all study variables with t tests and chi square analyses and no significant differences
were found.
Hypothesis three suggests that there is a difference in preference for IPV screening in the
community pharmacy between women have experienced IPV compared to women who have not
experienced IPV. This hypothesis was tested in this sample with an ANCOVA. The dependent
variable was the item “I think screening for IPV should be conducted in a pharmacy” which was
measured on a seven point scale. The independent variable was a dichotomous computed
variable scored as a one for a positive response to any of the three items assessing exposure to
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IPV (IPV was threatened, attempted, or committed against the respondent) and a zero for no
positive responses to any of those three items. The covariate included in the model was “I trust
the pharmacist when it comes to health matters”, which was also measured on a seven point
scale.
The ANCOVA analyses first included an omnibus test of the relationship between the
potential covariate (trust of pharmacist) and the independent variable (IPV exposure), indicating
that there was not a significant relationship between these variables (F(1, 58) =3.60; p=.063).
Although this relationship was not statistically significant, this is a common challenge when
using ANCOVA with nonrandom group assignment. As a result, caution in interpreting this
model is warranted. The homogeneity of variance assumption was tested with the BrownForsythe test and this test indicated that this assumption was not violated (Levene statistic based
on median(1,58) = 2.129; p=0.150). The homogeneity of regression coefficients assumption was
tested by including an interaction term for trust and IPV exposure in a model and the results
indicated this assumption was met (F(1,57)=1.606; p=.210) as the null hypothesis that the
regression coefficients are homogeneous was not rejected. The assumption that the covariate
trust and the independent variable IPV exposure are independent was also tested. The null
hypothesis that they are independent was not rejected (F(1,58)=0.94; p=.760). Finally, the
ANCOVA model with the dependent variable support for IPV screening in the pharmacy and the
independent variable IPV exposure covarying for trust of the pharmacist was analyzed. The
result does not support the hypothesis. In this sample, there are not significant differences in
acceptability of IPV screening in the community between IPV exposed and non-exposed women
after adjusting for trust of the pharmacist (F(1,58)=0.283; p=0.597), see Table 35.
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Table 35.

ANCOVA Summary

Source

df

Mean Square

F

Trust

Sum of
Squares
5.875

p

1

5.875

3.284 .075

Partial Eta
Squared
.056

Any IPV exposure

0.506

1

0.506

0.283 .597

.005

Error

98.401

58

1.789

Consumer Participant Feedback
A number of study participants provided comments in response to an open-ended
question soliciting any additional comments about domestic violence screening in a pharmacy
that they would like to share. A total of 11 participants (18.3%) provided comments. A review
of the comments indicates that some participants feel strongly that screening should be expanded
to the pharmacy setting, while other participants feel just as strongly that it should not. Concerns
reported about screening in the pharmacy setting included pharmacists training and preparation,
the time burden of screening everyone, lack of privacy, and victim safety. However, an IPV
victim who reported that pharmacy-based screening would have been very helpful. This
sentiment was echoed by a domestic violence shelter board member. Complete, unedited
comments are reported in Table 36.
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Table 36.

Consumer Study Participant Comments

My biggest concern about this type of screening is the training of the pharmacist. Do they know
what to look for? Further, I want them to care. If a pharmacist does not think that this is his or
her job, then they are likely to do a poor job of it. To be honest, the idea of a person I go to
about medication asking me about domestic violence on a regular basis seems strange to me.
However, I suspect that if it was offered, I would just get used to it.
It's not entirely clear to me what you mean by screening. I would not want to answer questions
every time I filled a prescription, but I would want pharmacists to be alert to potential signs of
domestic violence, and equipped to respond.
I am not sure it is appropriate to screen everyone, and if so, this should include men and women.
I would think it appropriate only if one suspects abuse.
I was a board member for a Domestic Violence shelter and think that ANYONE that could
intervene and help a victim would be great.
My concerns are that 1) pharmacists already have a heavy burden and adding domestic violence
screening would be a lot to ask of them and 2) privacy concerns for patients. Those little
consultation windows in pharmacies do not afford any privacy.
I was in an abusive relationship, which I got out of 20 years ago, but I still have "scars" from it.
I am now in a loving marriage with a wonderful man. When I was in the abusive marriage, I
think my pharmacist would have been a wonderful counselor for me. I trust my pharmacists and
am always very comfortable talking with them. I think this is a great plan!
The pharmacy is there to dispense drugs and occasionally provide advice about side affects and
fixes involving over the counter medicine. It is not right, nor is it any of their business, to ask
about domestic violence. I would switch pharmacies if mine ever mentioned domestic violence to
me, or asked what my status was. If I was the victim (which thank god I never have been) I am
certainly not going to talk to my fucking pharmacist about it. If I were the abuser, ditto. Stick
with drugs, stay the heck out of personal business. There are crisis centers, family members,
friends, churches, schools, social workers, etc. who are trained professionals and probably have
a closer relationship to the victim (in many cases an ACTUAL relationship, unlike the
pharmacist) and whom the victim would most likely turn to and feel more comfortable talking to
or seeking advice.
I use the Kroger pharmacy, and there's really no privacy there. I feel awkward enough having to
say my name out loud to pick up my order. Fortunately, I don't have personal experience with
domestic violence, but from what I know, the violence is frequently on less visible parts of the
body (covered by clothes), so I think it would be difficult for pharmacy employees to identify who
has been victimized? Anyway, good luck with the project.
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My daughter was a victim of domestic violence and fortunately was able to escape that
relationship after many years. Allowing someone to take home a form requesting informatin
about abuse would only add to it if the form were discovered. Most if not all abusers have
damaged their victims to the point they have no self esteem left. They try to keep it from
everyone. My reasoning is that any public place is no where to bring it out in the open.
Someone might be listening or watching and report it to the abuser. They tend to somehow have
a network of spies out there. I know it may sound far fetched, but it is true. Perhaps displaying
contact information such as the number for SAFE you posted on this for anyone who is in an
abusive situation would be less dangerous to the victim. They must be ready to get help before
they will take any action due to the fear of more hurt. / My daughter is an licensed counselor
now, owns her own business and helps many people. So, with help victims can reclaim thier
lives. / / Thank you for taking this issue to research and God Bless you for helping.
NO
I think domestic violence education is important. After going through this though, I'm not 100%
sure the pharmacy is where it should be discussed. It could be though, if done confidentially.
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5. DISCUSSION
Discussion of Study Results and Implications
In review, the objectives of this study were:
1. To investigate community pharmacists’ readiness to participate in IPV screening,
including examining training, knowledge, attitudes, behaviors, and intentions related to
IPV screening by developing and testing an instrument adapted from an existing
instrument named the PREMIS (Physician Readiness to Manage Intimate Partner
Violence Survey) tool.
2. To examine potential demographic differences in knowledge, attitudes and intention to
conduct IPV screening among pharmacists.
3. To examine perceptions of the characteristics of the IPV screening innovation in
community pharmacies.
4. To examine female consumer’s attitudes and preferences for IPV screening in community
pharmacies.

This investigation conducted two studies to address these study objectives with a goal of
exploring the potential to address the public health problem of interpersonal violence (IPV) by
expanding IPV screening to the community pharmacy environment. The PRECEDE-PROCEED

117

model was used to guide the assessment of factors that may predispose, reinforce, or enable IPV
screening in the community pharmacy setting. A review of the literature addressed Phases 1 and
2 of the PRECEDE-PROCEED model and documented the social and epidemiological
assessment of IPV and IPV screening. The study objectives provided the means by which Phase
3, educational & ecological factors that predispose, reinforce and enable an intervention, could
be assessed and initial data generated for this assessment. Specifically, the predisposing factors
of knowledge and attitudes regarding IPV and IPV screening at both the pharmacist and
consumer levels were assessed. Additionally, reinforcing factors such as the perceived attitudes
and behaviors related to IPV and IPV screening were assessed. Finally, enabling factors at the
pharmacist’s level were assessed. The results provide guidance regarding the development of
interventions.
The PREMIS instrument was adapted and tested in a national random sample of
practicing community pharmacists. This new measure, the Pharmacy PREMIS, was found to be
a valid tool that can be used to assess baseline knowledge, attitudes, behaviors, and intentions
regarding IPV screening with pharmacists. If IPV screening is to be successfully implemented in
any manner in the community pharmacy environment, education and training initiatives will be
critical. This measure provides a valid method to assess baseline knowledge, attitudes,
behaviors, and intentions and a mechanism to assess the potential impact of education and
training programs related to IPV and IPV screening.
Importantly, a similar, but not identical factor structure was found in the Pharmacy
PREMIS compared to previous studies with this instrument in other, non-pharmacist
populations. The background scales, including perceived preparation, perceived knowledge, and
actual knowledge translated well to the pharmacy setting. The factor structure of the opinions
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component of the instrument found four of the original factors (preparation, legal requirements,
alcohol and drugs, and constraints). However, the pharmacy version found a single factor which
we labeled workplace and self-efficacy that was split into two separate factors (workplace issues
and self-efficacy) in the previous studies. One reason for this finding may be related to the selfreported level of training and clinical experience with IPV and IPV screening. The pharmacists
reported less training and experience compared to the other health care provider populations.
The lack of knowledge and awareness of the details of the challenges related to IPV screening
may have made it difficult for pharmacists to tease apart the efficacy issues related to themselves
as clinicians as compared to their work environments. If educational and training initiatives for
pharmacists increase, this may change and the factor structure should be re-evaluated. It is also
interesting to note that the victim understanding and victim autonomy scales were not found in
the pharmacy PREMIS. Both of these scales had low reliability in the previous studies and it
was recommended that they be further explored. This is another example of how the lack of
training and exposure to IPV screening recommendations and IPV screening programs may have
impacted this finding. These results indicate that pharmacists do not have well-formed clinical
opinions regarding IPV victims in general and educational and training initiatives may impact
this.
The second study objective sought to determine if findings in other health care fields
related to gender and years of training were similar in pharmacists. The literature has
consistently shown that female health care providers are more comfortable with and willing to
engage in screening for IPV. This may be due to the fact that most professional associations
have advocated for screening for female patients only, effectively making IPV a women’s health
issue. The other individual characteristic that is commonly identified as being positively
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associated with willingness to conduct IPV screening is completing training more recently. This
can be explained in other health care professions because IPV training was been added to the
standard training curricula for most fields about ten years ago, although there has also been a
general increase in awareness of IPV as a public health problem in the United States that may be
impacting these results. Given that pharmacy training has not required inclusion of this topic, it
was worth exploring whether the general increase in awareness may also have impacted recent
pharmacy graduates. The findings from this study do not support that; length of time since
graduation was not significantly associated with willingness to engage in IPV screening. This
result argues for the consideration of inclusion of IPV training in the curriculum of schools of
pharmacy as general public health awareness campaigns are not sufficient to address this issue in
practicing community pharmacists.
The examination of perceptions of the innovation characteristics of the IPV screening in
the pharmacy environment is a novel contribution that provides valuable guidance regarding
what factors may act as either facilitators or barriers to adoption and implementation of IPV
screening programs. These items were not included in the original PREMIS instrument. This is
unfortunate because it is important to understand these issues if IPV screening is to be
successfully adopted and implemented. The literature on IPV screening programs in other health
care settings indicated that there are challenges to adoption, implementation, and dissemination;
however, most of the literature simply documents the barriers and has not utilized a framework
to guide the investigation. The use of the PRECEDE-PROCEED model was helpful in the
current study as it recommends the use of Rogers’ Diffusion of Innovation theory when
conducting research with the goal of potentially planning an intervention such as IPV screening.
This study found that pharmacists’ perceptions of the innovation characteristics were related to
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intention to conduct targeted screenings for IPV. Importantly, the pharmacists found IPV
screening to be compatible with their work and believed that offering IPV screening would serve
as a relative advantage. These findings are critical as pharmacists must believe that at a
minimum offering IPV screening will not hurt their business before they adopt IPV screening in
their practice.. The finding that pharmacists believe it would be difficult to offer screening on a
trial basis is further indication that there is a need for education and training to prepare
pharmacists in the event they would like to try to offer a screening program in their practice sites.
The community pharmacy environment is unique in that the pharmacist is likely more
aware of the impact of activities on the ability to maintain a patient as a “customer” compared to
other medical providers who may be engaged in IPV screening. If consumers desire IPV
screening, it might encourage pharmacists to offer this service. However, if consumers find IPV
screening in the pharmacy environment upsetting or distasteful to the point that they would
prefer to use a pharmacy that did not offer the service, then pharmacists are unlikely to initiate a
screening program. The final study objective sought to examine the consumer’s perspective to
address these issues.
The results of this convenience sample study of female pharmacy consumers indicated
that consumers may not yet be ready for IPV screening in the pharmacy environment. While
consumers trust pharmacists, they lack of awareness of pharmacists’ training. The results
delineated some concerns consumers have, including the lack of appropriate physical space in
the pharmacy and the time needed to conduct screenings. While there is neither clear support
nor opposition from consumers regarding support for IPV screening in the pharmacy
environment, it is likely that consumers would need to be educated about the training and
capability of pharmacists before IPV screening in the community pharmacy setting would be
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deemed acceptable. This may be a challenge that is more pronounced in communities with few
pharmacies offering of advanced pharmacy services. If consumers have never experienced
advanced pharmacy services, it is unlikely they can judge well the potential benefits and barriers
to screening programs in pharmacy settings.
It is also important to understand IPV victims’ perspectives regarding screening
programs. Their unique perspective can shed light on potential risks and benefits to victims that
a program may raise that investigators and practitioners may not foresee. It was interesting to
note that in this study IPV victims did not differ from women who have not been exposed to IPV
regarding interest in screening. While this finding is in keeping with studies of acceptability of
screening in other health care settings, it is valuable to learn that the pharmacy setting does not
immediately raise any particular areas of concern unique to IPV victims. Some of the comments
in the consumer study indicated that the respondents did not believe IPV screening in the
pharmacy environment was preferred, particularly because of privacy, training, and time
concerns. However, an individual who identified herself as an IPV victim reported that she
thinks screening is a good idea and that her pharmacist would have been helpful to her. These
comments indicate further investigation is warranted, as this employed a small, convenience
sample. Additional investigation in a larger sample from diverse communities may provide more
clarity regarding these issues from the consumer’s perspective.
Together these two survey studies provide additional data to utilize as part of the phase
three assessment of the PRECEDE-PROCEED model which calls for examination of
predisposing, reinforcing, and enabling factors. Recall that predisposing factors include provider
knowledge, attitudes, beliefs, and perceptions; reinforcing factors include attitudes of peers and
patients; and enabling factors include the availability of the tools necessary to conduct IPV
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screening. The Pharmacy PREMIS instrument is useful in generating insight into predisposing
and enabling factors and the consumer survey provided data regarding the reinforcing factors.
The relatively low levels of knowledge related to IPV and IPV screening and the indication that
they had given minimal consideration to these issues prior to this study, indicate that educational
initiatives are critical for IPV screening to be considered by pharmacists. When enabling factors
are considered, it is important to note that this study found relatively low levels of self and
workplace efficacy regarding ability to conduct IPV screening, both of which are enabling
factors that are critical to the successful adoption and implementation of screening. Despite
these results, pharmacists reported interested in continuing education regarding this issue and
some support for screening, particularly of targeted patient populations. Training, time, and
concerns related to payment were also voiced in the review of the comments. These issues are
enabling factors that must be addressed if screening is to be conducted in the pharmacy
environment. Finally, there are minimal reinforcing factors currently in place to support IPV
screening in the pharmacy environment. There is not currently a professional guideline or
recommendation related to IPV screening for pharmacists. The current study provides the first
examination of the attitudes of patients regarding screening and it is not clear that patients desire
this service.
IPV remains a serious public health threat that impacts at least one third of all women in
the U.S. The only known health system intervention that has the possibility to reduce and
prevent negative health outcomes from IPV is routine screening for IPV exposure. The data
from this investigation indicate that there is minimal awareness, knowledge, training, and skills
related to IPV and IPV screening in community pharmacists, despite the fact that they are the
most well positioned health care provider to conduct IPV screening. Initial efforts should be
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targeted at the predisposing factors related to IPV screening in the community pharmacy
environment. Given the minimal level of awareness of IPV, priority should be placed on
developing continuing education programs to inform practicing pharmacists of the prevalence of
this health threat and increase awareness of the value of routine screening. A similar initiative in
curricula in pharmacy training programs should immediately be considered as well. In fact, there
is likely significant demand for education on this issue. The respondents in this survey indicated
that they would enroll in continuing education about IPV [mean =5.15 ±1.79; scale 1 (strongly
disagree) to 7 (strongly agree)], with the largest response, 27.5%, endorsing strongly agree. The
next steps would be to further evaluate the potential barriers in the pharmacy setting, particularly
at the consumer level, and to develop educational and training programs to prepare pharmacists
to engage in screening.

Limitations
There are several limitations to this investigation. First, participants responded to a
survey on what they may consider a sensitive issue. It is possible that their discomfort with this
topic may impact their responses. Second, this study is limited to attitudinal, knowledge, and
logistical feasibility issues of utilizing community pharmacists to screen for IPV. This assumes
that IPV screening instruments with suitable characteristics (sensitivity, specificity) are available.
There remains a debate in the field regarding which is the most effective, efficient and
appropriate measure to use in universal screening programs. Third, the generalizability of the
results of this study is limited by the low response rates (2.40% in the pharmacists study and
3.05% in the consumer study). Finally, the potential for non-response bias may have impacted
the results. While analyses were conducted to look for this effect and none were detected, it
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remains possible that individuals with some characteristic (i.e., history of IPV involvement) may
differentially respond to the survey.
There are several limitations to the study of community pharmacists. First, survey
responses could have been impacted by the sensitive nature of this research topic. Second, based
on a review of the literature and the results of this investigation it is clear that community
pharmacists have had little formal education or exposure to issues related to intimate partner
violence. With more education opinions and perspectives may change and as a result responses
to many of the survey items may be impacted by this lack of knowledge and awareness. Finally,
while this study had more subjects than the prior investigations in practitioners with this
instrument, the sample size was slightly smaller than desired to conduct the factor analysis. A
larger sample is needed to confirm the identified factor structure.
There are several limitations of the study of pharmacy consumers. As in the study of
community pharmacists, participants responded to a survey on what they may consider a
sensitive issue. It is possible that their discomfort with this topic impacted their responses.
Second, this study is limited to individuals’ attitudes and beliefs, but not experiences, with IPV
screening in the pharmacy environment. Given the limited exposure to advanced pharmacy
practice services reported by this sample, it is possible that the respondents lack the experiences
necessary to evaluate and provide feedback regarding screenings in the pharmacy setting. Third,
this study utilized a convenience sample of female patients’ from a work environment. These
individuals are all working at least part-time, live in the same region, and have access to health
insurance. Potential gender and regional differences in attitudes and beliefs regarding IPV, the
limited experience of working individuals, differences in community pharmacy practice norms,
and other cultural differences may limit the generalizability of the results. Finally, the potential
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for non-response bias may have impacted the results. Analyses were conducted to look for this
effect and none were detected; however even if it is not detected it remains possible that
individuals with some characteristic (i.e., minimal community pharmacy use, history of IPV
involvement) may have differentially responded to the survey.

Future Research
Given the dearth of research on the role of the profession of pharmacy and the public
health problem of intimate partner violence, there is ample room for further investigation on this
topic. The results of this investigation can provide some guidance regarding the exploration of
professional guidelines, educational and training initiatives, and patient needs regarding IPV;
however, further research is needed to more fully develop these areas. In addition, re-evaluating
the Pharmacy PREMIS after initial educational initiatives are conducted with pharmacists would
be valuable. Further understanding the role of the characteristics of IPV screening that may
enhance or hinder the effective adoption and dissemination of this innovation is needed. There
is also need for further investigation into the perspective of pharmacy consumers regarding
intimate partner violence screening, including examination of the perspective of male consumers.

Conclusions
Intimate partner violence (IPV) is a public health problem of epidemic proportion and the
only known effective health care intervention is routine screening for exposure to IPV. Despite
professional guidelines for routine screening, this intervention has been poorly adopted by
physicians. Expansion of screening efforts to the community pharmacy setting provides an
opportunity to have a substantial impact on the health and well-being of pharmacy patients. This
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investigation is the first study to examine IPV screening related to the pharmacy environment.
To meet study objectives an existing measure of physicians’ readiness to manage intimate
partner violence (PREMIS) was adapted for the community pharmacy environment and validated
in a national random sample of practicing community pharmacists. Additionally, a study of
female consumers of pharmacy services was conducted to examine the acceptability of IPV
screening in the pharmacy environment. The results indicate that community pharmacists have
minimal exposure to education and training related to IPV and IPV screening. While
respondents expressed concern regarding training and time, they did indicate that participation in
screening may be valuable both to patient health and well-being and as a relative advantage for
their pharmacies. As hypothesized, female pharmacists were more likely to report intent to
screen targeted patients for IPV. Consumers agreed that IPV screening is important for health
care providers to do, but were uncertain as to whether pharmacists specifically should engage in
screening. Comments indicated that consumers are unaware that pharmacists are trained in
patient communication and counseling, suggesting a need for additional recognition of the skills
and capabilities of community pharmacists.
The potential for expanding IPV screening to the community pharmacy environment, at
least for targeted patient populations, should be prioritized among future studies of methods to
address the public health problem of intimate partner violence.

127

LIST OF REFERENCES

128

Reference List

Ackard, D. M., & Neumark-Sztainer, D. (2002). Date violence and date rape among adolescents:
associations with disordered eating behaviors and psychological health. Child Abuse
Negl., 26(5), 455-473.
ACOG. (2010). Screening Tools - Domestic Violence. Retrieved from
http://www.acog.org/departments/dept_notice.cfm?recno=17&bulletin=585
Alexander R.W., Bradley L.A., Alarcon G.S., Triana-Alexander, M., Aaron, L. A., Alberts K.R.
et al. (1998). Sexual and physical abuse in women with fibromyalgia: Association with
outpatient health care utilization and pain medication usage. Arthritis Care and Research,
11(2), 102-115.
Alsaker, K., Moen, B. E., Nortvedt, M. W., & Baste, V. (2006). Low health-related quality of life
among abused women. Qual.Life Res., 15(6), 959-965.
Alvarez, J., Pavao, J., Baumrind, N., & Kimerling, R. (2007). The relationship between child
abuse and adult obesity among california women. Am J Prev.Med, 33(1), 28-33.
Ambuel, B., Hamberger, L. K., & Lahti, J. (1996). Partner violence: a systematic approach to
identification and intervention in outpatient health care. Wis.Med.J., 95(5), 292-297.
American Academy of Family Practice. (1994). Family Violence. Am.Fam.Physician, 50, 16361646.
American Academy of Pediatrics. (1998). The role of the pediatrician in recognizing and
intervening on behalf of abused women. American Academy of Pediatrics Committee on
Child Abuse and Neglect. Pediatrics, 101(6), 1091-1092.
American College of Emergency Physicians. (1995). Emergency medicine and domestic
violence. Ann.Emerg.Med., 25, 442-443.
American College of Obstetricians and Gynecologists. (1995). ACOG technical bulletin.
Domestic violence. Number 209--August 1995 (replaces no. 124, January 1989).
American College of Obstetricians and Gynecologists. Int.J.Gynaecol.Obstet., 51(2),
161-170.
American Medical Association. (1992). American Medical Association diagnostic and treatment
guidelines on domestic violence. Arch.Fam.Med., 1, 39-47.
American Nurses' Association. (1992). Position statement on physical violence against women.
Am Nurse, 24(4), 8.
Arias, I., & Corso, P. (2005). Average cost per person victimized by an intimate partner of the
opposite gender: a comparisn of men and women. Violence Vict., 20(4), 379-391.
129

Armstrong, J. S., & Overton, T. S. (1977). Estimating nonresponse bias in mail surveys. J Mark
Res, 14, 396-402.
ASHP Council on Pharmacy Practice. (2008). ASHP Statement on the role of health-system
pharmacists in public health. Am J Health-Syst Pharm, 65, 462-467.
Babb, V. J., & Babb, J. (2003). Pharmacist involvement in Healthy People 2010. J Am Pharm
Assoc.(Wash.), 43(1), 56-60.
Bacchu, L., Mezey, G., & Bewley, S. (2002). Women's perceptions and experiences of routine
enquiry for domestic violence in a maternity service. BJOG., 109(1), 9-16.
Baldo, T. D., & Baldo, A. J. (1996). Intrafamilial assaults, disturbed eating behaviors, and further
victimization. Psychol.Rep., 79(3 Pt 1), 1057-1058.
Baldo, T. D., Wallace, S. D., & O'Halloran, M. S. (1996). Effects of intrafamilial sexual assault
on eating behaviors. Psychol.Rep., 79(2), 531-536.
Balousek, S., Plane, M. B., & Fleming, M. (2007). Prevalence of interpersonal abuse in primary
care patients prescribed opioids for chronic pain. J.Gen.Intern.Med., 22(9), 1268-1273.
Bates, L., & Brown, W. (1998). Domestic violence: examining nurses' and doctors' management,
attitudes and knowledge in an accident and emergency setting. Aust.J.Adv.Nurs., 15(3),
15-22.
Bauer, H. M., Rodriguez, M. A., Quiroga, S. S., & Flores-Ortiz, Y. G. (2000). Barriers to health
care for abused Latina and Asian immigrant women. J Health Care Poor Underserved,
11(1), 33-44.
Berenson, A. B., Wiemann, C. M., Wilkinson, G. S., Jones, W. A., & Anderson, G. D. (1994).
Perinatal morbidity associated with violence experienced by pregnant women.
Am.J.Obstet.Gynecol., 170(6), 1760-1766.
Berger, R. P., Bogen, D., Dulani, T., & Broussard, E. (2002). Implementation of a program to
teach pediatric residents and faculty about domestic violence. Arch.Pediatr.Adolesc.Med.,
156(8), 804-810.
Bergman, B., & Brismar, B. (1991). A 5-year follow-up study of 117 battered women. Am J
Public Health, 81(11), 1486-1489.
Bergman, B., & Ericsson, E. (1996). Family violence among psychiatric in-patients as measured
by the Conflict Tactics Scale (CTS). Acta Psychiatr.Scand., 94(3), 168-174.
Black, M. C., Basile, K. C., Breiding, M. J., Smith, S. G., Walters, M. L., Merrick, M. T. et al.
(2011). The National Intimate Partner and Sexual Violence Survey (NSIVS): 2010
Summary Report Atlanta, GA: National Center for Injury Prevention and Control,
Centers for Disease Control and Prevention.

130

Bonomi, A. E., Anderson, M. L., Rivara, F. P., & Thompson, R. S. (2007). Health outcomes in
women with physical and sexual intimate partner violence exposure. J.Womens Health
(Larchmt.), 16(7), 987-997.
Bonomi, A. E., Anderson, M. L., Rivara, F. P., & Thompson, R. S. (2009). Health care
utilization and costs associated with physical and nonphysical-only intimate partner
violence. Health Serv.Res., 44(3), 1052-1067.
Bonomi, A. E., Thompson, R. S., Anderson, M., Reid, R. J., Carrell, D., Dimer, J. A. et al.
(2006). Intimate partner violence and women's physical, mental, and social functioning.
Am.J.Prev.Med., 30(6), 458-466.
Breiding, M. J., Black, M. C., & Ryan, G. W. (2008). Prevalence and risk factors of intimate
partner violence in eighteen U.S. states/territories, 2005. Am J Prev.Med, 34(2), 112-118.
Brendtro M, & Bowker L. (1989). Battered Women: How nurses can help. Issues Ment.Health
Nurs., 10, 169-180.
Bunn, M. Y., Higa, N. A., Parker, W. J., & Kaneshiro, B. (2009). Domestic violence screening in
pregnancy. Hawaii Med.J., 68(10), 240-242.
Calis KA, Hutchison LC, Elliott ME, Ives TJ, Zillich AJ, Poirier T et al. (2004). Healthy People
2010: Challenges, Opportunities, and a Call to Action for American's Pharmacists.
Pharmacotherapy, 24(9), 1241-1294.
Calis, K. A., Hutchison, L. C., Elliott, M. E., Ives, T. J., Zillich, A. J., Poirier, T. et al. (2004).
Healthy People 2010: challenges, opportunities, and a call to action for America's
pharmacists. Pharmacotherapy, 24(9), 1241-1294.
Campbell, J. C., & Lewandowski, L. A. (1997). Mental and physical health effects of intimate
partner violence on women and children. Psychiatr.Clin.North Am., 20(2), 353-374.
Campbell, J. C., Webster, D., Koziol-McLain, J., Block, C., Campbell, D., Curry, M. A. et al.
(2003). Risk factors for femicide in abusive relationships: results from a multisite case
control study. Am.J.Public Health, 93(7), 1089-1097.
Cann, K., Withnell, S., Shakespeare, J., Doll, H., & Thomas, J. (2001). Domestic violence: a
comparative survey of levels of detection, knowledge, and attitudes in healthcare
workers. Public Health, 115(2), 89-95.
Cannon, E. A., Bonomi, A. E., Anderson, M. L., & Rivara, F. P. (2009). The intergenerational
transmission of witnessing intimate partner violence. Arch.Pediatr.Adolesc.Med., 163(8),
706-708.
Caralis, P. V., & Musialowski, R. (1997). Women's experiences with domestic violence and their
attitudes and expectations regarding medical care of abuse victims. South.Med.J., 90(11),
1075-1080.

131

Carter, L. S., Weithorn, L. A., & Behrman, R. E. (1999). Domestic violence and children:
analysis and recommendations. Future.Child, 9(3), 4-20.
Centers for Disease Control and Prevention. (1998). Rural health-care providers' attitudes,
practices, and training experience regarding intimate partner violence--West Virginia,
March 1997. MMWR Morb.Mortal.Wkly.Rep., 47(32), 670-673.
Centers for Disease Control and Prevention. (2007). Behavioral Risk Factor Surveillance System
Questionnaire Atlanta, GA: U.S. Department of Health and Human Services, Centers for
Disease Control and Prevention.
Centers for Disease Control and Prevention. (2010). Intimate Partner Violence: Data Sources.
Retrieved from
http://www.cdc.gov/ViolencePrevention/intimatepartnerviolence/datasources.html
Centers for Disease Control and Prevention. (2011). Behavioral Risk Factor Surveillance System
Questionnaire Atlanta, GA: U.S. Department of Health and Human Services, Center for
Disease Control and Prevention.
Chamberlain, L., & Perham-Hester, K. A. (2000). Physicians' screening practices for female
partner abuse during prenatal visits. Matern.Child Health J., 4(2), 141-148.
Chang, J. J., Theodore, A. D., Martin, S. L., & Runyan, D. K. (2008). Psychological abuse
between parents: associations with child maltreatment from a population-based sample.
Child Abuse Negl., 32(8), 819-829.
Chen, P. H., Rovi, S., Vega, M., Jacobs, A., & Johnson, M. S. (2005). Screening for domestic
violence in a predominantly Hispanic clinical setting. Fam.Pract., 22(6), 617-623.
Chen, P. H., Rovi, S., Washington, J., Jacobs, A., Vega, M., Pan, K. Y. et al. (2007).
Randomized comparison of 3 methods to screen for domestic violence in family practice.
Ann.Fam.Med., 5(5), 430-435.
Coker, A. L. (2007). Does physical intimate partner violence affect sexual health? A systematic
review. Trauma Violence Abuse, 8(2), 149-177.
Coker, A. L., Bethea, L., Smith, P. H., Fadden, M. K., & Brandt, H. M. (2002). Missed
opportunities: intimate partner violence in family practice settings. Prev.Med, 34(4), 445454.
Coker, A. L., Bond, S. M., & Pirisi, L. A. (2006). Life stressors are an important reason for
women discontinuing follow-up care for cervical neoplasia. Cancer
Epidemiol.Biomarkers Prev., 15(2), 321-325.
Coker, A. L., Davis, K. E., Arias, I., Desai, S., Sanderson, M., Brandt, H. M. et al. (2002).
Physical and mental health effects of intimate partner violence for men and women. Am J
Prev.Med, 23(4), 260-268.

132

Coker, A. L., Hopenhayn, C., DeSimone, C. P., Bush, H. M., & Crofford, L. (2009). Violence
against Women Raises Risk of Cervical Cancer. J.Womens Health (Larchmt.), 18(8),
1179-1185.
Coker, A. L., Pope, B. O., Smith, P. H., Sanderson, M., & Hussey, J. R. (2001). Assessment of
clinical partner violence screening tools. J Am Med Womens Assoc., 56(1), 19-23.
Coker, A. L., Smith, P. H., McKeown, R. E., & King, M. J. (2000). Frequency and correlates of
intimate partner violence by type: physical, sexual, and psychological battering. Am J
Public Health, 90(4), 553-559.
Cokkinides, V. E., Coker, A. L., Sanderson, M., Addy, C., & Bethea, L. (1999). Physical
violence during pregnancy: maternal complications and birth outcomes. Obstet Gynecol.,
93(5 Pt 1), 661-666.
Collins, K. S., Schoen, C., & Joseph, S. (1999). Health Concerns Across a Woman's Lifespan:
The Commonwealth Fund 1998 Survey of Women's Health Washington, DC: The
Commonwealth Fund.
Connor, P. D., Nouer, S. S., Mackey, S. T., Tipton, N. G., & Lloyd, A. K. (2011). Psychometric
properties of an intimate partner violence tool for health care students. J
Interpers.Violence, 26(5), 1012-1035.
Corrigan, J. D., Wolfe, M., Mysiw, W. J., Jackson, R. D., & Bogner, J. A. (2003). Early
identification of mild traumatic brain injury in female victims of domestic violence.
Am.J.Obstet.Gynecol., 188(5 Suppl), S71-S76.
Crofford, L. J. (2007). Violence, stress, and somatic syndromes. Trauma Violence Abuse, 8(3),
299-313.
Cullinane, P. M., Alpert, E. J., & Freund, K. M. (1997). First-year medical students' knowledge
of, attitudes toward, and personal histories of family violence. Acad Med, 72(1), 48-50.
Daugherty, J. D., & Houry, D. E. (2008). Intimate partner violence screening in the emergency
department. J.Postgrad.Med., 54(4), 301-305.
Davies, P., Walker, A. E., & Grimshaw, J. M. (2010). A systematic review of the use of theory in
the design of guideline dissemination and implementation strategies and interpretation of
the results of rigorous evaluations. Implement.Sci., 5, 14.
Davis, K. E., Coker, A. L., & Sanderson, M. (2002). Physical and mental health effects of being
stalked for men and women. Violence Vict., 17(4), 429-443.
Dearing, J. W. (2009). Applying Diffusion of Innovation Theory to Intervention Development.
Res Soc.Work Pract, 19(5), 503-518.

133

Dearing, J. W., Greene, S. M., Stewart, W. F., & Williams, A. E. (2011). If we only knew what
we know: Principles for knowledge sharing across people, practices, and platforms.
Translational Behavioral Medicine, 1(1), 15-25.
Dent, L. A., Harris, K. J., & Noonan, C. W. (2009). Randomized trial assessing the effectiveness
of a pharmacist-delivered program for smoking cessation. Ann.Pharmacother., 43(2),
194-201.
DeVellis, R. F. (2012). Scale Development: Theory and Applications. Applied Social Research
Methods Series (3rd ed.). Thousand Oaks, CA: Sage.
Dillman, D. A., Smyth, J. D., & Christian, L. M. (2009). Internet, Mail and Mixed-Mode
Surveys: the Tailored Design Method (3rd ed.). Hoboken, NJ: John Wiley and Sons, Inc.
Doucette, W. R., Witry, M. J., Farris, K. B., & McDonough, R. P. (2009). Community
pharmacist-provided extended diabetes care. Ann.Pharmacother., 43(5), 882-889.
Dowd, M. D., Kennedy, C., Knapp, J. F., & Stallbaumer-Rouyer, J. (2002). Mothers' and health
care providers' perspectives on screening for intimate partner violence in a pediatric
emergency department. Arch.Pediatr.Adolesc.Med., 156(8), 794-799.
Drossman, D. A. (1997). Irritable bowel syndrome and sexual/physical abuse history.
Eur.J.Gastroenterol.Hepatol., 9(4), 327-330.
Drossman, D. A., Talley, N. J., Leserman, J., Olden, K. W., & Barreiro, M. A. (1995). Sexual
and physical abuse and gastrointestinal illness. Review and recommendations.
Ann.Intern.Med., 123(10), 782-794.
Duffy, S. J., McGrath, M. E., Becker, B. M., & Linakis, J. G. (1999). Mothers with histories of
domestic violence in a pediatric emergency department. Pediatrics, 103(5 Pt 1), 10071013.
Faul, F., Erdfelder, E., Lang, A. G., & Buchner, A. (2007). G*Power 3: A flexible statistical
power analysis program for the social, behavioral, and biomedical sciences. Behav Res
Methods, 39(2), 175-191.
Feder, G., Ramsay, J., Dunne, D., Rose, M., Arsene, C., Norman, R. et al. (2009). How far does
screening women for domestic (partner) violence in different health-care settings meet
criteria for a screening programme? Systematic reviews of nine UK National Screening
Committee criteria. Health Technol.Assess., 13(16), iii-xiii, 1.
Fishman, P. A., Bonomi, A. E., Anderson, M. L., Reid, R. J., & Rivara, F. P. (2010). Changes in
health care costs over time following the cessation of intimate partner violence.
J.Gen.Intern.Med., 25(9), 920-925.
Ford, J., & Murphy, J. E. (1996). Chain pharmacists' attitudes on and awareness of domestic
abuse. J.Am.Pharm.Assoc.(Wash.), NS36(5), 323-328.

134

Friedman, L. S., Samet, J. H., Roberts, M. S., Hudlin, M., & Hans, P. (1992). Inquiry about
victimization experiences. A survey of patient preferences and physician practices.
Arch.Intern.Med, 152(6), 1186-1190.
Fuller, C. M., Galea, S., Caceres, W., Blaney, S., Sisco, S., & Vlahov, D. (2007). Multilevel
community-based intervention to increase access to sterile syringes among injection drug
users through pharmacy sales in New York City. Am J Public Health, 97(1), 117-124.
Gadomski, A. M., Wolff, D., Tripp, M., Lewis, C., & Short, L. M. (2001). Changes in health care
providers' knowledge, attitudes, beliefs, and behaviors regarding domestic violence,
following a multifaceted intervention. Acad.Med., 76(10), 1045-1052.
Garcia-Moreno, C. (2002a). Dilemmas and opportunities for an appropriate health-service
response to violence against women. Lancet, 359(9316), 1509-1514.
Garcia-Moreno, C. (2002b). Violence against women: what is the World Health Organization
doing? Int J Gynaecol Obstet, 78 Suppl 1, S119-S122.
Garimella, R., Plichta, S. B., Houseman, C., & Garzon, L. (2000). Physician beliefs about
victims of spouse abuse and about the physician role. J Womens Health Gend.Based.Med,
9(4), 405-411.
Gazmararian, J. A., Petersen, R., Spitz, A. M., Goodwin, M. M., Saltzman, L. E., & Marks, J. S.
(2000). Violence and reproductive health: current knowledge and future research
directions. Matern.Child Health J., 4(2), 79-84.
Gelles RJ. (1987). Family Violence. Newbury Park, CA: Sage Publications.
Gerbert, B., Abercrombie, P., & Caspers, N. (1999). How health care providers help battered
women: the survivors' perspective. Womens Health, 29, 115-135.
Gerbert, B., Caspers, N., Bronstone, A., Moe, J., & Abercrombie, P. (1999). A qualitative
analysis of how physicians with expertise in domestic violence approach the
identification of victims. Ann.Intern.Med., 131(8), 578-584.
Gidycz, C. A., Orchowski, L. M., King, C. R., & Rich, C. L. (2008). Sexual victimization and
health-risk behaviors: a prospective analysis of college women. J Interpers.Violence,
23(6), 744-763.
Grabenstein, J. D., Guess, H. A., Hartzema, A. G., Koch, G. G., & Konrad, T. R. (2001). Effect
of vaccination by community pharmacists among adult prescription recipients. Med Care,
39(4), 340-348.
Grabenstein, J. D., Guess, H. A., Hartzema, A. G., Koch, G. G., & Konrad, T. R. (2002).
Attitudinal factors among adult prescription recipients associated with choice of where to
be vaccinated. J Clin Epidemiol., 55(3), 279-284.

135

Green, L. W., & Kreuter, M. W. (1991). Health promotion planning: An education and
environmental approach (2nd ed.). Mountainview, CA: Mayfield.
Green, L. W., & Kreuter, M. W. (2005). Health program planning: An educational and
ecological approach (4th ed.). New York: McGraw-Hill.
Green, L. W., Kreuter, M. W., Deeds, S. G., & Partridge, K. B. (1980). Health education
planning: A diagnostic approach. Palo Alto, CA: Mayfield.
Greenfield, L., Rand, M., & Craven, D. (1998). Violence by intimates: Analysis of data on crimes
by current or former spouses, boyfriends and girlfriends Washington, DC: U.S.
Department of Justice.
Gremillion, D. H., & Kanof, E. P. (1996). Overcoming barriers to physician involvement in
identifying and referring victims of domestic violence. Ann.Emerg.Med, 27(6), 769-773.
Grisso, J. A., Schwarz, D. F., Hirschinger, N., Sammel, M., Brensinger, C., Santanna, J. et al.
(1999). Violent injuries among women in an urban area. N.Engl.J.Med., 341(25), 18991905.
Guth, A. A., & Pachter, L. (2000). Domestic violence and the trauma surgeon. Am.J.Surg.,
179(2), 134-140.
Gutmanis, I., Beynon, C., Tutty, L., Wathen, C. N., & Macmillan, H. L. (2007a). Factors
influencing identification of and response to intimate partner violence: a survey of
physicians and nurses. BMC Public Health, 7(12).
Gutmanis, I., Beynon, C., Tutty, L., Wathen, C. N., & Macmillan, H. L. (2007b). Factors
influencing identification of and response to intimate partner violence: a survey of
physicians and nurses. BMC Public Health, 7, 12.
Hair, J. F., Anderson, R. L., Thatham, R. L., & Black, W. C. (1998). Multivariate data analysis.
Upper Saddle River, NJ: Prentice Hall.
Heise, L. L. (1998). Violence against women: An ecological framework. Violence
Against.Women, 4(3), 262-290.
Hindin, P. K. (2006). Intimate partner violence screening practices of certified nurse-midwives.
J.Midwifery Womens Health, 51(3), 216-221.
Hogue, M. D., Grabenstein, J. D., Foster, S. L., & Rothholz, M. C. (2006). Pharmacist
involvement with immunizations: a decade of professional advancement. J Am Pharm
Assoc.(2003.), 46(2), 168-179.
Holt, S., Buckley, H., & Whelan, S. (2008). The impact of exposure to domestic violence on
children and young people: a review of the literature. Child Abuse Negl., 32(8), 797-810.

136

Humphreys, J., & Lee, K. A. (2009). Interpersonal violence is associated with depression and
chronic physical health problems in midlife women. Issues Ment.Health Nurs., 30(4),
206-213.
Institute of Medicine. (2004). Advancing the federal research agenda on violence against women
Washington, DC: National Academy Press.
Institute of Medicine. (2011). Clinical Preventive Services for Women: Closing the Gaps.
Washingon, DC: National Academy Press.
Jariwala, K. (2009). Value assessment of the RxSync service among university employees.
Unpublished manuscript, Department of Pharmacy Administration, University of
Mississippi, Oxford, MS.
Johnston, B. J. (2006). Intimate partner violence screening and treatment: the importance of
nursing caring behaviors. J.Forensic Nurs., 2(4), 184-188.
Joint Commission. (2011a). Comply with the Joint Commission Standard PC.01.02.09 on
Victims of Abuse. Retrieved from
http://www.futureswithoutviolence.org/section/our_work/health/_health_material/_jcaho
Joint Commission. (2011b). Comprehensive accreditation manual for hospitals: The official
handbook. Joint Commission. Retrieved from http://www.jcrinc.com/Joint-CommissionRequirements/Hospitals/#UPDATES
Kerner, J. F., Guirguis-Blake, J., Hennessy, K. D., Brounstein, P. J., Vinson, C., Schwartz, R. H.
et al. (2005). Translating research into improved outcomes in comprehensive cancer
control. Cancer Causes Control, 16 Suppl 1, 27-40.
Kimerling, R., Alvarez, J., Pavao, J., Mack, K. P., Smith, M. W., & Baumrind, N. (2009).
Unemployment among women: examining the relationship of physical and psychological
intimate partner violence and posttraumatic stress disorder. J Interpers.Violence, 24(3),
450-463.
Kolbo, J. R. (1996). Risk and resilience among children exposed to family violence. Violence
Vict., 11(2), 113-128.
Koop, C. E., & Lundberg, G. B. (1992). Violence in America: a public health emergency. Time
to bite the bullet back. JAMA, 267(22), 3075-3076.
Koss, M. P., Koss, P. G., & Woodruff, W. J. (1991). Deleterious effects of criminal victimization
on women's health and medical utilization. Arch.Intern.Med, 151(2), 342-347.
Krasnoff, M., & Moscati, R. (2002). Domestic violence screening and referral can be effective.
Ann.Emerg.Med., 40(5), 485-492.

137

Lapidus, G., Cooke, M. B., Gelven, E., Sherman, K., Duncan, M., & Banco, L. (2002). A
statewide survey of domestic violence screening behaviors among pediatricians and
family physicians. Arch.Pediatr.Adolesc.Med., 156(4), 332-336.
Lawrence W.Green. (2011). Retrieved from http://lgreen.net/precede.htm
Leserman, J., & Drossman, D. A. (2007). Relationship of abuse history to functional
gastorintestinal disorders and symptoms. Trauma Violence Abuse, 8, 331-343.
Lomas, J. (1991). Words without action? The production, dissemination, and impact of
consensus recommendations. Annu.Rev.Public Health, 12, 41-65.
Lopez, E. J., Jones, D. L., Villar-Loubet, O. M., Arheart, K. L., & Weiss, S. M. (2010). Violence,
coping, and consistent medication adherence in HIV-positive couples. AIDS Educ.Prev.,
22(1), 61-68.
Love, C., Gerbert, B., Caspers, N., Bronstone, A., Perry, D., & Bird, W. (2001). Dentists'
attitudes and behaviors regarding domestic violence. The need for an effective response.
J.Am.Dent.Assoc., 132(1), 85-93.
Malecha, A. T., Lemmey, D., McFarlane, J., Willson, P., Fredland, N., Gist, J. et al. (2000).
Mandatory reporting of intimate partner violence: safety or retaliatory abuse for women?
J.Womens Health Gend.Based.Med., 9(1), 75-78.
Max, W., Rice, D. P., Finkelstein, E., Bardwell, R. A., & Leadbetter, S. (2004). The economic
toll of intimate partner violence against women in the United States. Violence Vict.,
19(3), 259-272.
McCloskey, L. A., Lichter, E., Ganz, M. L., Williams, C. M., Gerber, M. R., Sege, R. et al.
(2005). Intimate partner violence and patient screening across medical specialties.
Acad.Emerg.Med., 12(8), 712-722.
McFarlane, J., Christoffel, K., Bateman, L., Miller, V., & Bullock, L. (1991). Assessing for
abuse: self-report versus nurse interview. Public Health Nurs., 8(4), 245-250.
McFarlane, J., Parker, B., & Soeken, K. (1996). Physical abuse, smoking, and substance use
during pregnancy: prevalence, interrelationships, and effects on birth weight.
J.Obstet.Gynecol.Neonatal Nurs., 25(4), 313-320.
McFarlane, J., Parker, B., Soeken, K., & Bullock, L. (1992). Assessing for abuse during
pregnancy. Severity and frequency of injuries and associated entry into prenatal care.
JAMA, 267(23), 3176-3178.
McFarlane, J., Parker, B., Soeken, K., Silva, C., & Reel, S. (1998). Safety behaviors of abused
women after an intervention during pregnancy. J.Obstet.Gynecol.Neonatal Nurs., 27(1),
64-69.

138

McFarlane, J., Soeken, K., & Wiist, W. (2000). An evaluation of interventions to decrease
intimate partner violence to pregnant women. Public Health Nurs., 17(6), 443-451.
McFarlane, J., Symes, L., Frazier, L., McGlory, G., Henderson-Everhardus, M. C., Watson, K. et
al. (2010). Connecting the dots of heart disease, poor mental health, and abuse to
understand gender disparities and promote women's health: a prospective cohort analysis.
Health Care Women Int., 31(4), 313-326.
McFarlane, J. M., Groff, J. Y., O'Brien, J. A., & Watson, K. (2005). Prevalence of partner
violence against 7,443 African American, White, and Hispanic women receiving care at
urban public primary care clinics. Public Health Nurs., 22(2), 98-107.
McFarlane, J. M., Groff, J. Y., O'Brien, J. A., & Watson, K. (2006). Secondary prevention of
intimate partner violence: a randomized controlled trial. Nurs.Res., 55(1), 52-61.
McGrath, M. E., Bettacchi, A., Duffy, S. J., Peipert, J. F., Becker, B. M., & St, A. L. (1997).
Violence against women: provider barriers to intervention in emergency departments.
Acad.Emerg.Med., 4(4), 297-300.
McGrath, M. E., Hogan, J. W., & Peipert, J. F. (1998). A prevalence survey of abuse and
screening for abuse in urgent care patients. Obstet.Gynecol., 91(4), 511-514.
McLeer, S. V., Anwar, R. A., Herman, S., & Maquiling, K. (1989). Education is not enough: a
systems failure in protecting battered women. Ann.Emerg.Med., 18(6), 651-653.
Mehuys, E., Van, B. L., De, B. L., Van, T., I, Annemans, L., Remon, J. P. et al. (2011).
Effectiveness of a community pharmacist intervention in diabetes care: a randomized
controlled trial. J Clin Pharm Ther., 36(5), 602-613.
National Center for Injury Prevention and Control. (2003). Costs of intimate partner violence
against women in the United States Atlanta, GA: Centers for Disease Control and
Prevention.
O'Reilly, R., Beale, B., & Gillies, D. (2010). Screening and intervention for domestic violence
during pregnancy care: a systematic review. Trauma Violence Abuse, 11(4), 190-201.
Olson, L., Anctil, C., Fullerton, L., Brillman, J., Arbuckle, J., & Sklar, D. (1996). Increasing
emergency physician recognition of domestic violence. Ann.Emerg.Med., 27(6), 741-746.
Papadakaki, M., Prokopiadou, D., Petridou, E., Kogevinas, M., & Lionis, C. (2012). Defining
Physicians' Readiness to Screen and Manage Intimate Partner Violence in Greek Primary
Care Settings. Eval.Health Prof..
Parkinson, G. W., Adams, R. C., & Emerling, F. G. (2001). Maternal domestic violence
screening in an office-based pediatric practice. Pediatrics, 108(3), E43.

139

Parsons, L., Goodwin, M. M., & Petersen, R. (2000). Violence against women and reproductive
health: toward defining a role for reproductive health care services. Matern.Child Health
J., 4(2), 135-140.
Parsons, L. H., Zaccaro, D., Wells, B., & Stovall, T. G. (1995). Methods of and attitudes toward
screening obstetrics and gynecology patients for domestic violence.
Am.J.Obstet.Gynecol., 173(2), 381-386.
Phelan, M. B. (2007). Screening for intimate partner violence in medical settings. Trauma
Violence Abuse, 8(2), 199-213.
Plichta, S. (1996). Violence, health and use of health services. In Women's Health and Care
Seeking Behavior (pp. 237-270). Baltimore: Johns Hopkins University Press.
Plichta, S. B. (2004). Intimate Partner Violence and Physical Health Consequences. Journal of
Interpersonal Violence, 19(11), 1296-1323.
Prosser, L. A., O'Brien, M. A., Molinari, N. A., Hohman, K. H., Nichol, K. L., Messonnier, M.
L. et al. (2008). Non-traditional settings for influenza vaccination of adults: costs and cost
effectiveness. Pharmacoeconomics., 26(2), 163-178.
Reid, S. A., & Glasser, M. (1997). Primary care physicians' recognition of and attitudes toward
domestic violence. Acad Med, 72(1), 51-53.
Renker, P. R., & Tonkin, P. (2006). Women's views of prenatal violence screening: acceptability
and confidentiality issues. Obstet.Gynecol., 107(2 Pt 1), 348-354.
Renker, P. R., & Tonkin, P. (2007). Postpartum women's evaluations of an audio/video
computer-assisted perinatal violence screen. Comput.Inform.Nurs., 25(3), 139-147.
Rennison, C. (2003). Intimate partner violence 1993-2001 Washington, DC: U.S. Department of
Justice, Office of Justice Programs.
Rhodes, K. V., Drum, M., Anliker, E., Frankel, R. M., Howes, D. S., & Levinson, W. (2006).
Lowering the threshold for discussions of domestic violence: a randomized controlled
trial of computer screening. Arch.Intern.Med., 166(10), 1107-1114.
Rittmayer, J., & Roux, G. (1999). Relinquishing the need to "fix it": medical intervention with
domestic abuse. Qual.Health Res., 9(2), 166-181.
Rivara, F. P., Anderson, M. L., Fishman, P., Bonomi, A. E., Reid, R. J., Carrell, D. et al. (2007a).
Healthcare utilization and costs for women with a history of intimate partner violence.
Am.J.Prev.Med., 32(2), 89-96.
Rivara, F. P., Anderson, M. L., Fishman, P., Bonomi, A. E., Reid, R. J., Carrell, D. et al.
(2007b). Intimate partner violence and health care costs and utilization for children living
in the home. Pediatrics, 120(6), 1270-1277.

140

Rivara, F. P., Anderson, M. L., Fishman, P., Reid, R. J., Bonomi, A. E., Carrell, D. et al. (2009).
Age, period, and cohort effects on intimate partner violence. Violence Vict., 24(5), 627638.
Rodriguez, M. A., Bauer, H. M., McLoughlin, E., & Grumbach, K. (1999). Screening and
intervention for intimate partner abuse: practices and attitudes of primary care physicians.
JAMA, 282(5), 468-474.
Rodriguez, M. A., McLoughlin, E., Bauer, H. M., Paredes, V., & Grumbach, K. (1999).
Mandatory reporting of intimate partner violence to police: views of physicians in
California. Am.J.Public Health, 89(4), 575-578.
Rodriguez, M. A., Quiroga, S. S., & Bauer, H. M. (1996). Breaking the silence. Battered
women's perspectives on medical care. Arch.Fam.Med, 5(3), 153-158.
Rodriguez, N., Ryan, S. W., Rowan, A. B., & Foy, D. W. (1996). Posttraumatic stress disorder in
a clinical sample of adult survivors of childhood sexual abuse. Child Abuse Negl., 20(10),
943-952.
Rogers, E. M. (2003). Diffusion of Innovations (5th ed.). New York: Free Press.
Saltzman, L. E., Fanslow, J. L., McMahon, P. M., & Shelley, G. (1999). Intimate partner
violence surveillance: uniform definitions and recommended data elements Atlanta, GA:
National Center for Injury Prevention and Control, Centers for Disease Control and
Prevention.
Saunders, D. G., Hamberger, L. K., & Hovey, M. (1993). Indicators of woman abuse based on a
chart review at a family practice center. Arch.Fam.Med., 2(5), 537-543.
Shearer, H. M., Forte, M. L., Dosanjh, S., Mathews, D. J., & Bhandari, M. (2006). Chiropractors'
perceptions about intimate partner violence: a cross-sectional survey. J.Manipulative
Physiol Ther., 29(5), 386-392.
Short, L. M., Alpert, E., Harris, J. M., Jr., & Surprenant, Z. J. (2006). A tool for measuring
physician readiness to manage intimate partner violence. Am J Prev.Med, 30(2), 173-180.
Silverstein, M., Conroy, K., & Sandel, M. (2008). Screening for social determinants of health in
pediatric primary care. Pediatr.Ann., 37(11), 740-746.
Sisley, A., Jacobs, L. M., Poole, G., Campbell, S., & Esposito, T. (1999). Violence in America: a
public health crisis--domestic violence. J.Trauma, 46(6), 1105-1112.
Stenson, K., Saarinen, H., Heimer, G., & Sidenvall, B. (2001). Women's attitudes to being asked
about exposure to violence. Midwifery, 17(1), 2-10.
Steyer, T. E., Ragucci, K. R., Pearson, W. S., & Mainous, A. G., III. (2004). The role of
pharmacists in the delivery of influenza vaccinations. Vaccine, 22(8), 1001-1006.

141

Sugg, N. K., Thompson, R. S., Thompson, D. C., Maiuro, R., & Rivara, F. P. (1999). Domestic
violence and primary care. Attitudes, practices, and beliefs. Arch.Fam.Med., 8(4), 301306.
Tabachnick, B. G., & Fidell, L. S. (2001). Using Multivariate Statistics. Boston, MA: Allyn &
Bacon.
Thompson, B. (2004). Exploratory and Confirmatory Factor Analysis. Washington,DC:
American Psychological Association.
Thompson, R. S., Bonomi, A. E., Anderson, M., Reid, R. J., Dimer, J. A., Carrell, D. et al.
(2006). Intimate partner violence: prevalence, types, and chronicity in adult women.
Am.J.Prev.Med., 30(6), 447-457.
Tinsely, H. E. A., & Tinsley, D. J. (1987). Uses of factor analysis in counseling psychology
research. Journal of Counseling Psychology, 34, 414-424.
Tjaden, T., & Thoennes, N. (2000). Full report of the prevalence, incidence, and consequences
of violence against women (NCJ 183781). Washington, DC: U.S. Department of Justice.
Turner CF, Ku L, & Rogers SM. (1998). Adolescent sexual behavior, drug use, and violence:
increased reporting with computer survey technology. Science, 280, 867-873.
U.S.Department of Health and Human Services, & U.S. (11 A.D.). Healthy People 2020 Injury
and Violence Prevention Objectives. Retrieved from
www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=24
U.S.Department of Justice. (2012). Intimate Partner Violence. Retrieved from U.S. Department
of Justice http://bjs.ojp.usdoj.gov/index.cfm?ty=tp&tid=971
U.S.Preventive Services Task Force. (2004). Screening for family and intimate partner violence:
Recommendation Statement. U.S.Preventive Services Taks Force. Retrieved from
http://www.uspreventiveservicestaskforce.org/3rduspstf/famviolence/famviolrs.htm
Ulrich, Y. C., Cain, K. C., Sugg, N. K., Rivara, F. P., Rubanowice, D. M., & Thompson, R. S.
(2003). Medical care utilization patterns in women with diagnosed domestic violence. Am
J Prev.Med, 24(1), 9-15.
Vos, T., Astbury, J., Piers, L. S., Magnus, A., Heenan, M., Stanley, L. et al. (2006). Measuring
the impact of intimate partner violence on the health of women in Victoria, Australia.
Bull.World Health Organ, 84(9), 739-744.
Wathen, C. N., & Macmillan, H. L. (2008). Self-report, medical staff interview, and physician
interview had similar effectiveness for screening for domestic violence in women.
Evid.Based.Nurs., 11(2), 45.
Weiss, S. J., Ernst, A. A., Cham, E., & Nick, T. G. (2003). Development of a screen for ongoing
intimate partner violence. Violence Vict., 18(2), 131-141.
142

Willis, G. (2005). Cognitive Interviewing. Thousand Oaks, CA: Sage.
Wilt, S., & Olson, S. (1996). Prevalence of domestic violence in the United States. J Am Med
Womens Assoc., 51(3), 77-82.
Wolfe, R., Lobozzo, J., Frye, V., & Sharp, V. (2003). Screening for substance use, sexual
practices, mental illness, and domestic violence in HIV primary care.
J.Acquir.Immune.Defic.Syndr., 33(4), 548-549.
Wright, R. J., Wright, R. O., & Isaac, N. E. (1997). Response to battered mothers in the pediatric
emergency department: a call for an interdisciplinary approach to family violence.
Pediatrics, 99(2), 186-192.
Yancey, A. H., Gabel-Hughes, K. S., Ezell, S., & Zalkind, D. L. (1994). The relationship
between violent trauma and nonemployment in Washington, DC. J Natl.Med Assoc.,
86(9), 661-666.
Zeitler, M. S., Paine, A. D., Breitbart, V., Rickert, V. I., Olson, C., Stevens, L. et al. (2006a).
Attitudes about intimate partner violence screening among an ethnically diverse sample
of young women. J.Adolesc.Health, 39(1), 119-8.
Zeitler, M. S., Paine, A. D., Breitbart, V., Rickert, V. I., Olson, C., Stevens, L. et al. (2006b).
Attitudes about intimate partner violence screening among an ethnically diverse sample
of young women. J.Adolesc.Health, 39(1), 119-8.
Zorrilla, B., Pires, M., Lasheras, L., Morant, C., Seoane, L., Sanchez, L. M. et al. (2010).
Intimate partner violence: last year prevalence and association with socio-economic
factors among women in Madrid, Spain. Eur.J Public Health, 20(2), 169-175.

143

List of Appendices

144

Appendix: A

145

INITIAL COVER LETTER
Dear Community Pharmacist:
We are conducting a research study as a part of a dissertation project to explore pharmacists’
knowledge and opinions about domestic violence and domestic violence screening. The survey
should take about 20 minutes to complete. Your responses will be kept confidential and your
employer will not receive this data in any way. The survey includes three non-required questions
about your own experience with domestic violence which might arouse distress. The University
of Mississippi’s Institutional Review Board (IRB) has reviewed this study. The IRB has
determined that this study fulfills the human research subject protections obligations required by
state and federal law and University policies. If you have any questions, concerns, or reports
regarding your rights as a participant of research, please contact the IRB at (662) 915-7482.
We value your participation in this study, as it will allow us to better understand community
pharmacists’ opinions about domestic violence and domestic violence screening. The survey
should take about 20 minutes to complete and we greatly encourage you to participate.
Participation is voluntary and you may quit the survey at any time. To thank respondents for
their time and effort, you will have the option at the conclusion of the survey to be entered into a
drawing for one of four $50 gift certificates to Amazon.com (chance of winning estimated to be
1 in 150). Additionally, you will be able to indicate if you would like a summary of the results of
this study. If you have questions about this study, please contact Marie Barnard by email at
mbarnard@olemiss.edu. Again, thank you very much for assisting us with this very important
project.
By clicking the link below, you are agreeing to participate in this research project.
Follow this link to the Survey:
(Link)
Or copy and paste the URL below into your internet browser:
(Link)
Sincerely,
Marie Barnard, M.S. Donna West-Strum, R.Ph., Ph.D.
Graduate Student Associate Professor and Chair
The University of Mississippi The University of Mississippi
School of Pharmacy School of Pharmacy
Please print this page for your records.
Follow the link to opt out of future emails:
(Unsubscribe Link)
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FIRST FOLLOW-UP EMAIL
We recently sent you an email asking you to respond to a survey exploring pharmacists'
knowledge and opinions about domestic violence and domestic violence screenings. Your
responses to this survey are important and will help us better understand community pharmacists'
opinions about this issue.
This survey should take about 20 minutes to complete. We encourage you to take a few minutes
and complete the survey. To thank respondents for their time and effort, you will have the option
at the end of the survey to be entered into a drawing for one of four $50 gift certificates to
Amazon.com (chance of winning estimated to be 1 in 150). The survey includes three nonrequired questions about your own experience with domestic violence which might arouse
distress. The University of Mississippi's Institutional Review Board has reviewed this study and
determined that this study fulfills the human research subject protections required by state and
federal law and university policies. If you have any questions, concerns, or reports regarding
your rights as a research participant, please contact the IRB at (662)915-7482. If you have any
questions about this study, please contact Marie Barnard at mbarnard@olemiss.edu. Thank you!
By clicking this link, you are agreeing to participate in this research project.
Follow this link to the Survey:
(Link)
Or copy and paste the URL below into your internet browser:
(Link)

Sincerely,
Marie Barnard, M.S. Donna West-Strum, R.Ph., Ph.D.
Graduate Student Associate Professor and Chair
The University of Mississippi The University of Mississippi
School of Pharmacy School of Pharmacy

Follow the link to opt out of future emails:
(Unsubscribe link)

Please print this page for your records
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THIRD FOLLOW-UP EMAIL
This is a follow-up to ask your assistance with a dissertation research project to explore
pharmacists’ knowledge and opinions about domestic violence and domestic violence
screening. The survey should take about 20 minutes to complete. Your responses will be kept
confidential and your employer will not receive this data in any way. The survey includes three
non-required questions about your own experience with domestic violence which might arouse
distress. The University of Mississippi’s Institutional Review Board (IRB) has reviewed this
study. The IRB has determined that this study fulfills the human research subject protections
obligations required by state and federal law and University policies. If you have any questions,
concerns, or reports regarding your rights as a participant of research, please contact the IRB at
(662) 915-7482.
We value your participation in this study, as it will allow us to better understand community
pharmacists’ opinions about domestic violence and domestic violence screening. We greatly
encourage you to participate. Participation is voluntary and you may quit the survey at any
time.
To thank respondents for their time and effort, you will be sent via email a $10 Amazon.com
gift certificate for completing the survey.
Additionally, you will be able to indicate if you would like a summary of the results of this
study. If you have questions about this study, please contact Marie Barnard by email at
mbarnard@olemiss.edu. Again, thank you very much for assisting us with this very important
project.
By clicking this link, you are agreeing to participate in this research project.
Follow this link to the Survey:
(Link)
Or copy and paste the URL below into your internet browser:
(Link)
Sincerely,
Marie Barnard, M.S.
Graduate Student
The University of Mississippi
School of Pharmacy

Donna West-Strum, R.Ph., Ph.D.
Associate Professor and Chair
The University of Mississippi
School of Pharmacy

Follow the link to opt out of future emails:

(Unsubscribe link)
Please print this page for your records
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FOURTH FOLLOW-UP EMAIL
There are only a few more days to participate in this study. Please consider participating! You
will receive a $10 Amazon.com gift certificate as an honorarium.
This is a follow-up to ask your assistance with a dissertation research project to explore
pharmacists’ knowledge and opinions about domestic violence and domestic violence screening.
The survey should take about 20 minutes to complete. Your responses will be kept confidential
and your employer will not receive this data in any way. The survey includes three non-required
questions about your own experience with domestic violence which might arouse distress. The
University of Mississippi’s Institutional Review Board (IRB) has reviewed this study. The IRB
has determined that this study fulfills the human research subject protections obligations required
by state and federal law and University policies. If you have any questions, concerns, or reports
regarding your rights as a participant of research, please contact the IRB at (662) 915-7482.
We value your participation in this study, as it will allow us to better understand community
pharmacists’ opinions about domestic violence and domestic violence screening. We greatly
encourage you to participate. Participation is voluntary and you may quit the survey at any time.
To thank respondents for their time and effort, you will be sent via email a $10 Amazon.com
gift certificate for completing the survey.
Additionally, you will be able to indicate if you would like a summary of the results of this
study. If you have questions about this study, please contact Marie Barnard by email at
mbarnard@olemiss.edu. Again, thank you very much for assisting us with this very important
project.
By clicking this link, you are agreeing to participate in this research project.
Follow this link to the Survey: (Link)
Or copy and paste the URL below into your internet browser:
(Link)

Sincerely,
Marie Barnard, M.S. Donna West-Strum, R.Ph., Ph.D.
Graduate Student Associate Professor and Chair
The University of Mississippi The University of Mississippi
School of Pharmacy School of Pharmacy
Follow the link to opt out of future emails:
(Unsubscribe link)

Please print this page for your records
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